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Glossary
Absorbance When a beam of light passes through the sample, the
light absorption occurs because of the atoms or
molecules taking away the energy from the light. In
general, the absorbance of a sample is directly
proportional to the optical path length of the sample
holder and the concentration of the sample.
Anabolics Anabolic osteoporosis agents such as Teriparatide
(human parathyroid hormone [1-34]) reduce fracture
incidence by improving other bone qualities in
addition to increasing bone mass by directly
stimulating bone formation.
Antibody Antibody is a large, Y-shaped protein produced
mainly by plasma cells that is used by the immune
system to identify and neutralize pathogens such as
bacteria and viruses. The antibody recognizes a
unique molecule of the harmful agent, called an
antigen. Antibody and antigen interact by spatial
complementarity (lock and key).
Antigen An antigen is any substance that causes the immune
system to produce antibodies against it. Each antibody
is specifically produced by the immune system to
match an antigen.
Antiresorptives Antiresorptive osteoporosis agents limit bone loss by
decreasing the rate of absorption by osteoclasts, which
are cells that absorb bone. By reducing how quickly
osteoclasts work, antiresorptives may prevent further
loss of bone mass. There are a number of classes of
antiresorptives, including bisphosphonates, calcitonin,
estrogen therapy or hormone therapy, and estrogen
agonists/antagonists.
Biomarker A biomarker is any substance, structure or process that
can be measured in the body or its products and
influence or predict the incidence of outcome or
disease.
xxii Glossary
Bone Turnover Marker Bone turnover markers are bone tissue proteins or
their fragments/enzymes released from bone cells
during bone turnover. These markers include collagen
breakdown products and other molecules released
from osteoclasts and osteoblasts during the process of
bone resorption and formation.
Calibration curve A calibration curve is a general method for
determining the concentration of a substance in an
unknown sample by comparing the unknown to a set
of standard samples of known concentration. It shows
how the instrumental response, the so-called
analytical signal, changes with the concentration of the
analyte (the substance to be measured).
Chemiluminescence CL is the light produced by a chemical reaction. The
CL intensity is directly proportional to the
concentration of a limiting reactant involved in the CL
reaction. As a principle, in CL, reactants A and B react
with an excited intermediate to form a product and
emit the light which can be detected and analyzed by
an optical detection system.
Conjugated Antibody A conjugated antibody is a monoclonal or polyclonal
antibody linked to a label and used for detection in a
diverse range of assay techniques.
FET FET is a transistor that uses an electric field to control
the shape and electrical conductivity of a charge
carrier channel in a semiconductor material. FET’s
conductivity is regulated by the voltage applied to the
gate contact. This voltage imposes an electric field into
the device, which in turn attracts or repels charge
carriers to or from the region between the source and
drain contacts.
Fluorescence Fluorescence is the emission of certain wavelength of
visible light from a substance by the absorption of an
excitation light of different wavelengths. Fluorescence
detection is the most commonly observed form of
optical detection, because of its high sensitivity and
the ease of integrating a label.
Glutathione GSH is a thiol-containing aminoacid with high affinity
towards gold nanoparticles through the formation of
Au-S bond.
Immunoassay An immunoassay is a biochemical test that measures
the presence or concentration of an analyte (usually
proteins) in a solution (biological liquids such as
xxiii
serum or urine for medical and research purposes)
through the use of an antibody or an antigen.
Limit of Detection LoD is the lowest quantity of a substance that can be
distinguished from the blank value within a stated
confidence limit (generally 1 %). It is estimated from
the mean of the blank, the SD of the blank and some
confidence factor. Another consideration that affects
the LoD is the accuracy of the model used to predict
concentration from the raw analytical signal.
Limit of Quantification LoQ is the lowest concentration at which the analyte
can not only be reliably detected but at which some
predefined goals for bias and imprecision are met. The
LoQ may be equivalent to the LoD or it could be at a
much higher concentration.
Molecular Pathway A biological/molecular pathway is a series of actions
among molecules in a cell that leads to a certain
product or a change in a cell. Such a pathway can
trigger the assembly of new molecules, such as a fat or
protein. Pathways can also turn genes on and off, or
spur a cell to move.
Nanoprobe Nanoprobe refers generically to any chemical or
biological technique that deals with nanoquantitles. In
other words, that is introducing nanoparticles in
aqueous solution to serve in the detection, diagnosis,
and treatment of various diseases.
Positive Predictive Value
PPV is the probability that subjects with a positive
screening test truly have the disease. In other words, it
is the ability of the test to correctly label people who
test positive. It is calculated in two ways:
￿ PPV = (# true positives) / (# true positives + #
false positives)
￿ PPV = sensitivity x prevalence / sensitivity x
prevalence + (1-sensitivity) x (1-prevalence)
Proteomics Proteomics is a rapidly growing field of molecular
biology that is concerned with the systematic,
high-throughput approach to protein expression
analysis of a cell or an organism. Typical results of
proteomics studies are inventories of the protein
content of differentially expressed proteins across
multiple conditions.
Relative Standard Deviation
xxiv Glossary
RSD is a special form of SD calculated using 100∗SDx¯ ,
where SD is the sample standard deviation and x¯ is
the sample mean.
Surrogate Marker A surrogate marker is an event or a laboratory value
that researchers hope can serve as a reliable substitute
for an actual disease. A common example of this is
blood cholesterol levels. These levels are surrogates, or
substitutes, for heart disease.
Surface plasmon resonance
When a polarized light hits a prism covered with a
thin film of metal at a specific (resonance) angle, SPR
occurs. SPR effect is sensitive to the binding of analyte
because the increase in mass causes a proportional
increase in the refractive index at the interface
between a thin metal film and an ambient medium.
For an immunoassay, before an antigen binds to an
immobilized antibody, the refractive index of the
prism is constant. After the binding event, the
refractive index changes. In this way, it is possible to
monitor the biomolecular interaction on the metal
film. Therefore, SPR provides a non-invasive,
label-free approach for detecting the concentration of
analytes, kinetics, and affinity in real time.
T-score T-score is the comparison of a person’s bone density
with that of a healthy 30-year-old of the same sex. at
-1.0 and above.
Theranostics Theranostics is used to define ongoing efforts in clinics
to develop more specific, individualized therapies for
various diseases, and to combine diagnostic and
therapeutic capabilities into a single agent.
ULD limit is the largest intrinsic intensity that the
source can have and yet have a given probability of
remaining undetected.
Voltammetry Voltammetry is an electroanalytical method used in
analytical chemistry. In voltammetry, a
time-dependent potential is applied to an
electrochemical cell and the resulting current is
measured as a function of that potential. The
technique provides quantitative and qualitative
information about the species involved in the
oxidation or reduction reaction.

  ﭼ$ﯿﺪه
ﺻﻮرت ﻣﯽ  )DMB( ﺗﺮاﮐﻢ ﻣﻮاد ﻣﻌﺪﻧﯽ اﺳﺘﺨﻮان ﺘﻔﺎده از ﺳﻨﺠﺶاﺳ ﺎﮐﻪ اﻣﺮوزه ﺑ ،ﺗﺸﺨﯿﺺ ﭘﻮﮐﯽ اﺳﺘﺨﻮان
ﻣﺎرﮐﺮﻫﺎي  ﻔﺎده ازاﺳﺘﻪ ﻫﻤﯿﻦ دﻟﯿﻞ ﺑﻪ ﻧﻈﺮ ﻣﯽ رﺳﺪ رﻧﺞ ﻣﯽ ﺑﺮد. ﺑﻣﺘﻌﺪدي ، از ﻣﺤﺪودﯾﺖ ﻫﺎي ﮔﯿﺮد
در  sMTB اﺳﺘﻔﺎده از. ﮐﻤﮏ ﮐﻨﻨﺪه ﺑﺎﺷﻨﺪ ﺑﻬﺒﻮد ﺗﺸﺨﯿﺺ ﭘﻮﮐﯽ اﺳﺘﺨﻮاندر ﺪ ﻨﻣﯽ ﺗﻮاﻧ )sMTB( اﺳﺘﺨﻮاﻧﯽ
در اﻓﺮاد درﻣﺎن ﺑﻠﮑﻪ در ﺷﻨﺎﺳﺎﯾﯽ ﭘﺎﯾﺶ روﻧﺪ و اﺑﺰار ارزﯾﺎﺑﯽ رﯾﺴﮏ ﺑﺎﻟﯿﻨﯽ، ﻧﻪ ﺗﻨﻬﺎ در  DMB ﻣﻘﺎﯾﺴﻪ ﺑﺎ
 sMTB ارزش ﺗﺸﺨﯿﺼﯽاز ﻣﺰاﯾﺎي ﻣﺘﻌﺪدي ﺑﺮﺧﻮردار اﺳﺖ. اﯾﻦ در ﺣﺎﻟﯽ اﺳﺖ ﮐﻪ ، ﺷﮑﺴﺘﮕﯽ ﻣﻌﺮض ﺧﻄﺮ
ﺑﺎ دﻗﺖ ﺑﺎﻻ  sMTB ﭼﻨﺪاﻧﺪازه ﮔﯿﺮي ﻫﻤﺰﻣﺎن و ﺑﻪ اﯾﻦ ﺗﺮﺗﯿﺐ ﭘﺎﯾﯿﻦ ﺑﻮده در ﭘﯿﺶ ﺑﯿﻨﯽ ﭘﻮﮐﯽ اﺳﺘﺨﻮان 
  ﺖ ﻻزم ﻣﯽ ﺑﺎﺷﺪ.ﺑﺮاي ﻏﻠﺒﻪ ﺑﺮ اﯾﻦ ﻣﺤﺪودﯾ
، ﻓﻦ آوري ﻫﺎي (enicidem dezilanosrep) ﻓﺮديﺑﺎ وﺟﻮد ﭘﯿﺸﺮﻓﺖ ﻫﺎي اﺧﯿﺮ در ﭘﺮوﺗﺌﻮﻣﯿﮑﺲ و ﭘﺰﺷﮑﯽ 
اﻟﮑﺘﺮوﮐﻤﯽ ( و ASILE) ﺳﻨﺠﺶ اﯾﻤﻮﻧﻮﺳﻮرﺑﻨﺖ ﻣﺘﺼﻞ ﺑﻪ آﻧﺰﯾﻢﻣﺎﻧﻨﺪ ، MTB ﻣﻮﺟﻮد ﺑﺮاي اﻧﺪازه ﮔﯿﺮي
ﻧﯿﺎز دارد. ﺑﻪ ﺑﺮﭼﺴﺐ ﻫﺎي ﺧﺎص و اﺑﺰار ﮔﺮان ﺑﻮده ﺑﻠﮑﻪ  وﻗﺖ ﮔﯿﺮ و ﭘﺮ زﺣﻤﺖ(، ﻧﻪ ﺗﻨﻬﺎ AILCEﯿﻨﺴﻨﺲ )ﻟﻮﻣ
و ﺑﻪ ﺳﻤﺖ ﺗﻮﺳﻌﻪ  در ﺳﺎﻟﻬﺎي اﺧﯿﺮ آﺷﮑﺎر، ﺗﻤﺮﮐﺰ ﻣﻄﺎﻟﻌﺎت ﻣﺮﺗﺒﻂ ﺑﺎ ﺳﻼﻣﺖ  ياﯾﻦ ﻣﺤﺪودﯾﺖ ﻫﺎﺗﻮﺟﻪ ﺑﻪ ﺑﺎ 
ﻋﯿﻦ ﻗﺎﺑﻞ اﺳﺘﻔﺎده ﻣﺠﺪد و در  ،ﻗﺎﺑﻞ ﺣﻤﻞﺑﺪون ﺑﺮﭼﺴﺐ،  )COP( ﺳﺎﺧﺖ ﺣﺴﮕﺮﻫﺎي زﯾﺴﺘﯽ ﻧﻘﻄﻪ ﻣﺮاﻗﺒﺖ
 ﺑﻪ وﯾﮋه ﺑﺮاي ﺗﺸﺨﯿﺺ و ﻧﻈﺎرت ﺑﯿﻤﺎرﯾﻬﺎي ﻣﺨﺘﻠﻒ ﺣﺎل ﻗﺎﺑﻞ اﺳﺘﻔﺎده ﺑﺮاي اﻧﺪازه ﮔﯿﺮي ﻫﻤﺰﻣﺎن ﭼﻨﺪ ﻣﺎرﮐﺮ
( ﻧﯿﺰ tops-eht-noدر ﻣﺤﻞ ) ﻫﻤﭽﻨﯿﻦ ﺑﻪ ﻋﻨﻮان دﺳﺘﮕﺎه ﻫﺎي ﺗﺸﺨﯿﺼﯽاﯾﻦ دﺳﺘﮕﺎه ﻫﺎ ﮐﻪ . ﻣﯽ ﺑﺎﺷﺪ
  آﺳﺎن ﺑﺎﺷﻨﺪ.ﺗﻔﺴﯿﺮ ﺑﺎ ﻗﺎﺑﻠﯿﺖ رزان و ، ااﺧﺘﺼﺎﺻﯽ، ﺑﺎﯾﺪ ﺳﺎده، ﺣﺴﺎس، ﺳﺮﯾﻊ، ﺷﻨﺎﺧﺘﻪ ﻣﯽ ﺷﻮﻧﺪ
ارزﯾﺎﺑﯽ روﻧﺪ  ﺟﻬﺖﻣﯿﻨﯿﺎﺗﻮري  ارزان ﻗﯿﻤﺖ وﺑﺮاي ﺳﺎﺧﺖ ﺣﺴﮕﺮﻫﺎي زﯾﺴﺘﯽ  ﺗﻘﺎﺿﺎ، ﺑﻪ ﻫﻤﯿﻦ ﺻﻮرت
ﻫﯿﭻ ﯾﮏ از ﺗﺎﮐﻨﻮن، ، هﺑﺮرﺳﯽ ﻫﺎي اﻧﺠﺎم ﺷﺪ ﺑﺎ ﺗﻮﺟﻪ ﺑﻪ. ﺎﻻ رو ﺑﻪ رﺷﺪ ﻣﯽ ﺑﺎﺷﺪﺑﺎزﺳﺎزي اﺳﺘﺨﻮان ﺑﺎ دﻗﺖ ﺑ
  .ﺒﻮده اﻧﺪﻧﺣﺴﮕﺮﻫﺎي زﯾﺴﺘﯽ اﺳﺘﺨﻮان ﻣﻮﺟﻮد در اﯾﻦ زﻣﯿﻨﻪ ﻣﻮﻓﻖ 
ﻣﻨﺎﺳﺐ ﺑﺎ آﻧﺎﻟﯿﺖ ﻫﺪف و ﻫﻤﭽﻨﯿﻦ ﻣﺒﺪل ﻪ اﺗﺼﺎل اﻧﺘﺨﺎﺑﯽ/اﺧﺘﺼﺎﺻﯽ ﻣﺎده ﺷﻨﺎﺳﺎﮔﺮ ﺑﯿﻮﺳﻨﺴﻮر ﮐﺎرآﻣﺪ ﺑﯾﮏ 
 ﺗﺸﺨﯿﺺ ﭘﺎﯾﯿﻦ ﺣﺪو  )N/S( زﻣﺎن ﭘﺎﺳﺦ، ﻧﺴﺒﺖ ﺳﯿﮕﻨﺎل ﺑﻪ ﻧﻮﯾﺰﺑﺮاﺳﺎس اﺗﺼﺎل ﻧﺸﺎن دادن ﻓﺮآﯾﻨﺪ ﺑﺮاي 
  ز دارد. ( ﻧﯿﺎDOL)
دﺳﺘﮕﺎه ﺑﻪ ﯾﮏ ﻗﺎﺑﻞ ﺗﺒﺪﯾﻞ ﻣﯿﮑﺮوﺳﯿﺎﻟﯽ ﮐﻪ ﺑﻪ راﺣﺘﯽ  ﯿﮏﭘﺮوﺗﺌﻮﻣ ﯾﮏ ﻣﯿﺰﺳﺎﺧﺖ ، ﮔﺰارش وژهﺮﭘدر اﯾﻦ 
ادﻏﺎم ﺗﮑﻨﻮﻟﻮژي ﺣﺎﺻﻞ . اﯾﻦ ﭘﻠﺖ ﻓﺮم ﻣﯽ ﺑﺎﺷﺪ اراﺋﻪ ﺷﺪه اﺳﺖ( rekramoib) يﻧﺸﺎﻧﮕﺮﺗﺸﺨﯿﺺ ﺑﺮاي ﻫﺮ 
ﯾﮏ ﻣﺤﻔﻈﻪ واﮐﻨﺶ/ﺗﺸﺨﯿﺺ ﺑﺮاي اﻧﺪازه ﮔﯿﺮي  ازو ﺑﻮده ﺳﻨﺠﺶ اﻟﮑﺘﺮوﺷﯿﻤﯿﺎﯾﯽ ﺳﯿﺴﺘﻢ ﻣﯿﮑﺮوﺳﯿﺎﻟﯽ ﺑﺎ 
اﻣﮑﺎن ﭘﻠﺖ ﻓﺮم  اﯾﻦاﺳﺖ. ﻃﺮاﺣﯽ ﻣﻨﺤﺼﺮ ﺑﻪ ﻓﺮد ﺗﺸﮑﯿﻞ ﺷﺪه ﺳﻄﺢ ﺳﺮﻣﯽ ﻧﺸﺎﻧﮕﺮﻫﺎي زﯾﺴﺘﯽ ﻣﺘﻔﺎوت 
ﺳﺎﺧﺘﺎرﻫﺎي ﻣﯿﮑﺮوﺳﯿﺎﻟﯽ و اﻟﮑﺘﺮوﺷﯿﻤﯿﺎﯾﯽ ﺑﻪ ﻃﻮر ﺎﻻ را ﻓﺮاﻫﻢ ﻣﯽ آورد و ﺣﺴﺎﺳﯿﺖ ﺑاﻧﺪازه ﮔﯿﺮي ﻧﺸﺎﻧﮕﺮﻫﺎ ﺑﺎ 
  .ﺳﺎزي ﻣﯽ ﺑﺎﺷﻨﺪﺑﻬﯿﻨﻪ ﻗﺎﺑﻞ ﻣﺴﺘﻘﻞ 
 و ﻣﻮﻟﮑﻮﻟﻬﺎي زﯾﺴﺘﯽ آﻧﺘﯽ ﺑﺎدي، ﯾﮏ )sPNuA( ﻧﺎﻧﻮذرات ﻃﻼ ﻣﯿﺎنﮔﺎم ﻧﺨﺴﺖ، از ﻃﺮﯾﻖ ﺗﻌﺎﻣﻞ  در
. اﯾﻦ روش ﻏﯿﺮآﻧﺰﯾﻤﯽ ﻧﺸﺎﻧﮕﺮﻫﺎ ﺳﺎﺧﺘﻪ ﺷﺪ اﻟﮑﺘﺮوﺷﯿﻤﯿﺎﯾﯽﺑﺮاي اﻧﺪازه ﮔﯿﺮي ﻃﻼ  (eborponan) ﮐﺎوﺷﮕﺮﻧﺎﻧﻮ
ﺑﻠﮑﻪ ﺗﺎ ﺣﺪ  آوردﻓﺮاﻫﻢ را آﻧﺘﯽ ﺑﺎدي ﺑﺮ روي ﻧﺎﻧﻮذرات ﺣﺠﻢ ﺑﺎﻻﯾﯽ از ﺳﺎده ﺑﺮاي ﺑﺎرﮔﺬاري ﻣﺘﺪي ﻧﻪ ﺗﻨﻬﺎ 
ﺑﻪ ﻫﻤﺮاه ﯾﮏ اﻟﮑﺘﺮود  ،اﯾﻦ ﻧﺎﻧﻮﮐﺎوﺷﮕﺮ. ﺑﺨﺸﯿﺪﺑﻬﺒﻮد  ﻓﺮآﯾﻨﺪ ﺗﻮﻟﯿﺪ اﯾﻦ ﮐﺎوﺷﮕﺮ را ﻧﯿﺰ ﭘﺬﯾﺮيزﯾﺎدي ﺗﮑﺮار
ﺑﻪ ﻋﺒﺎرت دﯾﮕﺮ، ﯾﮏ ﯾﺎ ﭼﻨﺪ ﻧﺸﺎﻧﮕﺮ ﺑﮑﺎر ﺑﺮده ﺷﻮد.  اﻟﮑﺘﺮوﺷﯿﻤﯿﺎﯾﯽ اﻧﺪازه ﮔﯿﺮيﺑﺮاي  ﺪﻣﯽ ﺗﻮاﻧﯾﮑﺒﺎر ﻣﺼﺮف، 
ﻣﺨﺘﻠﻒ  ﺑﺮاي اﻧﺪازه ﮔﯿﺮي ﻏﻠﻈﺖ ﻫﺎيﺗﻮان ﺑﺎﻻ ﺑﺎ دﻗﯿﻖ )ﺗﮏ/ ﺗﺴﻬﯿﻢ ﺷﺪه( ي اﺑﺰار ﺪﻧﺎﻧﻮﮐﺎوﺷﮕﺮ ﻣﯽ ﺗﻮاﻧ اﯾﻦ
  .ﺪﻧﺸﺎﻧﮕﺮﻫﺎي ﻣﺨﺘﻠﻒ اﯾﺠﺎد ﻧﻤﺎﯾ
. ﻣﻮﺟﻮد در آن ﺑﻮد ﺳﺎﺧﺘﺎر و ﮐﺎرﮐﺮد آﻧﺘﯽ ﺑﺎديﺑﺎ ﺣﻔﻆ اﯾﻦ ﮐﺎوﺷﮕﺮ ﺑﺮ روي ﺳﻄﺢ اﻟﮑﺘﺮود  ﻧﺸﺎﻧﺪنﮔﺎم ﺑﻌﺪي 
وﯾﮋﮔﯽ ﻫﺎي اﻟﮑﺘﺮوﺷﯿﻤﯿﺎﯾﯽ ﺑﻬﺒﻮد ﺑﺮ روي ﺳﻄﺢ اﻟﮑﺘﺮود ﻃﻼ ﺑﻪ ﻣﻨﻈﻮر  رﺳﻮب ﻧﺎﻧﻮذرات ﻃﻼدر اﯾﻦ راﺳﺘﺎ، 
ﮐﻮﭼﮏ ﻓﺮآﯾﻨﺪ  PNuAﺑﺪﻧﺒﺎل ﻧﺸﺎﻧﺪن ﻪ ﻧﻮﯾﺰ ﺑﺳﯿﮕﻨﺎل ﻧﺴﺒﺖ ﺑﺎﻻﺗﺮ . ﺑﻪ ﻋﺒﺎرت دﯾﮕﺮ، ﺻﻮرت ﮔﺮﻓﺖ ﺳﻄﺢ
ﻣﺮور . ﭘﺎﺳﺦ ﻣﯽ ﺷﻮدﺗﻘﻮﯾﺖ ﺳﯿﮕﻨﺎل  ﺳﯿﺴﺘﻢ را ﺑﻬﺒﻮد ﺑﺨﺸﯿﺪه و از ﻃﺮف دﯾﮕﺮ ﺑﺎ اﻓﺰاﯾﺶ ﺳﻄﺢ ﺑﺎﻋﺚﺳﺎزي 
 ﺑﻪ روﺷﻬﺎي ﻣﺨﺘﻠﻒ اﻣﮑﺎن ﭘﺬﯾﺮ اﺳﺖ و ﺑﻪ ﻫﻤﯿﻦ ﻣﻄﺎﻟﻌﺎت ﻧﺸﺎن داد ﮐﻪ ﻧﺸﺎﻧﺪن ﻃﻼ ﺑﺮروي اﻟﮑﺘﺮود ﻃﻼ
و آﺑﮑﺎري ( MAS)ﺧﻮد ﻣﻮﻧﺘﺎژ ﺗﮏ ﻻﯾﻪ روش ، (LBLﻻﯾﻪ ﺑﻪ ﻻﯾﻪ ) رﺳﻮبﻬﺎي روﺷدر اﯾﻦ ﭘﺮوژه دﻟﯿﻞ 
وﻟﺘﺎﻣﺘﺮي ﺑﺎﻋﺚ اﻓﺰاﯾﺶ ﻗﺎﺑﻞ ﻣﺸﺎﻫﺪه در ﭘﯿﮏ ﺑﻪ روش   sPNuA. ﻧﺘﺎﯾﺞ ﻧﺸﺎن داد ﮐﻪ آﺑﮑﺎريﻧﺪﻣﻘﺎﯾﺴﻪ ﺷﺪ
ﺑﻪ اﯾﻦ روش اﺻﻼح ﺷﺪه  ي. اﻟﮑﺘﺮودﻫﺎﻣﯽ ﺑﺨﺸﺪﺑﻬﺒﻮد  را اﻟﮑﺘﺮودﯿﻨﺘﯿﮏ ﺷﺪه و ﺑﺪﯾﻦ ﺗﺮﺗﯿﺐ ﮐ ﺟﺮﯾﺎن
  دادﻧﺪ.ﻧﺸﺎن از ﺧﻮد را ﺑﯿﺸﺘﺮي ﭘﺎﯾﺪاري و ﺗﮑﺮارﭘﺬﯾﺮي ﻫﻤﭽﻨﯿﻦ 
و از ﻃﺮﯾﻖ ﭘﯿﻮﻧﺪ ﮐﻮواﻻﻧﺴﯽ  ﺳﻄﻪاﻮﺑ( XTC) 1ﺗﻠﻮﭘﭙﺘﯿﺪ ﻧﻮع  ـ C و ﮐﻼژن ﮐﺮاس ﻟﯿﻨﮏ )cO( اﺳﺘﺌﻮﮐﻠﺴﯿﻦ
 و ﻏﻠﻈﺘﻬﺎي ﻣﺨﺘﻠﻒ آﻧﺘﯽ ژنﻧﺸﺎﻧﺪه ﺷﺪﻧﺪ   PNuA ﺎي اﺻﻼح ﺷﺪه ﺑاﻟﮑﺘﺮودﻫﺎي ﻃﻼﮐﺮاس ﻟﯿﻨﮑﺮﻫﺎ ﺑﺮروي 
  .ﻫﺎي ﻣﺮﺑﻮﻃﻪ ﺗﻮﺳﻂ آﻧﻬﺎ اﻧﺪازه ﮔﯿﺮي ﺷﺪ
اﻣﺮوزه اﺳﺘﻔﺎده از ﻓﻦ آوري ﻣﯿﮑﺮوﺳﯿﺎﻟﯽ در ﺳﺎﺧﺖ دﺳﺘﮕﺎه ﻫﺎي ﺗﺸﺨﯿﺼﯽ ﻧﻘﻄﻪ ﻣﺮاﻗﺒﺖ و ﺑﺮاي ﻣﺒﺎرزه ﺑﺎ  
اﯾﻦ ﺳﯿﺴﺘﻤﻬﺎ ﻣﺴﺎﺋﻞ ﺑﻬﺪاﺷﺖ ﺟﻬﺎﻧﯽ ﺑﻪ ﻃﻮر ﮔﺴﺘﺮده اي در ﺣﺎل ﺗﻮﺳﻌﻪ ﻣﯽ ﺑﺎﺷﺪ. اﯾﻦ ﺑﻪ دﻟﯿﻞ ﻣﺰاﯾﺎي ﺑﺎﻟﻘﻮه 
ﺳﻄﺢ ﺑﻪ ﺣﺠﻢ، و ﻫﻤﭽﻨﯿﻦ ﺗﻮاﻧﺎﯾﯽ ﺎﻻي ﺷﺎﻣﻞ ﻧﯿﺎز ﺑﻪ ﺣﺠﻢ ﮐﻢ ﻧﻤﻮﻧﻪ و ﻣﻌﺮف، ﺗﻮان و ﺣﺴﺎﺳﯿﺖ ﺑﺎﻻ، ﻧﺴﺒﺖ ﺑ
ﮐﻮﭼﮏ ﺳﺎزي ﻣﯽ ﺑﺎﺷﺪ. ﺑﻪ ﻫﻤﯿﻦ دﻟﯿﻞ در اﯾﻦ ﭘﺮوژه ﺗﺼﻤﯿﻢ ﺑﻪ ادﻏﺎم ﺗﺮاﺷﻪ اﻟﮑﺘﺮوﺷﯿﻤﯿﺎﯾﯽ ﺑﺎ ﺳﯿﺴﺘﻢ 
ﻧﯿﺎز ﺑﻪ ﻓﺮآﯾﻨﺪﻫﺎي ﭘﺎﮐﺴﺎزي ﻣﺘﻌﺪد در  ﻣﯿﮑﺮوﺳﯿﺎﻟﯽ ﺷﺪ. ﺳﺎﺧﺖ ﮐﺎﻧﺎﻟﻬﺎي ﻣﯿﮑﺮوﺳﯿﺎﻟﯽ ﻣﻌﻤﻮﻻ ﭘﺮﻫﺰﯾﻨﻪ ﺑﻮده و
آزﻣﺎﯾﺸﮕﺎه، ﻟﯿﺘﻮﮔﺮاﻓﯽ ﻧﻮري، ﻗﻠﻢ زﻧﯽ و ﯾﺎ ﭘﺨﺖ در ﻣﺤﯿﻂ ﻫﺎي اﺗﺎق ﺗﻤﯿﺰ داﺷﺘﻪ و ﺑﻪ ﻫﻤﯿﻦ دﻟﯿﻞ اﺻﻼح و ﯾﺎ 
ﺗﻐﯿﯿﺮ ﻃﺮح ﻣﻌﻤﻮﻻ دﺷﻮار ﻣﯽ ﺑﺎﺷﺪ. ﻋﻼوه ﺑﺮ اﯾﻦ، ﺑﺴﺘﻦ ﻣﻨﺎﺳﺐ ﻣﺤﻮﻃﻪ ﮐﺎﻧﺎل ﺑﺪون ﺗﻐﯿﯿﺮ ﻃﺮﺣﻬﺎي ﮐﻮﭼﮏ 
ﺪ اﺗﺼﺎل ﭼﺎﻟﺶ ﺑﺮاﻧﮕﯿﺰ اﺳﺖ. ﺑﻨﺎﺑﺮاﯾﻦ ﻣﺎ از ﯾﮏ روش ارزان، ﻗﺎﺑﻞ اﻋﺘﻤﺎد و و ﯾﺎ اﻧﺴﺪاد ﮐﺎﻧﺎل در ﺣﯿﻦ ﻓﺮاﯾﻨ
ﺳﺮﯾﻊ ﺑﺮاي ﺳﺎﺧﺖ ﮐﺎﻧﺎل ﻣﯿﮑﺮوﺳﯿﺎﻟﯽ ﺑﺎ اﺳﺘﻔﺎده از ﻧﻮارﭼﺴﺐ دو ﻃﺮﻓﻪ ﺑﻬﺮه ﺟﺴﺘﯿﻢ. ﺑﺎ ﮐﻤﮏ اﯾﻦ روش ﻧﻪ 
ﺗﻨﻬﺎ ﺳﺎﺧﺖ ﮐﺎﻧﺎل ﺑﺎ اﺑﻌﺎد ﻣﻘﻄﻌﯽ  ﯾﮑﻨﻮاﺧﺖ ﺑﻠﮑﻪ اﻣﮑﺎن اﯾﺠﺎد ﺳﯿﺴﺘﻢ ﻫﺎي ﺗﺮﮐﯿﺒﯽ، ﻣﺘﺸﮑﻞ از ﻻﯾﻪ ﻫﺎي 
  ﺘﻠﻒ، ﺑﺎ ﺗﻮﺟﻪ ﺑﻪ ﭼﺴﺒﻨﺪﮔﯽ ﻣﻨﺎﺳﺐ ﺑﯿﻦ ﻻﯾﻪ ﻫﺎ اﻣﮑﺎن ﭘﺬﯾﺮ ﺑﻮد.ﻣﺨ
ادﻏﺎم ﺷﺪﻧﺪ.  ﻮﮐﯿﺖﺘﺌﻫﺎي ﻣﯿﮑﺮوﺳﯿﺎﻟﯽ ﺑﺮاي ﺳﺎﺧﺖ ﺳﯿﺴﺘﻢ اﺳ ﺳﺎﺧﺘﺎراﻟﮑﺘﺮوﺷﯿﻤﯿﺎﯾﯽ و  ﺗﺮاﺷﻪدر ﻣﺮﺣﻠﻪ آﺧﺮ 
در اﯾﻦ ﭘﻠﺖ ﻓﺮم ﻣﺒﺘﻨﯽ ﺑﺮ واﮐﻨﺶ آﻧﺘﯽ ﺑﺎدي و آﻧﺘﯽ ژن ﮐﻠﯿﻪ ﻣﺮاﺣﻞ ﻣﻌﺮﻓﯽ ﻧﻤﻮﻧﻪ، اﻧﮑﻮﺑﺎﺳﯿﻮن و اﻧﺪازه ﮔﯿﺮي 
ﺷﯿﻤﯿﺎﯾﯽ در ﮐﺎﻧﺎﻟﻬﺎي ﻣﯿﮑﺮوﺳﯿﺎﻟﯽ اﺗﻔﺎق ﻣﯽ اﻓﺘﺎد. اﻟﮑﺘﺮودﻫﺎي ﻃﻼي ﻣﻮﺟﻮد در ﻣﺤﻔﻈﻪ ﻣﯿﮑﺮوﺳﯿﺎﻟﯽ اﻟﮑﺘﺮو
ﻣﯽ دادﻧﺪ  ﺑﺮاي ﻧﺸﺎﻧﺪن آﻧﺘﯽ ﺑﺎدﯾﻬﺎﯾﯽ ﮐﻪ در ﻣﺮاﺣﻞ ﺑﻌﺪي ﺑﺼﻮرت اﻧﺘﺨﺎﺑﯽ ﺑﺎ آﻧﺘﯽ ژن ﻣﺮﺑﻮﻃﻪ واﮐﻨﺶ
ل آﻧﺘﯽ ژن اﺳﺘﻔﺎده در دﻣﺎي اﺗﺎق ﺑﺮاي اﻧﺪازه ﮔﯿﺮي ﻏﻠﻈﺖ ﻣﺤﻠﻮﮐﺮوﻧﻮآﻣﭙﺮوﻣﺘﺮي ﻋﺎﻣﻠﺪار ﺷﺪه ﺑﻮدﻧﺪ. روش 
  ﺷﺪ. 
دﻗﺖ، ﺣﺴﺎﺳﯿﺖ و اﺧﺘﺼﺎﺻﯽ ﺑﻮدن ﻻزم ﺑﺮاي ﺳﻨﺠﺶ ﺳﻄﺢ ﺳﺮﻣﯽ  اﺳﺘﺌﻮﮐﯿﺖ ﻧﺘﺎﯾﺞ ﻧﻬﺎﯾﯽ ﻧﺸﺎن داد ﮐﻪ
  ﻣﻌﺎدل XTCو ﺑﺮاي  1/49Lm/gn را دارد. ﺣﺪ ﭘﺎﯾﯿﻦ ﺗﺸﺨﯿﺺ ﺑﺮاي اﺳﺘﺌﻮﮐﻠﺴﯿﻦ  XTC اﺳﺘﺌﻮﮐﻠﺴﯿﻦ و
ﻣﻮرد  XTC و cO اﻧﺪازه ﮔﯿﺮي ﺳﻄﺢ ﺳﺮﻣﯽ ﻧﺸﺎﻧﮕﺮﻫﺎي ﺑﻮد. اﯾﻦ دﺳﺘﮕﺎه ﻫﻤﭽﻨﯿﻦ ﺑﺮاي 2/77 Lm/gp
ﻣﻘﺎﯾﺴﻪ ﺷﺪ. اﯾﻦ ﻧﺘﺎﯾﺞ ﺣﺎﮐﯽ از ﺗﻄﺎﺑﻖ ﻗﺎﺑﻞ ﻗﺒﻮل  AILCE اﺳﺘﻔﺎده ﻗﺮار ﮔﺮﻓﺖ و ﻧﺘﺎﯾﺞ ﺑﺎ ﻣﻘﺎدﯾﺮ ﺣﺎﺻﻠﻪ از
  ﻣﯿﺎن ﻧﺘﺎﯾﺞ داﺷﺖ.
و ﻣﯽ ﺗﻮاﻧﺪ ﺳﻄﺢ ﺳﺮﻣﯽ  هﺑﻮد اﺧﺘﺼﺎﺻﯽﺣﺴﺎس و ﺳﺮﻣﯽ   cOﺳﺎﺧﺘﻪ ﺷﺪه ﺑﺮاي اﻧﺪازه ﮔﯿﺮي ﻏﻠﻈﺖ ﺳﻨﺴﻮر 
اﯾﻦ ﻣﺮﺟﻊ ﻧﺮﻣﺎل ﮐﻪ ﺑﺎ ﺗﻮﺟﻪ ﺑﻪ  ﻣﯿﻠﯽ ﻟﯿﺘﺮ ﺗﺸﺨﯿﺺ دﻫﺪ/ﻧﺎﻧﻮﮔﺮم 57 -ﺗﺎ 2/5در ﻃﯿﻒ وﺳﯿﻌﯽ از را ﻧﺸﺎﻧﮕﺮ 
 0052ﺎﺗ 1ز ﺑﺎ ﻣﻮﻓﻘﯿﺖ ا XTC ﺑﻪ ﻃﻮر ﻣﺸﺎﺑﻪ، ﺳﻄﺢ. اﺳﺖ ( ﻗﺎﺑﻞ ﻗﺒﻮلﻣﯿﻠﯽ ﻟﯿﺘﺮ/ﻧﺎﻧﻮﮔﺮم 24ﺗﺎ 9)ﻧﺸﺎﻧﮕﺮ 
ﻗﺎﺑﻞ ﻗﺒﻮل اﺳﺖ. از ( Lm/gp 054ﺗﺎ -05ﻗﺎﺑﻞ اﻧﺪازه ﮔﯿﺮي ﺑﻮد ﮐﻪ ﺑﺎ ﺗﻮﺟﻪ ﺑﻪ ﻣﺮﺟﻊ ﻧﺮﻣﺎل ﻧﺸﺎﻧﮕﺮ )  Lm/gp
ﺳﺎﺧﺘﻪ ﺷﺪه ﻫﯿﭻ واﮐﻨﺶ ﻣﺘﻘﺎﻃﻌﯽ ﺑﺮاي ﺳﺎﯾﺮ ﻧﺸﺎﻧﮕﺮﻫﺎ )ﮐﺮاس ﻟﭗ ﺑﺘﺎ و ﻫﻮرﻣﻮن  ، ﺳﻨﺴﻮرﻃﺮف دﯾﮕﺮ
ارﺗﺒﺎط  ( ﻧﺸﺎن ﻧﺪادﻧﺪ.XTCو اﺳﺘﺌﻮﮐﻠﺴﯿﻦ و ﻫﻮرﻣﻮن ﭘﺎراﺗﯿﺮوﺋﯿﺪ ﺑﺮاي ﺳﻨﺴﻮر  cOﭘﺎراﺗﯿﺮوﺋﯿﺪ ﺑﺮاي ﺳﻨﺴﻮر 
ﻧﺸﺎن داد ﮐﻪ ﺑﺮروي ﺳﺮم ﺧﻮن ﺑﯿﻤﺎران  XTCو  cO ﻫﺮ دو ﻧﺸﺎﻧﮕﺮو  AILCE ﻣﯿﺎن ﻧﺘﺎﯾﺞ ﻗﺎﺑﻞ ﻗﺒﻮل
ﻣﻮﻟﮑﻮﻟﻬﺎي ﺳﺎﯾﺮ و ﺑﺎﻟﯿﻨﯽ را داﺷﺘﻪ در ﻣﺤﺪوده ﺧﺘﻪ ﺷﺪه ﻗﺎﺑﻠﯿﺖ اﻧﺪازه ﮔﯿﺮي ﺳﻄﺢ ﺳﺮﻣﯽ ﻧﺸﺎﻧﮕﺮﻫﺎ ﺎﺳﺳﻨﺴﻮر 
ﺑﺎ اﯾﻦ ﺣﺎل، اﯾﻦ واﻗﻌﯿﺖ ﮐﻪ آﻧﺘﯽ ژن ﻗﺎﺑﻞ ﻣﻼﺣﻈﻪ اي اﯾﺠﺎد ﻧﻤﯽ ﮐﻨﻨﺪ. ﯿﺮ ﻧﺘﺎﯾﺞ ﺗﻐﯿدر  ،ﻣﻮﺟﻮد در ﺳﺮم
 ﺑﻮد، در ﺣﺎﻟﯽ ﮐﻪاﻧﺴﺎﻧﯽ ﮐﺎﻣﻞ  در واﻗﻊ ﭘﭙﺘﯿﺪﻣﻨﺤﻨﯽ ﮐﺎﻟﯿﺒﺮاﺳﯿﻮن  رﺳﻢاﺳﺘﻔﺎده ﺑﺮاي ﻣﻮرد اﺳﺘﺌﻮﮐﻠﺴﯿﻦ 
ر ﻃﺮاﺣﯽ ﺷﺪه ﻣﻤﮑﻦ اﺳﺖ ﻧﺘﺎﯾﺞ ﻣﺎ را ﺗﺤﺖ ﺗﺎﺛﯿﺮ ﻗﺮا cO ﻣﯿﺎﻧﯽزﻧﺠﯿﺮه  ﺑﺮاي اﻧﺪازه ﮔﯿﺮي AILCE ﮐﯿﺘﻬﺎي
  داده ﺑﺎﺷﺪ.
اﻧﺪازه ﺳﺎﺧﺘﻪ ﺷﺪه ﺑﺮاي اﻟﮑﺘﺮوﺷﯿﻤﯿﺎﯾﯽ  دﺳﺘﮕﺎهدر ﻣﻘﺎﯾﺴﻪ ﺑﺎ روش ﻫﺎي ﻣﺮﺳﻮم،  ﻣﯽ ﺗﻮان ﻧﺘﯿﺠﻪ ﮔﺮﻓﺖ ﮐﻪ 
ﺑﻮده و از دﯾﮕﺮ ﻣﺰاﯾﺎي اﯾﻦ ﺳﯿﺴﺘﻢ ﺗﺸﺨﯿﺼﯽ ﺳﺎده ﻣﯽ اﻧﺘﺨﺎﺑﯽ و ﺣﺴﺎس  ﭘﯿﺸﻨﻬﺎد ﺷﺪهﻫﺎي ﻧﺸﺎﻧﮕﺮﮔﯿﺮي 
  . ﺎﻻ اﺷﺎره ﻧﻤﻮدو ﺛﺒﺎت ﺑ ﻧﻤﻮﻧﻪﻧﯿﺎز ﺑﻪ ﻣﻘﺪار ﮐﻤﺘﺮ  و ﮐﺎﻫﺶ زﻣﺎن اﻧﺪازه ﮔﯿﺮيﻪ ﺑﺗﻮان 
ﺪه ﺑﺎ اﯾﻦ روش و ﻧﺘﺎﯾﺞ ﻧﺸﺎن دﻫﻨﺪه دﻗﺖ، ﺣﺴﺎﺳﯿﺖ، اﺧﺘﺼﺎﺻﯽ ﺑﻮدن و ﺛﺒﺎت ﺗﺮاﺷﻪ اﻟﮑﺘﺮوﺷﯿﻤﯿﺎﯾﯽ ﺳﺎﺧﺘﻪ ﺷ 
در ﻧﺘﯿﺠﻪ اﻣﮑﺎن اﺳﺘﻔﺎده از آن ﺑﺮاي ﺑﺮﻧﺎﻣﻪ ﻫﺎي ﮐﺎرﺑﺮدي ﺑﺎﻟﯿﻨﯽ در آﯾﻨﺪه ﺑﻮد. ﮐﻞ ﻣﺪت اﻧﺪازه ﮔﯿﺮي ﺑﺮاي اﯾﻦ 
دﻗﯿﻘﻪ اﺳﺖ، اﯾﻦ در  01ﺳﻨﺴﻮر )ﺷﺎﻣﻞ ﺑﺎرﮔﺬاري آﻧﺘﯽ ژن، اﻧﮑﻮﺑﺎﺳﯿﻮن، ﺷﺴﺘﺸﻮ و اﻧﺪازه ﮔﯿﺮي ﻏﻠﻈﺖ( ﺣﺪود 
  .ﺪازه ﮔﯿﺮي ﻧﯿﺎز داردﺑﻪ زﻣﺎن ﺑﯿﺸﺘﺮي ﺑﺮاي اﯾﻦ اﻧ AILCE ﺣﺎﻟﯽ اﺳﺖ ﮐﻪ
. ﻣﯽ ﺑﺎﺷﺪ MTB ﺳﺎﺧﺘﻪ ﺷﺪه ﺑﺮاي اﻧﺪازه ﮔﯿﺮيﻣﯿﮑﺮوﺳﯿﺎﻟﯽ ، اﯾﻦ اوﻟﯿﻦ دﺳﺘﮕﺎه ﺑﺎ ﺗﻮﺟﻪ ﺑﻪ ﻣﻄﺎﻟﻌﺎت ﻣﺎ
ﺑﺮاي اﻧﺪازه ﮔﯿﺮي اﯾﻦ ﻧﺸﺎﻧﮕﺮﻫﺎ در ﻗﺎﺑﻞ ﻗﺒﻮل اﺳﺘﺌﻮﮐﯿﺖ  ﺣﺴﺎﺳﯿﺖدﻫﻨﺪه ﻧﺸﺎن ﻣﻮﺟﻮد ﻫﻤﭽﻨﯿﻦ ﻧﺘﺎﯾﺞ 
 اﯾﻦ ﮐﺎر، ﺗﻨﻬﺎ دو و اﻟﮑﺘﺮوﮐﻤﯿﻠﻮﻣﯿﻨﺴﺎﻧﺲ ﻣﯽ ﺑﺎﺷﺪ. در ASILE ﻣﻘﺎﯾﺴﻪ ﺑﺎ روﺷﻬﺎي ﻣﺮﺳﻮم ﻣﻮرد اﺳﺘﻔﺎده ﯾﻌﻨﯽ
ﺳﺎﯾﺮ ﻧﺸﺎﻧﮕﺮﻫﺎي  ﺳﺎﺧﺘﻪ ﺷﺪه ﻗﺎﺑﻠﯿﺖ اﺳﺘﻔﺎده ﺑﺮاي اﻧﺪازه ﮔﯿﺮيﻣﻮرد ﻣﻄﺎﻟﻌﻪ ﻗﺮار ﮔﺮﻓﺘﻨﺪ اﻣﺎ ﺳﯿﺴﺘﻢ  MTB
ﻧﺸﺎن ﻣﯽ دﻫﺪ ﮐﻪ ﺳﯿﺴﺘﻢ ﺳﺎﺧﺘﻪ ﺷﺪه اﻣﺎ ﺑﺨﺸﯽ داﺷﺘﻪ . اﯾﻦ ﻧﺘﺎﯾﺞ ﻧﯿﺎز ﺑﻪ اﻋﺘﺒﺎر را ﻧﯿﺰ دارا ﻣﯽ ﺑﺎﺷﺪ زﯾﺴﺘﯽ
  .ﺤﻘﯿﻘﺎت در ﺳﺎﺧﺖ دﺳﺘﮕﺎه ﻫﺎي ﺗﺸﺨﯿﺼﯽ ﺑﺮاي ﺑﯿﻮﻣﺎرﮐﺮﻫﺎ ﻣﯽ ﺑﺎﺷﺪﻫﻤﺮاﺳﺘﺎ ﺑﺎ ﺗ

Samenvatting
Diagnose van osteoporose wordt hedendaags gedaan op basis van metingen van
de mineraaldichtheid van beenderen “bone mineral density“ (BMD), deze me-
thode heeft echter beperkingen. Er wordt aangenomen dat “bone turnover mar-
kers“ (BTM) kunnen helpen bij het detecteren van osteoporose. Hoewel het ge-
bruik van BTMs in het diagnosticeren van osteoporose verschillende voordelen
heeft over BMD, niet alleen in het monitoren van de behandeling maar ook in
het identificeren van risico’s, blijft de diagnostische waarde in het voorspellen
van osteoporose laag, en dus worden er verschillende BTMs gebruikt op het-
zelfde moment wat leidt tot een hogere nauwkeurigheid en een lagere variantie
om deze limitatie te overwinnen.
Ondanks recente vooruitgang in proteomics en gepersonaliseerde geneeskunde
blijven beschikbare technologieën voor BTM metingen, namelijk enzyme-linked
immunosorbent assays (ELISA) en elektrochemiluminescentie (ECLIA), tijdro-
vend en arbeidsintensief, ze vereisen ook speciale labels, dure instrumenten. Met
deze duidelijke beperkingen, is de focus van gezondheid gerelateerde studies
verschoven naar de ontwikkeling van draagbare, herbruikbare en multiplex, vrij
van labels, Point-of-Care (PoC) biosensoren vooral voor het diagnosticeren en
monitoren van verscheidene ziektes.
Er is dus een groeiende vraag naar het ontwikkelen van verschillende types bio-
sensoren die geminiaturiseerde platformen aanbieden om het remodelleringspro-
ces van beenderen beter weer te geven. Voor zover wij weten, is er geen enkele
bestaande biosensor die slaagt op dit vlak.
Een efficiënte biosensor is sterk afhankelijk van selectieve binding van het her-
kenningselement met de doel analyten en de transducer voor het signaleren van
de binding in termen van responsietijd, signaal-ruisverhouding “signal-to-noise
ratio“ (S/N) en detectiegrenzen “limits of detection“ (LoD).
In deze studie, melden wij een microfluïdisch proteomics platform dat gemak-
kelijk gebruikt kan worden voor de diagnose van biomarkers. Dit platform inte-
greert microfluïdische technologie met elektrochemische detectie en belichaamt
een reactie/detectie kamer die serumniveaus van verschillende biomarkers kan
opmeten. Het unieke ontwerp van dit platform biedt de mogelijkheid voor gro-
tere gevoeligheid omdat zowel de microfluïdische als elektrochemische structu-
ren onafhankelijk van elkaar geoptimaliseerd kunnen worden.
Als eerste stap, door de inherente interactie tussen gouden nanodeeltjes (AuNPs)
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en antilichamen, werd een nieuwe gouden nanoprobe ontwikkeld voor gebruik
in niet-enzymatische elektrochemische immuno-assays. Deze één-pot methode
biedt niet alleen een eenvoudige methode voor het voorzien van een hooge ge-
halte van antilichaamen aan de nanodeeltjes maar verbeterd ook aanzienlijk de
herhaalbaarheid en controleerbaarheid van de nanoprobe voorbereiding. Met an-
dere woorden, door het gebruiken van deze nanoprobe kan een hoge through-
put methode (single/multiplex sensors) ontwikkeld worden om verschillende en
grote hoeveelheden keuze markers te screenen.
De volgende stap was de immobilisatie van de probe op het elektrodeoppervlak
met behoud van zowel de structuur en functionaliteit van de antilichamen. De
afzetting van gouden nanodeeltjes (AuNPs) op het oppervlak van de gouden
electrode zorgt voor betere elektrochemische eigenschappen van het oppervlak.
Met andere woorden, de hoge signaal-ruisverhouding verbeterd de miniaturisa-
tie van de sensor-elementen, terwijl het oppervlak, dat hoge specificiteit vertoont,
ideaal is om het signaal antwoord te versterken. Volgens bestaande literatuur kan
dit gebeuren op verscheidene manieren. Wij vergeleken de laag per laag “layer-
by-layer“ depositie, self-assembled monolayer techniek en elektrodepositie me-
thoden. Onze resultaten toonden aan dat cyclische voltammetrie elektrodepositie
van AuNPs zorgen voor een observeerbare toename in de piekstroom, waardoor
de elektrode-kinetiek verbeterd. Deze gemodificeerde elektroden toonde ook een
aantal voordelen met betrekking tot stabiliteit en reproduceerbaarheid.
Osteocalcine (Oc) en collageen type 1 cross-linked C-telopeptide (CTX) werden
vervolgens covalent geïmmobiliseerd op de AuNP gemodificeerde gouden elek-
trodes door crosslinkers en verschillende concentraties van overeenkomstig anti-
geen werden aangebracht voor directe bepaling.
Tegenwoordig worden microfluïdische technologieën op grote schaal gebruikt in
het ontwikkelen van point-of-care diagnostiek om globale gezondheidsaspecten
aan te kaarten omwille van hun potentiële voordelen van lage sample en rea-
gens consumptie, hoge throughput en gevoeligheid, groot oppervlak-volume ra-
tio en andere voordelen gerelateerd met miniaturisatie. Om deze redenen beslo-
ten wij onze elektrochemische chip te integreren in een microfluidïsch systeem.
Het maken van microfluidïsche kanalen is meestal kostelijk en vergt laboratium-
intensieve schoonmaking, fotolithographie en etching of baking stappen in cle-
anroom omgeving, wat het moeilijk maakt om dit proces te modificeren. Ook is
het voldoende insluiten van de kanalen zonder het vervormen van de kleinere
features of zonder het verstoppen van de kanalen gedurende het bonding pro-
ces een hele uitdaging. Daarom hebben wij een goedkope, betrouwbare en snelle
methode ontworpen om microfluidïsche kanalen te maken gebruik makend van
dubbelzijdige tapes, wat het mogelijk maakt om niet alleen de doorsnede hoog
uniform te houden over het gehele kanaal maar ook voldoende hechting geeft
voor hybride systemen, bestaande uit verschillende lagen.
Daarna werden de elektrochemische sensor en de microfluidïsche chips geïnte-
greerd om een osteokit systeem te ontwikkelen. De sensing-interface fabrica-
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tie, sample incubatie en elektrochemische detectie in dit antilichaam-antigeen-
gebaseerd platform zijn allemaal uitgevoerd d.m.v. het gebruik van microfluid-
ïsche kanalen. Microgefrabiceerde Au electrodes, die in een microfluidïsche ka-
mer waren ingebracht, werden gefunctionaliseerd om antilichamen te immobili-
seren, die op hun beurt selectief de overeenkomstige antigenen vastleggen. Chro-
noamperometrische technieken op kamertemperatuur werden gebruikt om de
concentratie van antigeen-oplossingen op te meten. De omvang van de respons
stroom varieerde lineair met de logaritmische concentratie van de relatieve bio-
marker, en werd dus gebruikt om de concentratie van de relatieve biomarker in
de serum samples te kwantificeren.
We hebben de implementatie, haalbaarheid en specificiteit van dit platform (Os-
teokit) aangetoond door het meten van serum niveaus van Oc en CTX. De de-
tectie limiet van Oc was 1.94 ng/mL, waar die van CTX 2.77 pg/mL was. Het
toestel werd ook gebruikt om de serum niveaus van Oc en CTX op te meten en
de resultaten werden vergeleken met dat van ECLIA, waarvan het resultaat aan-
vaardbare gelijkenis toonde.
De ontwikkelde sensor was gevoelig en specifiek voor serum Oc en kan serumni-
veaus van demarker detectereen in een bereik van 2.5 tot 100 ng/mL. De normale
referentie van de marker is 9 tot 42 ng/mL, wat suggereert dat de sensor OC kan
detecteren. Op een gelijkaardige manier als hierboven beschreven werden CTX
niveaus succesvol gemeten in een bereik van 1 tot 2500 pg/mL. Dit is terwijl de
normale referentie van de marker 50 tot 450 pg/mL is, wat aantoont dat de sen-
sor CTX op een acceptabele manier kan detecteren.
Onze sensor vertoonde geen kruisreactiviteit voor andere biomarkers (voor b-
CrossLaps en parathyroïd hormoon (PTH) in Oc sensor en voor Oc en PTH in
CTX sensor). De goede correlatie tussen ECLIA en Osteokit toont aan dat onze
sensor gebruikt kan worden in een klinisch relevant bereik en dat andere macro-
molecules in het serum onze resultaten niet verstoren. Het feit dat Oc antigeen,
dat gebruikt werd om onze calibratie curve op te stellen, een volle lengte proteïne
is, terwijl ECLIA ontwikkeld werd om N-mid Oc op te meten, kan onze resulta-
ten beïnvloed hebben.
De ontwikkelde elektrochemische chips toonden hoge gevoeligheid, specificiteit,
stabiliteit en betrouwbaarheid, wat veelbelovend is voor klinische toepassingen.
De totale responsietijd van de sensor is ongeveer 10 minuten (belading van anti-
geen, incubatietijd, spoelen met PBS en testen), terwijl ECLIA enkele uren duurt.
Er werd geconcludeerd dat in vergelijking met conventionele methodes de elek-
trochemische sensor de voorgestelde marker kan detecteren met hoge selectivi-
teit, gevoeligheid, gereduceerde interferentie, korte meet-tijd, nood aan minder
samples en een beter stabiliteit in een eenvoudig detectie systeem.
Voor zover wij weten, is dit het eerste toestel dat gefabriceerd werd om BTMs te
meten. Onze resultaten toonden aan dat de gevoeligheid van Osteokit vergelijk-
baar zijn met de “state-of-art“-methodes van dit moment, ELISA en elektroche-
miluminescentie. Slechts twee belangrijke BTMs zijn onderzocht in deze studie,
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maar het detectie systeem kan gemakkelijk aangepast worden voor andere bio-
markers in de toekomst. Deze resultaten hebben verdere validatie nodig maar
kunnen wijzen op de richting waarin het veld van de diagnostische biomarkers
evolueert.
Summary
Osteoporosis diagnosis, which is nowadays generally made based on bone min-
eral density (BMD) measurements, suffers from certain limitations. Thus it is
believed that bone turnover markers (BTMs) can help improve osteoporosis de-
tection. While the use of BTMs in osteoporosis diagnosis has certain advantages
over BMD and clinical risk assessment tools, not only in monitoring treatment
but also in identifying those at-risk, the diagnostic value of BTMs in predicting
osteoporosis is low, and thus several BTMs are used at the same time with higher
accuracy and lower variability to overcome this limitation.
Despite recent advancements in proteomics and personalized medicine, avail-
able technologies for BTM measurement, enzyme-linked immunosorbent assays
(ELISA) and electrochemiluminescence (ECLIA), are time consuming, laborious,
require special labels and expensive instruments. With these apparent limita-
tions, the focus of health-related studies has shifted towards the development of
portable, reusable and at the same time multiplex, label-free Point-of-Care (PoC)
biosensors particularly for diagnosis and monitoring of different diseases. Also
known as on-the-spot diagnostic devices, these PoC biosensors should be simple,
sensitive, rapid, specific, cheap, and easy to interpret.
Thus, there is a growing demand to fabricate different types of biosensors to pro-
vide low cost miniaturized platforms to assess bone remodeling process more
accurately. To our knowledge, none of the existing bone biosensors have suc-
ceeded in this regard.
An efficient biosensor relies heavily on selective/specific binding of the recogni-
tion element with the target analytes as well as the transducer for signaling the
binding event in terms of response time, signal-to-noise (S/N) ratio, and limits of
detection (LoD).
In this work, we report a microfluidic proteomic platform that can easily be trans-
lated into a biomarker diagnostic. This platform integrates microfluidic technol-
ogy with electrochemical sensing and embodies a reaction/detection chamber to
measure serum levels of different biomarkers. The unique design of the platform
offers the potential for greater sensitivity as the microfluidic and electrochemical
structures can be independently optimized.
As the first step, through the inherent interaction between gold nanoparticles
(AuNPs) and antibody biomolecules, a novel gold nanoprobe was developed
to be used in the non-enzymatic electrochemical immunoassay. This one-pot
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method not only provides a simple method for loading high-content antibody
on nanoparticles but also greatly improves the repeatability and controllability of
the nanoprobe preparation. Combined with a disposable electrode, it could be
used for a single/multiplexed electrochemical immunosensing method. In other
words, using this nanoprobe, high throughput instrumentation applying (sin-
gle/multiplexed sensors) could be developed to screen a variety and vast quan-
tities of samples for choice markers.
The next step was the immobilization of this probe on the electrode surface while
saving the structure and functionalization of the antibodies. The deposition of
gold nanoparticles (AuNPs) on the surface of gold electrode is believed to en-
hance the electrochemical characteristics of the surface. In other words, their high
signal to noise ratio improves miniaturization of the sensor elements, whereas
their high surface area makes them ideal for amplifying the signal response.
According to the existing literature, this could be performed in various ways.
We thus compared the layer-by-layer deposition, self-assembled monolayer tech-
nique and electrodeposition methods. Our results showed that cyclic voltamme-
try electrodeposition of AuNPs causes an observable increase in the peak current,
causing improved electrode kinetics. These modified electrodes also showed sev-
eral advantages with respect to stability and reproducibility.
Osteocalcin (Oc) and collagen type 1 cross-linked C-telopeptide (CTX) were then
covalently immobilized on the AuNP-modified gold electrodes by cross linkers
and different concentrations of corresponding antigens were applied for direct
determination.
As nowadays, microfluidic technologies are widely employed in developing
point-of-care diagnostics to address global health issues because of their poten-
tial advantages of low sample and reagent consumption, high throughput and
sensitivity, large surface-to-volume ratio, and other benefits related to miniatur-
ization, we decided to integrate our electrochemical chip into a microfluidic sys-
tem. The fabrication of microfluidic channels is commonly costly and requires
laboratory-intensive cleaning, photolithography, and etching or baking steps in
cleanroom environments, making it difficult to modify. Besides, proper channel
enclosure without deforming small features or without clogging of the channel
during the bonding process is challenging. We therefore developed a cheap, reli-
able and rapid method for the fabrication of microfluidic channels using double-
sided tapes, enabling not only highly uniform cross-sectional dimensions along
the channels but also proper adhesion in hybrid systems, composed of different
layers.
As the last step, the electrochemical ssystem and the microfluidic chips were in-
tegrated to develop the Osteokit system. The sensing interface fabrication, sam-
ple incubation, and electrochemical detection in this antibody-antigen-based plat-
form were all performed using microfluidic channels. Microfabricated Au elec-
trodes encased in a microfluidic chamber were functionalized to immobilize the
antibodies, which can selectively capture the corresponding antigen. Chronoam-
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perometry technique at room temperature was used tomeasure the concentration
of the antigen solutions. The magnitude of the response current varied linearly
with the logarithmic concentration of the relative biomarker, and thus was used
to quantify the concentration of the relative biomarker in serum samples.
We demonstrated the implementation, feasibility and specificity of this platform
(Osteokit) in assaying serum levels of Oc and CTX. The detection limit of Oc was
1.94 ng/mL, whereas that of CTX was 2.77 pg/mL. The device was also used to
measure serum levels of the both Oc and CTX and the results were compared to
that of ECLIA. The results of which showed acceptable concordance.
The developed system was sensitive and specific for serum Oc and could detect
serum levels of the marker within the range of 2.5 - 100 ng/mL. This is while the
normal reference of the marker is 9 - 42 ng/mL, suggesting that the system can
acceptably detect Oc. Similarly, CTX levels were successfully measured from 1 -
2500 pg/mL. This is while the normal reference of the marker is 50-450 pg/mL,
suggesting that the system can acceptably detect CTX.
Our system showed no cross-reactivity for other biomarkers (b-CrossLaps and
parathyroid hormone (PTH) for Oc system and Oc and PTH for CTX system).
The good correlation between the ECLIA and Osteokit showed that they can be
used in the clinically relevant range and other macromolecules available in serum
do not affect our results. However, the fact that the Oc antigen used to develop
our calibration curve was a full-length protein, while ECLIA was designed to
measure N-mid Oc may have affected our results.
The developed electrochemical chips showed ultrahigh sensitivity, specificity, sta-
bility and reliability, thus providing a highly promising potential for clinical ap-
plications. The total assay time for this system is about 10 min (loading of anti-
gen, incubation time, flushing with PBS and testing), while ECLIA needs several
hours to be performed.
It was concluded that compared to conventional methods, the proposed electro-
chemical device resulted in selective and sensitive measurement of the proposed
BTM levels with reduced interference reactions, reducedmeasurement time, need
for less amount of sample and better stability in a simplified detection system.
To our knowledge, this is the first such device fabricated to measure BTMs. Our
results also showed the sensitivity of Osteokit to be comparable with the current
state of art, ELISA and electrochemiluminescence. In this work, only two ma-
jor BTMs were studied, but the assay system could easily be adapted to other
biomarkers in future experiments. These results require further validation but
may suggest a direction towards which the field of diagnostic biomarkers is mov-
ing.

1
Introduction
1.1 Importance of Point-of-Care Testing in Osteoporo-
sis Management
1.1.1 The Concept of Bone Remodeling
Bone is a dynamically and metabolically active organ that is continuously sub-
jected to resorption and formation by the coordinated action of the two different
categories of bone cells, namely osteoclasts (cells responsible for resorbing bone),
and osteoblasts (cells responsible for building bone) and their descendants osteo-
cytes. These two processes are collectively called bone turnover or bone remod-
eling and they are coupled in time and space [1]. (Figure 1.1) After middle age,
bone loss occurs as resorption exceeds formation. This process is also known as
osteoporosis [2].
1.1.2 What is Osteoporosis?
Osteoporosis, literally meaning ’porous bone’, is the most frequently found
metabolic bone disease. (Figure 1.2) The systemic skeletal disease is character-
ized by
￿ Low bone mass
￿ Micro-architectural deterioration of the bone
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(a) (b)
Figure 1.1: a) Formation and resorption status leading to stable bone mass. b)
Formation and resorption status leading to bone loss.
Figure 1.2: Healthy (L) and osteoporotic (R) bone (Same scale).
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￿ Increased bone fragility and fracture risk
Osteoporosis has been operationally defined on the basis of bone mineral density
(BMD) assessment. Using the operational definition of the World Health Organi-
zation (WHO) based on BMD measurement at the spine, hip or forearm by Dual
X-ray absorptiometry (DXA) devices [3]:
￿ Normal: BMD lies within 1 standard deviation (SD) of the average value
for young healthy adult (T-score at -1.0 and above).
￿ Low bone mass (“osteopenia”): BMD lies between 1.0 and 2.5 SD below
that of the average value for young healthy adult (T-score between -1.0 and
-2.5).
￿ Osteoporosis: BMD lies 2.5 SD or more below that of the average value for
young healthy adult (T-score at or below -2.5).
Epidemiology of Osteoporosis
Osteoporosis is a multifactorial systemic disease that affects a large number of
people in different parts of the world. (Figure 1.3) It is more prevalent than breast
and prostate cancer, which are considered as the most common tumors in each
gender.
Osteoporosis is currently considered as a serious global public health concern,
with over 200 million people suffering from the disease worldwide. According to
the WHO criteria, osteoporosis affects 30% of postmenopausal white women in
the US (9.4 million women) [4].
The prevalence of osteoporosis in the EU is estimated at 27.6 million in 2010 [5].
In Belgium, 120,695 men aged over 50 (6.5%) and 476,875 women of the same age
group (22.4%) were reported to suffer from osteoporosis in 2010.
Latest figures show that 25,969,046 and 3,024,798 Iranians suffer from osteopenia
and osteoporosis, adding that the rate would experience a rapid surge and reach
40,303,730 and 3,592,708 by 2020 [6]. (Figure 1.4)
Osteoporosis Risk Factors
Despite the common misperception that osteoporosis is always the result of bone
loss due to aging, reports have shown that failing to reach optimal (i.e., peak)
bone mass during childhood and adolescence may result in osteoporosis in the
absence of accelerated bone loss [7]. Hence sub-optimal bone growth in child-
hood and adolescence is as important as bone loss due to the development of
osteoporosis.
A number of factors can increase the likelihood of developing osteoporosis; these
factors are divided into two main groups: (Table 1.1)
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Figure 1.3: Worldwide risk of developing osteoporosis in different decades.
Table 1.1: Risk factors attributed to osteoporosis
Major Risk Factors Minor Risk Factors
Age ≥ 65 years Rheumatoid arthritis
Family history of osteoporotic
fracture
Past history of clinical hyperthy-
roidism
Fragility fracture after age 40 Chronic anticonvulsant therapy
Vertebral compression fracture Low dietary calcium intake
Apparent osteopenia on X-ray film Smoking
Malabsorption syndrome Excessive alcohol intake
Primary hyperparathyroidism Excessive caffeine intake
Propensity to fall Weight < 57 kg
Systemic glucocorticoid therapy
for > 3 months
Weight loss > 10% of weight at
age 25
Hypogonadism Chronic heparin therapy
Early menopause (before age 45)
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Figure 1.4: Number of Iranians suffering from different degrees of bone loss.
Complications of Osteoporosis
Osteoporosis is often called a ’silent disease’ as bone loss occurs without any
symptoms. The affected individual, therefore, would not become aware of hav-
ing the condition until his/her bones become so weak that a sudden strain or fall
causes fracture or vertebral collapse.The end-stage of osteoporosis and its ma-
jor complication, fracture, is associated with diminished life-quality, shortened
life-span and heavy health care costs [8]. In addition to morbidity, osteoporotic
fractures also increase mortality risk in affected patients [9].
After the age of 50, nearly 40% of women and 13% of men in western countries
will sustain a fragility fracture [4]. (Figure 1.5)This is while fractures, particularly
hip fractures, impose a heavy burden on a country’s healthcare system. Health-
care expenditure attributed to osteoporotic fractures in the US in 1995 was esti-
mated to be USD 13.8 billion [10].
A study conducted by Hernlund et al showed that hip fractures only account for
17% of all osteoporotic fractures in Europe in 2013 but comprise 54% of the direct
cost of fracture [5]. In Belgium, with 10 million inhabitants, 13,150 hospital stays
per year for hip fractures have generated an annual cost of 118,047,194 USD [11].
Iran accounts for 0.85% of the global burden of hip fractures and 12.4% of the
burden of hip fractures in the Middle East [13]. Based on existing reports, a large
6 Introduction
(a)
(b)
Figure 1.5: a) Hip fracture world map b) Iran and Belgium have a high risk for
hip fracture in both genders.
adopted from International Osteoporosis Foundation (IOF) Map[12]
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number of the Iranian population, mainly elderly, experience at least one fracture
in their life [14]. About 472.1 fractures per 100,000 (individuals aged more than
50) population occur in the country [15] [16].
1.1.3 Osteoporosis Detection Techniques
Assessment of the bone micro-architecture requires bone biopsy, which is inva-
sive and thus not routinely used in clinical practice. Therefore, BMD assessment
remains the gold standard to diagnose osteoporosis.
Dual-energy X-ray absorptiometry (DXA)
Dual energy x-ray absorptiometry (DXA) is the widely available noninvasive
method for assessing BMD with the aim of identifying individuals with osteo-
porosis and, possibly, those at- risk for fracture [17][18]. (Figure 1.6)
DXA Setbacks Although osteoporosis is one of the strongest risk factors for
fracture, only about half of the fractures occur in women with BMD values lower
than the diagnostic threshold for the disease. This is mainly because previous
studies have shown that BMD can only detect osteoporosis when a large amount
of bone is lost [19].
In other words, BMD represents one important, but not exclusive, dimension
of bone strength and therefore can provide an estimation of the likelihood of a
future fracture. Moreover, DXA is incapable of assessing bone quality, which
consists of its micro- and macro-architecture and turnover, and its results depend
on many factors such as the presence of lumbar osteoarthritis [20].
On the other hand, while BMD changes are considered as a valid end point for
verifying the efficacy of osteoporosis treatments, BMD changes and fracture risk
reduction rate following medication is not measurable at early stages [21]. It
takes more than two years for DXA to be able to detect changes in bone mass
and thus possible response to treatment [22].
In addition, there have been major advances in the number and range of agents
available for osteoporosis treatment, all with proven anti-fracture efficacy [23].
These agents have differing modes of action in protecting against fracture and
these need to be taken into account when developing monitoring strategies.
Ideally, only those individuals who are at high risk of sustaining a fracture
should receive anabolic or anti-resorptive medication and treatment should be
targeted on the basis of risk assessment rather than the BMDmeasurement alone.
Furthermore, BMD alone is incapable of diagnosing patients suffering from
secondary osteoporosis, caused by certain underlying medical conditions or
the use of medications that may cause bone loss [7]. In other words, bone loss
could be secondary to an increase in bone resorption (due to postmenopausal
state, secondary hyperparathyroidism, high inflammatory status, ...) or de-
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Figure 1.6: Dual-energy X-ray absorptiometry (DXA) device.
crease in bone formation (due to steroid use, adynamic bone disorders due to
hypoparathyroidism and/or vit-D deficiency etc.). Osteoporosis management
in these patients is therefore based on the treatment of the underlying cause
and mostly requires additional measurement of certain markers including bone
turnover markers (BTMs).
Other Imaging Modalities
Quantitative computerized tomography (QCT) QCT measures volumetric
bone density of the spine and hip and analyzes cortical and trabecular bone sep-
arately [24].
It is however not recommended for screening (application of T-scores to predict
the risk of fracture has not been validated with QCT). Moreover, it is more costly
and results in greater exposure to radiation than DXA.
Peripheral measurements The most commonly used techniques in this cate-
gory are the following, all of which have their pros and cons [25]:
￿ Ultrasonography
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￿ Peripheral Dual-energy X-ray Absorptiometry (pDXA)
￿ Peripheral Quantitative Computed Tomography (pQCT) of the heel, radius,
or hand
￿ High-Resolution Peripheral Quantitative Computed Tomography (HR-
pQCT), which provides a virtual biopsy of the bone
Fracture Risk Assessment Tool (FRAX)
In an attempt to better estimate fracture risk even when BMDmeasurement is not
available, WHO developed the FRAX tool, which can calculate the 10-year proba-
bility of osteoporotic fracture based on clinical risk factors [26]. The introduction
of the multivariate algorithm-based fracture risk assessment tool has evolved the
definition of the disease and based the treatment decisions on absolute risk of
fracture threshold. The application of the tool in clinical practice has resulted in
a higher positive predictive value (PPV), reduced number of individuals needed
to be treated to prevent one fracture and more importantly enhanced sensitivity
[27].
There are, however, a number of general and methodology-specific limitations
for FRAX, as the tool only evaluates nine of the many risk factors related to os-
teoporosis and more importantly does not consider all the medications which
influence fracture risk. Moreover, in this model, risk factors are quantified in a
binary approach.
QFracture and Garvan are among other existing fracture risk assessment tools
[28]. QFracture includes a larger number and wider variety of clinical risk factors
compared with FRAX and GARVAN, and is reported to be more accurate than
them. This is while FRAX is considered as the most validated instrument.
1.1.4 Early Diagnosis in Osteoporosis Detection
Osteoporosis, once thought to be a natural part of ageing among women, is no
longer considered age or gender-dependent. It is largely preventable due to the
remarkable progress in the scientific understanding of its causes, diagnosis, and
treatment [29]. Optimization of bone health is a process that must occur through-
out the lifespan in both males and females. Factors that influence bone health at
all ages are essential to prevent osteoporosis and its consequences [30].
Many osteoporosis guidelines recommend intervention to be considered for men
and women who have sustained a fragility fracture, stressing that these individ-
uals are at increased risk of a second fracture [31].
Despite recent advances in diagnosis of osteoporosis, assessment of fracture risk,
development of interventions that reduce risk of fractures, and the development
of practical guidelines, surveys indicate that only a minority of men and women
at high fracture risk actually receive treatment [32]. Recent statistics show that
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less than 20% of patients who sustain a fragility fracture receive therapies to re-
duce the risk of future fracture within the year following the fracture [33]. The
therapeutic care gap is even wider in the elderly in whom the importance and
impact of treatment is well-known. Studies have shown that as few as 10% of
older women with fragility fractures receive any osteoporosis therapy (estrogens
not considered) [31].
Many studies therefore have expressed the importance of prevention and there-
fore early detection before any fracture has happened in reducing the burden of
the disease [9]. According to these studies, in view of the fact that the restoration
of diminished bone volume seems quite difficult, early diagnosis of osteoporosis
is the most valuable strategy for preventing osteoporotic fractures.
Early diagnosis can help to not only identify those who would benefit from inter-
vention but also determine the optimal manner in which response to treatment
should be monitored.
1.2 Current Work
1.2.1 Application field of current work
Current trends towards theranostics and provision of personalized diagnostic
therapy tailored to an individual has emphasized the need for inexpensive point-
of-care (PoC) devices, capable of performing rapid analysis, with small volumes
of sample, minimum number of assay steps, and no need for highly skilled per-
sonnel for routine check up and patient screening. PoC diagnostics are analytical
testing platforms that can be used both in a clinical laboratory and in the vicinity
of a patient using portable equipment [34].
Therefore, the entire clinical diagnosis and treatment community is witnessing
a paradigm shift from conventional diagnostic devices to the miniaturized and
PoC devices [35]. These devices can fulfill the increasing demand of the medical
sector for fully automated instruments that can directly use unprocessed speci-
mens and that require minimal electronic or mechanical maintenance [36].
PoC diagnostics have the potential to provide rapid and accurate results, at rea-
sonable costs. An ideal diagnostic device should provide a suitable environ-
ment for interaction of the analyte to be tested in a given sample with the bio-
recognition molecule (e.g.protein, lipid, nucleic acid, whole cell), which is immo-
bilized onto the sensor surface.
PoC diagnostics are critically dependent on the combination of the analytical
tools and the rapidly emerging knowledge on molecular biomarkers. They can
be used to identify both physiological and biological entities associated with dis-
eases, and have evolved from simple single physiological parameters to novel
markers that span fields from genomics to metabolomics.
As mentioned above, the restoration of diminished bone volume seems difficult
to achieve and thus early diagnosis of osteoporosis is the most valuable strategy
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for preventing osteoporotic fractures. Prevention of fracture starts by early identi-
fication of fracture prone individuals [37]. However, the prediction of rapid bone
loss, incidence of osteoporosis, and osteoporotic fracture remains difficult. The
identification of individuals who would best benefit from intervention and for
those on treatment, the optimal manner in which response to treatment should
be monitored are therefore important gaps in the clinical armamentarium in os-
teoporosis management.
Recent studies have pointed out the importance of BTMs in this regard [38]. BTMs
are bone tissue proteins or their fragments/enzymes released from bone cells
during bone turnover.
Bone remodeling rate therefore can be assessed by measuring BTMs in serum or
urine. A more detailed explanation of BTMs and their characteristics could be
found in Chapter 3. Biochemical markers of bone turnover have been investi-
gated in osteoporosis for three main purposes:
￿ to monitor anabolic or anti-resorptive therapy
￿ to predict potential bone loss and the risk of developing osteoporosis
￿ to improve assessment of fracture risk in individuals
Although BTMs have shown clinically interesting associations with the rate of
bone loss, the routine use of BTMs in clinical practice is not generally recom-
mended, as these tests vary in sensitivity and specificity and their appropriate
role in patient management is not yet known [39].
This is while Enzyme-Linked Immunosorbent Assay (ELISA), Electrochemilumi-
nescence immunoassay (ECLIA) and other prevailing laboratory techniques in
the current state of the art for biomarker quantification do not lend themselves
well to miniaturized automated systems for application at PoC [40]. Moreover,
they are time consuming, expensive, labor intensive, require highly trained per-
sonnel and lack consistency in laboratory accuracy. Thus performing rapid mul-
tiplexed measurements to monitor several biochemical parameters at the same
time to reach a rapid and accurate medical decision still remains a largely unmet
challenge.
Biosensors on the other hand can help determine reaction kinetics of marker in-
teraction in real-time. The technique needs only one step (reaction) and can thus
be used for point of care screening. As a result, several biosensors were devel-
oped during the past years to improve measurement of some of these markers,
none of them are routinely used in practice. Detailed explanation of these sensors
is discussed in Chapter 3.
In this context, multiplexed detection of different biomarkers integrated with mi-
crofluidic systems has potential to play a very influential role in diagnostics; and
advances in microfluidics, arrays, sensors, and naomaterials have paved the way
for the development of lab-on-a-chip instruments [41]. Microfluidics is an ex-
tremely attractive technology because of its ability to manipulate small volumes
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of fluid (micro- to nanoliters) within given spatial dimensions, and the ease of
multiplexing and integrating this system into low-cost,compact and portable de-
vices for on-chip testing [42]. It, therefore, provides a very promising way to
miniaturize immunoassays, which has played an important role in the diagnosis
of different diseases in the past 50 years. Such devices also provide added benefits
such as portability, increased reliability, improved sensitivity, decreased analysis
time, minimal reagent consumption and parallel processing [43][44]. Among dif-
ferent techniques used to generate a signal in these platforms, the electrochemical
method has shown the most suitable results because of its simple instrumenta-
tion and easy signal quantification [45]. A clear challenge resides in the integra-
tion and operation of such microfluidic platforms for measurement of different
biomarkers, such as BTMs.
In this thesis, we describe a microfluidic proteomic platform that can easily
be translated into a biomarker diagnostic. This platform integrates microflu-
idic technology with electrochemical sensing and embodies a reaction/detection
chamber to measure serum levels of different biomarkers. The unique design
of the platform offers microfluidic and electrochemical structures to be indepen-
dently optimized.
We demonstrated the implementation, feasibility and specificity of this platform
(Osteokit) in assaying serum levels of BTMs using osteocalcin (Oc) and Cross-
linked Telopeptides of type I collagen (CTX). It was concluded that the whole
platform is simple in design, inexpensive and easy to manufacture whilst offer-
ing accurate measurements. The use of microfluidic components together with
electrochemical detection, suggests that the proposed device could be operated
as a hand-held device in future.
This work serves as the basis for a clinical diagnostic that can be used by health-
care providers to identify patients at-risk of osteoporotic fracture, those who may
benefit more from treatment and monitor treatment effectiveness.
1.2.2 Structure of the thesis
Upon the development of a ’New Biomarker Assay’ and before the device enters
the market, several steps are executed: Assay Development, Analytical Valida-
tion, Clinical Utility Validation, Clinical Implementation. (Figure 1.7) The first
two steps are discussed in this PhD.
￿ Chapter 1 consists of an introduction, explaining the importance of Point-
of-Care (PoC) testing in osteoporosis management and the application field
of this PhD work followed by the scientific goals and strategy.
￿ Chapter 2 consists of a literature overview on BTMs and existing bone
biosensors. In the next section, special attention is paid to methods used
to deposit gold nanoparticles on a gold electrode, and protein immobiliza-
tion techniques.
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Figure 1.7: New Biomarker Assay Development Steps.
￿ The third chapter provides scientific information and background of the
major scientific subjects of this thesis. The first part, focuses on biosensors
and then basic principles of electrochemistry and microfluidic devices are
provided.
￿ Chapter 4 includes the verification of the conjugated AuNP-antibody
nanoprobe fabricated for electrochemical biosensors.
￿ Chapter 5 explains the fabrication process of the electrodes used in this the-
sis. Different modification methods to deposit AuNPs on gold electrodes
are also compared in this chapter.
￿ Chapter 6 discusses characteristics and validation process of the Oc and
CTX biosensors.
￿ Chapters 7 and 8 discuss the Osteokit prototype fabrication technology and
experiment results, respectively.
￿ Chapter 9 consists of general conclusions and future prospects of the per-
formed research.
Additional information on BTMs and their characteristics are listed in Appendix
A. All the information regarding the ’materials and reagents’ as well as the ’ap-
paratus’ used in this work is provided in Appendix B.
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1.2.3 Scientific Goals
Regarding osteoporosis, the goal of this work was to develop a reliable, cost-
effective, powerful detection and monitoring tool for fracture risk indication and
treatment monitoring so that the patient can receive the most appropriate ther-
apy and that physicians can monitor the disease progression.
In this regard we decided to develop a microfluidic platform capable of mea-
suring serum levels of several biomarkers with high accuracy. The plan was to
develop a unique architecture which enabled low sample volume requirements,
short assay time, simplicity of fabrication and use, and low-cost instrumentation
and at the same time portability, high sensitivity and specificity for the biomark-
ers. (Figure 1.8) Furthermore, we wanted our measurement results to be compa-
rable in sensitivity with the current gold standard ECLIA.
Here, we propose the development of a functional conjugated AuNP-antibody
nanoprobe to be used to modify the surface of the electrode for sensing purposes
as the first step. This nanoprobe was directly reacted with antigen following their
pre-incubation in solution or the probe was assembled onto the electrode to bind
with antigen, by so-caled ’in-solution’ or ’on-chip’ methods, respectively.
￿ A detailed description of the characteristics of the in-solution nanoprobe is
provided in Chapter 4.
￿ Stable immobilization of the nanoprobe on the electrode, while keeping the
antibodies’ bioactivity in microreactor environment, and thus supporting
high quality and low-background noise in electrochemical sensing was our
next goal. In this work, gold electrodes were coated with AuNPs by elec-
trodeposition using cyclic voltammetry (Chapter 5). This goal is not limited
to the development of the modified surface but also includes characteri-
zation of the modified surfaces using advanced chemical surface analysis
techniques including XPS, STEM and AFM.
￿ One of the most crucial steps in biosensor fabrication is assessing the sen-
sitivity and selectivity of the system. In this work a calibration curve was
plotted for each of the measured markers and the final results were com-
pared with that of the current state-of-art ECLIA.
￿ The application of micro-manufacturing technology and development of
microfluidic chips allowed considerable throughput portability and the ca-
pacity for a high level of integration, and thus fulfilled the requirements of
fluidic sample-based point-of-care diagnostics. This also lowered the con-
sumed reagent and sample volume as well as the analysis time without
compromising the detection limit of the device, which are required for PoC
devices.
￿ In the final stage, the parameters which were taken into account to im-
prove the sensitivity and specificity of themicrofluidic platform are studied.
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Figure 1.8: Thesis Workflow.
Hence, the reproducibility of the measurements were investigated through
comparing the results with ECLIA.
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Literature Overview
2.1 Introduction
This chapter focuses on:
1. Biochemical markers of bone turnover and their role in osteoporosis
diagnosis
2. Bone biosensors: knowing the present and predicting the future
3. Protein immobilization strategies for biosensing purposes
2.2 Bone Turnover Markers and osteoporosis
2.2.1 Introduction
In the last decade, proteome analytical techniques have made a quantum
leap forward and became powerful tools in addressing a broad variety of
clinical problems through improving the prediction, diagnosis and prog-
nostication of diseases and elucidating underlying molecular pathways [1].
Accurate assessment of the biomarkers of these diseases are prerequisites
to achieving these goals.
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2.2.2 What are biomarkers
The definition of biomarkers has evolved over the past decade, with WHO
suggesting that “A biomarker is any substance, structure or process that can
be measured in the body or its products and influence or predict the inci-
dence of outcome or disease” [2][3].
Qualified biomarkers are valuable tools to diagnose patients earlier in the
clinical course of disease, to predict outcomes and guide interventional ap-
proaches, to stratify participants in clinical trials, and to monitor response
to therapy, and even in personalized medicine. Besides providing useful in-
formation in guiding clinical decisionmaking, these biomarkers are increas-
ingly linked to specific molecular pathway deregulations and/or pathogen-
esis to justify application of certain therapeutic/interventional strategies
[4].
In other words, biomarkers are key molecular, chemical or cellular charac-
teristics that can be objectively measured and evaluated as an indicator for
a normal biological or pathogenic process such as the onset, manifestation,
or progression of a disease as well as pharmacological response to a ther-
apeutic intervention [5]. Regarding the context of use, biomarkers can be
either disease- or therapy-related.
￿ Disease-related biomarkers are diagnostic (used to establish the dis-
ease state), prognostic (provide information regarding potential clin-
ical outcome irrespective of the treatment), or predictive (provide in-
formation regarding potential clinical outcome in response to specific
treatment).
￿ Therapy-related biomarkers provide information regarding the effec-
tiveness of a particular drug in treating or managing a disease.
The Biomarkers and Surrogate End Point Working Group, alternatively, has
classified biomarkers as [6]:
￿ Type 0 biomarkers: Markers of natural history of the disease that cor-
relate with clinical indices (e.g., Complete blood count)
￿ Type I biomarkers: They represent the effects of a therapeutic inter-
vention in accordance with drug mechanism of action (e.g., Decrease
in urokinase-type plasminogen activator (uPA) gene expression upon
dasatinib treatment in prostate cancer)
￿ Type II biomarkers: They are surrogate end points as a change in these
markers indicate clinical benefit (e.g., Decrease in blood/urine glucose
level).
Concerning their origins, biomarkers are categorized as following: (Figure
2.1)
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￿ Protein biomarkers 1: Proteins are vital biomolecules that function
as the working unit for activities, ranging from the storage and
metabolism of energy to the regulation of cellular functions. An ab-
normal expression of proteins or expression of unique proteins is often
associated with specific disease.
Protein biomarkers are primarily found in the blood or urine [7]. Most
of them serve multiple clinical purposes during early or late disease
progression. They can also be used to monitor treatment response
and/or detect recurrence during follow-ups.
Analyzing protein biomarkers involves several challenges, mainly be-
cause they are sensitive to their ambient environment, including tem-
perature, ionic strength and pH. Moreover, the direct analysis of traces
of proteins in crude or complex biological samples against the high
background of other proteins in high abundance is difficult.
￿ Enzyme biomarkers
￿ Nucleic acids-based biomarkers (DNA and RNA)
￿ Small chemical products of cellular metabolism
￿ Direct analysis of cells
For a biomarker to become accepted for clinical application it has to have
the following characteristics:
￿ Readily and consistently detectable in biological fluids, tissues, or
other biological specimens.
￿ Rapidly detectable and stable.
￿ High sensitivity and specificity.
￿ Strong correlation with the phenotype or outcome of interest.
￿ Detectable via a simple, noninvasive, and cost-effective test.
￿ Consistent across genders.
2.2.3 Bone turnover markers (BTMs)
An important determinant of bone strength that cannot be assessed using
BMD or clinical risk factor assessment tools is bone turnover [8]. BTMs can
be useful in determining the number and the activity of bone cells. More
specifically in terms of clinical utility, BTMs can help predict the risk of
developing osteoporosis or experiencing fracture or potential response to
therapy. They are also used in the assessment of early postmenopausal sta-
tus [9].
1Considering the concept of this thesis, only the first category is briefly explained
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Figure 2.1: Different origins of biomarkers.
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As a result, biochemical markers of bone turnover have been investigated
for three main purposes [10]:
￿ to monitor anabolic or anti-resorptive therapy
￿ to predict potential bone loss and the risk of developing osteoporosis
￿ to improve assessment of fracture risk in individuals
Advantages of using BTMs
DXA is thewidely available noninvasive and acceptedmethod for assessing
BMD to identify individuals with osteoporosis and, possibly, those at-risk
for fracture [3]. While BMD changes are considered as a valid end point for
verifying the efficacy of osteoporosis treatments, BMD changes and fracture
risk reduction rate following medication is not measurable at early stages
[4]. Moreover, DXA is incapable of assessing bone quality, which consists of
its micro- and macro-architecture and turnover and its results are affected
with advancing age, bone conditions such as osteoarthritis [5].
BTMs have shown promising results in osteoporosis care, such as:
￿ Samples of blood and urine are easily collected.
￿ They have a relative specificity for bone resorption or formation
￿ They provide complementary information to BMD
￿ Changes in BTMs occur earlier than that of BMD
Fig 2.2 compares the impact of various risk factors (low BMD, a prior frac-
ture or high urinary CTX) on ten-year probability of hip fracture in Swedish
women (women aged 65 years and over in OFELY study, and those of 80
years and over in EPIDOS study) according to age and relative risk. The
difference in the impact of each of these risk factors alone on hip fracture
probability is rather negligible. However, the combination of these risk fac-
tors improves the relative risk. In other words, the presence of two of these
risk factors increases the risk of hip fracture probability by 2.0- to 2.6- fold,
whereas with all these risk factors, a 3-fold increase is noted. Combination
of these risk factors also enlarge the range of risk stratification and permit
the identification of individuals above a threshold risk.
Moreover, BMD alone is incapable of diagnosing patients suffering from
secondary osteoporosis, caused by certain underlying medical conditions
or treatments that may interfere with the attainment of peak bone mass and
thus result in bone loss. The treatment process in these patients may include
treating the underlying cause of the disease which is based on additional
tests including BTM assessment [12]. BTM measurements may also help
to diagnose certain bone pathologies characterized by high bone turnover
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Fx = Fracture
RR= Relative Risk
Figure 2.2: Sensitivity of BMD and different bone markers in predicting hip
fracture [11].
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such as Paget disease, osteomalacia, multiple myeloma, and bone metas-
tases.
Furthermore, since bone biopsy is invasive and cannot be repeated in clini-
cal practice and because bone histomorphometry is less available due to the
lack of specialized laboratories, the use of BTMs has gained momentum.
BTMs reflect whole-body rates of bone resorption and formation as they
provide a more representative index of the overall bone loss than that ob-
tained by BMD values measured at specific skeletal sites containing differ-
ent ratios of cancellous to cortical components with differentmetabolic rates
[8].
In view of the rapid and considerable changes noted in BTM values during
the course of osteoporosis treatment, these markers can also be used to as-
sess compliance and treatment response [13]. In other words, the better the
compliance, the greater would be the decrease noted in BTM values, and
the lower would be the fracture incidence.
The most effective antiresorptive treatments lower BTM values to a drug-
and dose-dependent plateau within a few weeks or months (3 - 6 months),
providing a surrogate marker with adequate sensitivity and specificity to
BMD which needs a 2-year time to show the changes [14]. Bone resorption
decreases significantly after 3 weeks of anti-resorptive treatment, whereas
at least 6 weeks are needed for a significant decrease to be noticeable in
the bone formation markers’ values. At the same time considering BMD’s
short-term precision error (1± 1.5 %), a two-year period is needed before
at least a 3 ± 5 % change, suggestive of an acceptable response to a potent
bisphosphonate, is noted on the new BMD [15].
BTMs can also help identify patients who benefit more from anti-resorptive
drugs [16]. It has been reported that baseline bone turnover values can
predict treatment response, suggesting a higher increase in BMD values in
patients with higher turnover rate after the use of anti-resorptive medica-
tion. DesaiMeena et al showed increasing levels of bone resorptionmarkers
(Cross-linked Telopeptides of type I collagen (CTX) and Deoxypyridinoline
(Dpd)) during the aging process, suggestive of a negative correlation be-
tween these markers and BMD [17]. The increase noted in levels of CTX
and Dpd was significantly higher than the changes reported in the BMD
values at femur and spine. Women with marker values of at least two stan-
dard deviations greater than the mean are reported to be at a 75 - 80 % risk
of experiencing rapid bone loss [18].
Dresner-Pollak et al reported that N-telopeptide crosslinks (NTX), Oc, and
serum parathyroid hormone explained 43% of the bone loss variability at
hip in women [19]. Such a relation was not found in men. Similarly, Drake
et al suggested that it is not possible to identify osteoporotic men who
would be good candidates for alendronate therapy based on biochemical
or hormonal markers [20]. In another study, fracture risk was reported to
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be higher in men with increased P1NP or beta CTX levels but not TRAP5b
[21].
Several studies have shown that biochemical markers of bone-remodeling
are independent predictors of fracture, especially in spine and hip [16]. This
is mainly explained by the fact that high rate of bone loss is a risk factor for
fracture, independent of BMD values.
Disadvantage of using BTMs
Recent national guidelines from different countries have also adopted dif-
ferent roles for BTMs in the diagnosis and monitoring of osteoporosis treat-
ments, revealing differing opinions regarding the utility of BTMs in the di-
agnosis and management of osteoporosis [22]. Despite all, the routine use
of BTMs in the clinical practice is not recommended. This is mainly because
BTM values depend not only on the bone turnover rate, but also on factors
including age, gender and many more. Moreover the strength of the as-
sociation between BTMs and the rate of bone loss largely depends on the
accuracy of the measurement techniques [23]. Analytical variability, to be
discussed later in this section, is also an important limitation in this regard.
2.2.4 BTM Classification
In order to provide a list of existing BTMs, and their pros and cons in as-
sessing bone loss, more than 950 scientific communications were reviewed.
In brief, the articles were gathered in following steps:
￿ Designing the search protocol
￿ Designing a quality assessment form
￿ Designing the data extraction form
￿ Searching electronic databases
￿ Hand searching
￿ Data extraction
￿ Data imputation and analysis
Data Sources International databases, including PubMed/MEDLINE,
Web of Science, and Embase as well as congress abstracts conference pro-
ceedings, theses, and reports in related databases were assessed for related
Mesh terms including all subheadings:
(’Osteoporosis’[MeSH] OR ’Bone’ [MeSH]) AND (’Biological Markers’
[MeSH])
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Inclusion criteria All studies conducted between January 1985 and De-
cember 2011 on the accuracy of bone turnover markers in predicting os-
teoporosis and its complications as well as those on new methods to study
BTMs in this regard were included. There was no restriction on the lan-
guage of the publication.
Exclusion criteria Studies conducted on children and secondary osteo-
porosis (chronic renal failure (CRF)) were excluded.
A list of most important BTMs and a short description on them is pro-
vided in Appendix A.
Considering the various results reported in these studies, the IOF, the Inter-
national Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
and National Bone Health Alliance (NBHA) formed a committee of experts
in 2011 to examine the efficacy of BTMs and tomake clear recommendations
on their use in clinical practice [24]. They concluded that CTX and P1NP are
defined as the reference analytes for studying osteoporosis in clinical prac-
tice.
2.2.5 Biomarker Setbacks (with focus on BTMs)
The inevitable biological challenges for biomarker detection have encour-
aged researchers to continuously devote great effort in this field. As for
osteoporosis, these challenges include:
Marker Limitations
Serum or Urine Serum-based assays are better than urine, because of their
lower imprecision and day-to-day variation (within person reliability), bet-
ter reproducibility (variable ionic strength of urine samples and need for
creatinine (Cr) excretion correction).
Resorption or Formation Markers Changes in resorption marker values
occur earlier than that of formation markers.
Single or Multiple Markers Osteoporosis is a multifactorial disease and
a single biomarker has only a limited ability to predict bone loss and frac-
ture risk with high specificity and sensitivity [25]. Moreover, to avoid false
positives, arising from population variations in the expression of a single
biomarker, simultaneous evaluation of a panel of biomarkers is typically
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important and required.
In addition, no biomarker has been reported as an ideal screening tool that
can meet the diagnostic, prognostic, and predictive requirements simulta-
neously. A model developed by Cosman et al showed that urine Hydrox-
yproline (Hyp), serumCTX, serum Bone Alkaline Phosphatase (BALP), and
calcium intake predicts 42% of BMD change at lumbar spine in untreated
postmenopausal women [17]. Together, the measurement of pyridinium
cross-links and BALP or Oc is also reported as an index of bone turnover
rate, which can help identify fast losers at high risk of osteoporosis or those
in need of aggressive therapy [19].
Measurement Technique Limitations
Similar to other analytes, BTMs have their specific technical and analytical
limitations. The relatively poor quality assurance of the measurement tech-
niques along with their large coefficient of variation (C.V.) and assay vari-
ability are other factors limiting the use of BTMs in clinical practice. Thus
assay sensitivity and specificity need to be improved, and the techniques
must be standardized and validated. Thus, the validation of new tech-
niques to measure biomarkers for efficient osteoporosis diagnosis is quite
necessary and challenging. In addition, many questions have been raised
regarding how new tests will be developed, evaluated, and integrated into
clinical practices.
The main limitations in BTM measurements are categorized in two main
groups:
Analytical variability Recent improvements in technology, particularly
the introduction of automated immunoassays, has reduced the analytical
C.V. of BTMs to about 5–15% [26]. However, considering the lack of a uni-
form standardization technique, it would be difficult to compare values ob-
tained by dissimilar methods in different laboratories. The intra-individual
reproducibility of BTMs is still a concern, especially when therapeutic ap-
proaches should be chosen based on a single measurement.
Studies have shown an intra-individual variability of around 10% and be-
tween 15- 25% for serum and urinemarkers, respectively [27]. This suggests
that a least significant change (LSC) of at least 25–30% and 40–70% must be
observed so that a significant change is considered for each of these mark-
ers, correspondingly. Compared with urinary resorption markers, this in-
dex is reported to be lower for serum bone formation markers. Moreover,
it is preferable to measure a marker in serum as no correction for creatinine
excretion would be needed and the ionic strength would be less variable in
this case. It should also be kept in mind that some markers are sensitive
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to thermo-degradation, UV radiation, hemolysis and other ambient influ-
ences.
Immunoassays, particularly, ELISA, have been extensively used in routine
clinical diagnostics and are still the gold standard for the detection of pro-
teins in physiological samples [28]. The same is true for BTMs.
Even though universally available, the use of ELISA has its limitations, es-
pecially in terms of sensitivity, dynamic range, and sample volume. On the
other hand, ELISAs are best suited when only a few biomarkers are needed
to be verified/validated on a large number of samples. They could also be
a very tedious, expensive and time-consuming process. ELISAs require an-
tibodies against each targeted protein/peptide and thus it is possible that
high-quality assays would be unavailable for proteins of interest [29]. In
addition, ELISA assays have limited multiplex capability and the cross re-
activity is always a cause for concern. (Figure 2.3)
Continuous efforts have been devoted to further optimize these standard
methods or to find new and better techniques for the measurement of
biomarkers. The new techniques are often fluorescence or chemilumines-
cence based.
More recent studies thus have focused on developing newer technologies
to overcome these setbacks. Next section would provide a detailed expla-
nation of the developed bone biosensors. Although robust and highly ef-
ficient, most of these methods still suffer from lack of accuracy, sensitivity,
and specificity for clinical diagnostic applications.
Pre-Analytical variability The BTMs’ pre-analytical variability should
also be taken into account during their clinical interpretation [30]. This vari-
ability is broadly divided into two categories: (Table 2.1)
￿ Uncontrollable factors such as age, gender, renal function, menopausal
status, disease or recent fracture. The use of appropriate reference
ranges or suitable adjustments can help overcome this variability to
some extent.
￿ Controllable factors such as circadian rhythm, menstrual or physical
activity status. The effects of these factors can be minimized by stan-
dardizing the timing and conditions under which the samples are col-
lected.
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Figure 2.3: Schematic view of the sandwich ELISA format.
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Table 2.1: Sources of biological variability
Source Nature of effect
Uncontrollable Sources
Age BTM increase with age in men and women
Menopausal status BTM increase within a few months after the last menstrual period
Gender BTM are higher in older women than older men
Fracture BTM increase after a fracture (maximal at 2 to 12 weeks, but effect lasts for up to 52 weeks)
Pregnancy and lactation BTM are increased during pregnancy; highest levels during third
trimester, even higher postpartum
Drug BTM may be decreased (glucocorticoids) or increased (anticonvulsants)
Underlying Diseases BTM often increased (thyrotoxicosis, chronic kidney disease)
Immobility Bone formation markers decrease and resorption markers increase
Geography Minor changes amongst countries, usually explained by differences in lifestyle
Ethnicity Minor changes, such as lower Oc in African Americans vs. Caucasians
Controllable Sources
Circadian Most striking for bone resorption markers; highest values in sec-
ond half of night and on waking; lowest values in afternoon and
evening
Fasting status Feeding results in a decrease in BTM; for example, s-CTX decreases by 20% after breakfast
Exercise Changes occur but depend on type of exercise and age of subjects
Menstural Minor decreases in bone resorption and increases in bone formation during luteal phase
Seasonal Minor decreases in BTM over winter
Diet Small reduction in BTM immediately following calcium supplementation
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Uncontrollable Sources of Biological Variability
￿ Age and Renal Function
BTM levels are significantly higher in children, particularly in the first
year of life and during puberty [31]. After mid-puberty, BTM levels
decrease but it is not until the fourth decade of life when they reach the
baseline values. Thereafter, the majority of BTMs remain constant in
men. Inwomen however amarked increase is noted at themenopause.
In the elderly, an increase in the levels of Oc as well as other markers
metabolized and/or excreted by the kidney (pyridinoline crosslinks
and related peptides) is noted due to gradual renal impairment which
occurs during aging.
￿ Gender
Compared with their female counterparts, BTM levels are higher in
men in their third and fourth decades. As for older ages, however, the
levels are higher in postmenopausal women [32].
￿ Ethnicity
Bone resorption markers are lower in black youngsters compared with
their white counterparts. Though, this difference only becomes appar-
ent in women after menopause [32].
￿ Fractures
The levels of BTMs vary throughout the fracture healing process.
These changes are dependent on various factors, including the size
of the fracture and the time needed for it to heal [33]. During the first
4 weeks of fracture, bone resorption and formation markers both in-
crease by 20±50% and remain elevated for 6 months to one year.
￿ Pregnancy and Lactation
During pregnancy and lactation, the maternal skeleton is required to
provide the growing fetus and infant with more calcium [34]. Thus,
bone turnover ratio (Dpd/Oc) rises during pregnancy. This is mainly
because of placental clearance of Oc during this time. At term, bone re-
sorption (NTX) and formation markers (P1NP) are increased by some
200% and 60%, respectively.
After delivery, urinary NTX and CTX levels decrease but the levels of
less bone-specific markers such as Pyd still continue to increase. Dur-
ing the first months of lactation, there is an elevation in BTM levels,
which based on the results of some studies is about twice the level
noted in aged- matched non-lactating subjects.
￿ Drugs
Antiresorptive treatments for osteoporosis and other metabolic bone
diseases such as HRT, selective estrogen receptor modulators and bis-
phosphonates, rapidly reduce BTMs by up to 70% [35]. Corticosteroids
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promptly inhibit bone formation [36]. This is reported as a significant
and rapid fall in Oc levels followed by a delayed and mild decrease
in P1CP, P1NP and BALP values. Anti-convulsants and GnRH ago-
nists both increase markers of bone turnover significantly. Thiazide
diuretics, however, have a decreasing effect on bone turnover. Oral
contraceptives are believed to increase serum and urinary calcium, Oc
and urinary levels of Pyd and Dpd [37]. This effect is reported to be
age-dependent.
￿ Diseases
Apart frommetabolic bone diseases, certain non-skeletal diseases such
as liver or kidney disorders may also affect markers of bone turnover.
Certain metabolic bone diseases such as Paget’s disease, primary hy-
perparathyroidism, thyrotoxicosis, and acromegaly are responsible for
increased levels of both bone formation and resorption markers [38].
This is while Cushing’s disease or multiple myeloma may cause an in-
crease in bone resorption and a decrease in bone formation markers.
Mild decrease in bone formation and resorption markers at the same
time is reported in patients with diseases such as hypoparathyroidism
or hypopituitarism.
￿ Immobility
Resting is associated with a very rapid increase in the values of bone
resorption markers [39]. Urinary excretion of Pyd and Dpd are signif-
icantly increased after only 2 days of resting. Non- significant or no
change is reported for the markers of bone formation during bed rest
or immobility.
￿ Between-day variability
The day-to-day variation in BTMs ranges between 16–26% for the uri-
nary excretion of Pyd and Dpd, 7–25% for free pyridinoline, 13–35%
for NTX, 12–35% for CTX, and 10–12% for TRAP [40].
Controllable Sources of Biological Variability
￿ Circadian rhythm
In adults, circadian rhythm is the main source of undesirable but con-
trollable biological variability. Controlling the time of sample collec-
tion therefore is of great importance. Except for alkaline phosphatase,
which has a long half-life, the highest values of the markers are mea-
sured in the early morning hours and the lowest are noted late in the
afternoon [41].
As for BALP, the peaks are measured between 11:00 and 14:00 and
another at 23:30. Compared with formation markers, resorption mark-
ers have a significantly greater amplitude of change during the circa-
dian cycle [42]. The steepest morning decline has been described for
36 Literature Overview
serum CTX. Bisphosphonate treatment and calcium supplementation,
if taken at night, can suppress the circadian rhythm of bone resorption
markers.
￿ Menstrual status
A 10-20% variability is noted in BTM levels across the menstrual cycle
[43]. Several studies have shown higher bone formation markers dur-
ing the luteal phase, and higher bone resorption markers during the
mid -follicular, late-follicular and early luteal phases.
￿ Seasonal effects
While overall seasonal changes are reported to be responsible for only
up to 12% of the variability in BTM levels, some studies consider the
fluctuations of vitamin D repletion as the reason behind the higher
difference between BTM levels measured in summer and winter [44].
High serum levels of Oc is reported during winter and spring; this
is while BALP has an inverse rhythm with the lowest amounts re-
ported in the winter and spring. On the contrary, no significant sea-
sonal rhythm is reported for P1CP. Most bone resorption markers, on
the other hand, are higher during the winter time. A single study how-
ever has shown high urinary Pyd excretion during the summer time.
￿ Physical activity
Exercising has both long-term and acute effects on the variability of
bone turnover markers [45]. Moderate intensity resistance training is
reported to reduce bone resorption in short time, improving the overall
bone turnover rate.
￿ Diet
Except for HYP and CTX, diet, particularly collagen ingestion has no
effect on serum/urinary levels of most BTMs [46]. The effect of the
fasting–eating pattern on BTMs is however stronger than that of the
physical activity. Fasting greatly affects the urinary and serum levels
of CTX [47].
2.2.6 Conclusion
Considering the above mentioned facts, it is considered that the combina-
tion of several biomarkers and BMD at the same time could be useful in
improving the identification of individuals at high risk for fracture [48].
As the existing BTMs could also be classified into two groups, as following,
the selection of biomarkers should be made based on the final goal of the
measurement system.
￿ BTMs that predict Bone Loss
￿ Bone Formation Markers: P1NP, BALP, Oc
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￿ Bone Resorption Markers: Dpd, CTX, NTX
￿ BTMs that predict Fracture
￿ Bone Formation Markers: BALP, P1CP, P1NP, Oc
￿ Bone Resorption Markers: TRAP, CTX, NTX
2.3 Bone biosensors: knowing the present and pre-
dicting the future
2.3.1 Current approaches to assess bone remodeling
Asmentioned in Chapter 1, bone health depends on how the cellular mech-
anisms in the body create balance in the remodeling process [49]. Over the
past few decades, research has been conducted in the field of biosensors to
study bone-cell mechanosensation and detect the concentration of BTMs in
biological samples for robust diagnosis.
Technological developments have greatly enhanced assay performance pro-
ducing reliable, rapid, non-invasive cost effective biosensors with improved
sensitivity and specificity which can help improve Point-of-Care (POC)
through real-time and remote health monitoring; the use of these devices is
still limited to research and cannot be deployed in clinical practice because
of their limitations and setbacks. In the following, the latest advancements
in the field of bone biosensing technologies are provided.
Based on the existing literature, bone biosensors can be classified in three
main categories (Table 2.2):
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Table 2.2: Existing bone biosensors
Device Characteristics Pros & Cons
IMPACT3500 [50]
Technology: Strain gauge
Measures: Strain (Elastic range, fa-
tigue limit, occurrence of fractures
Usage: Monitoring implant strain
Location: Implant
LoD: Elastic range: 300 µs (100-400 µs),
fatigue limit: 150 µs
Pros: Real-time study
Cons: Invasive, non-
biodegradable, depen-
dency of sensor response
substantially on the
position of the neutral
axis
Biomechanical
bone sensor
[51][52]
Technology: Piezoelectric transducers
Measures: Frequency response func-
tion (FRF)
Usage: Monitor structural dynamic
parameters of bones
Location: Healing of critical bones af-
ter surgery
LoD: Damping ratio: 0.035
Pros: Direct evaluation
Cons: Invasive, non-
biodegradable
Continued on next page
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Table 2.2 – Continued from previous page
Device Characteristics Pros & Cons
Multi-axial bone
sensor
Technology: Piezoresistive shear
stress sensor
Measures: Stress, resolution, response
to tensile and bending loads
Usage: Monitor healing process at
fracture/graft site
Location: Injured Bone
LoD: Sensitivity: 0.13 mV(mA.MPa) for 1.4
N full scales shear force range, mean
hysteresis Error: 3.5% [53] Resolution
to 100 Pa, in 1 s- Response to tensile
and bending loads up to 250 kPa [54]
Pros: Direct evaluation
Cons: Invasive, non-
biodegradable
Sirivisoot biosen-
sor [55]
Technology: CNT
Measures: Changes in CNT conduc-
tivity, osteoblast adhesion
Usage: Release bone growth factor-
Monitoring bone remodeling
LoD: 20% increase in osteoblast adhe-
sion
Pros: Biodegradable,
improved bone growth
Cons: Invasive
Continued on next page
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Table 2.2 – Continued from previous page
Device Characteristics Pros & Cons
Nanofet sensor
[56]
Technology: Label-free nanowire field
effect transistor
Measures: Proteins released by osteo-
cytes under mechanical stress
Usage: Studying load-induced remod-
eling process
Location: Serum
LoD: 10 fg/mL
Pros: Non-invasive,
Label-free
Cons: Indirect evalu-
ation
Automated assay
Technology: Automated assay [57]
Measures: P1NP
Usage: Assessing serum P1NP levels
(useful in osteoporosis)
Location: Serum
LoD: 5 µg/L
Pros: Fully automated
Cons: Single marker
Multiplex Auto-
mated Assay
Technology: Automated assay
Measures: P1NP, CTX, Oc, PTH [58]
Usage: Assessing several biomarkers
(useful in osteoporosis)
Location: Serum
LoD: 0.26g/L, 0.002g/L, 0.51g/L, 0.39
ng/L
Pros: Multiple markers,
Fully automated
Cons: Trained staff,
laboratory equipment
Multiplex Auto-
mated Assay
Technology: Automated assay
Measures: CTX, Oc, PTH [59]
Usage: Assessing several biomarkers
(useful in osteoporosis)
Location: Serum
Pros: Multiple markers,
Fully automated
Cons: Trained staff,
laboratory equipment
Continued on next page
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Table 2.2 – Continued from previous page
Device Characteristics Pros & Cons
Calcium mi-
crochip [60]
Technology: Reflectance measure-
ments from arsenazo III
Measures: Calcium ions
Usage: Assessing serum calcium levels
(useful in different diseases)
Location: Serum
LoD: 2.68× 10−5 M
Pros: Non-invasive
Cons: Single marker
TRAP sensor [61]
Technology: Electrochemical can-
tilever
Measures: TRAP, TRAP 5a, TRAP 5b
Usage: Assessing Serum TRAP levels
(useful in osteoporosis)
Location: Serum
Pros: Non-invasive, high
accuracy, low blood sam-
ple
Cons: Single marker
CTX sensor [62]
Technology: Label-free electrochemi-
cal
Measures: CTX
Usage: Assessing Serum CTX levels
(useful in osteoporosis)
Location: Serum
LoD: 50 ng/mL
Pros: Non-invasive, La-
bel free, High accuracy,
low blood sample
Cons: Single marker
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2.3.2 Biomechanical Sensors
In early 1892, Wolff suggested that stress plays an important role in de-
termining bone structure, adding that this effect becomes more prominent
during overload and disuse scenarios [63]. Moreover, currently used x-ray
imaging systems cannot provide the accurate information needed about the
biomechanical quality of bone regeneration at the bone graft or implant site.
Thereaftermore attentionwas focused onmechanically-induced adaptation
of bones [64]. During the past decades, different sensors were therefore de-
veloped to non-invasively assess bone growth and strength [65][66][67][68].
While strain gauges are the gold-standard for in-vivo measurement of bone
strain, their use in humans is limited because of the need for surgery to
implant the sensors and cyanoacrylate adhesives to bond the sensors on
the bones. Numerous extracellular sensors are fabricated for bone-cell
mechanosensation in live subjects [69]. When bone is stressed in a suc-
cession of load-unload cycles, repeated microscopic damage to the bone oc-
curs. The slow and overtime bone deformation process also known as strain
in the "fatigue zone," may lead to fracture [70]. The IMPACT 3500 project
showed that monitoring the deformation of femoral implants is a powerful
tool for identifying dangerous overloads, anticipating implant failures and
observing the healing process [50]. In this technique, the implant strain was
measured using a resistive 5 kW strain gauge bonded to the floor of the im-
plant cavity.
Yang et al similarly developed a flexible, implantable sensor array for mea-
suring surface strain on live bones. They reported that the Polydimethyl-
siloxane (PDMS)-based strain gauge with piezoresistive readout could be
used as part of an implantable, wireless array for real-time monitoring of
bone remodeling process [66].
Vibrational analysis of bones has also been used to assess the diseased and
fractured bones in research. Lack of reliability and reproducibility of the
results however has limited its use in clinical practice. In this regard, Os-
teosonicTM was built by NASA to monitor bone fractures through analyz-
ing the vibration response of bone tissue [71]. In 2003, Nogata et al, simi-
larly estimated bone quality using ultrasound [72]. The method was based
on the difference in the speed of ultrasound propagation through a two-
dimensional area fraction of cancellous bone. Considering the good corre-
lation between BMD values measured by DXA and the bone area fraction
assessed by ultrasound, the technique is believed to be helpful in diagnos-
ing osteoporosis.
Later, scientists developed a mechanical pressure sensor that could be em-
bedded within orthopedic implants, to monitor the bone healing process at
the fracture site [73]. The ultrasonic device measured the mechanical load-
ing on the implant through studying the fluid level in the spirals.
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Figure 2.4: PZT patch bonded to a 1D slender structure.2
Piezoelectric sensors are shown to provide reproducible response regard-
ing the changes in the mechanical properties of bones. Bhalla et al therefore
used piezoelectric ceramic (PZT) transducers to evaluate mechanical and
structural dynamic properties of bones, including modal frequencies and
corresponding damping ratios derived from frequency response function
(FRF) [51]. They reported that the technique could be used for monitoring
the bone healing process after surgery as well as the diagnosis of ailments
such as osteoporosis. (Figure 2.4)
Bender et al also used piezoelectric sensors to monitor capsule formation
through studying the changes in mechanical properties of the tissue sur-
rounding the implant. The sensor helped provide the surgeon with post-
operative status of the implant [52].
Hsieh et al developed a contact-type micro piezoresistive sensor to mea-
sure shear stress at the knee prosthesis site using Micro-electro-mechanical
system (MEMS) technology [53]. The fabricated sensor exhibited a sensi-
tivity of 0.13mV/mA-MPa for a 1.4N full-scale shear force range and the
overall mean hysteresis error of 3.5%. Alfaro et al also developed a MEMS
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Figure 2.5: Envisioned implantable CMOS-MEMS multiaxis stress sensor.3
stress sensor to detect shear stress at a microstrain scale in bone [54]. The
ultra-miniature wireless sensor was comprised of an array of piezoresistive
sensors that could be permanently implanted within bone to assess new cell
growth. (Figure 2.5)
The scientists later investigated the idea of making biodegradable versions
of such devices to overcome the need for a second surgery to remove the
device from the healed fracture site. Sirivisoot et al developed a biosensor
composed of a conductive, biodegradable polymer layer that could sense
and control bone regrowth near the newly implanted orthopedic material
[55]. The biosensor released bone growth factor to help improve bone for-
mation and thus the regeneration of the tissue needed for the success of
the orthopedic implant. The polypyrrole and poly-lactic-co-glycolic acid
polymer layers also degraded following sufficient bone grew, resulting in
changes in conductivity that can be measured by the carbon nanotubes
(CNTs) grown out of the anodized titanium (Ti) on the sensor. This was also
used to inform the surgeon regarding the amount of bone formed around
the implant at different stages. Li et al fabricated a sensitive Nano-field-
effect transistor (FET) biosensor to study osteocyte mechanotransduction
[56]. The novel nanomanipulation-based label free sensor was designed to
assess the amount of proteins released from the mechanically-stimulated
osteocytes. A novel microbend optical biosensor, inspired by Brain Neural
Network, was also developed to improve the performance of biosensors in
detecting early osteoporosis [74]. The sensor was used to detect and mea-
sure surface displacement, pressure and strain on live bones.
Later Umbrecht et al developed a wireless implantable passive strain sen-
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Figure 2.6: Schematic of the WIPSS sensor concept.4
sor (WIPSS) for monitoring the deformation of orthopedic implants based
on a hydro-mechanical amplification effect [75]. (Figure 2.6) The biocom-
patible ultrasound-based sensor had a strain resolution of 1.7 ± 0.2e-5 over
dynamic inputs of 0.1-5 Hz.
2.3.3 Multiplex Automated Assays
While the biomechanical sensors mentioned above can provide the scien-
tists with information on pressure and strain levels on live bones, BTMs
(Appendix A) can describe the status of the cellular and extracellular com-
ponents of the skeletal matrix, reflecting bone metabolism. When ap-
plied and interpreted correctly, these inexpensive and comparatively non-
invasive tools can help with the diagnosis and treatment of metabolic bone
diseases [76].
Currently, BTMs are measured individually by manual or automated im-
munoassays. These assays were first confined to urine samples; newer
techniques, however, measure serum levels of the markers, overcoming the
need for correction for urinary creatine levels. Single assay methods have
several limitations, including limited precision and need for large sample
volumes of 50 to 300 µL in both techniques and significant labor time in the
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manual assays.
Multiplex protein arrays, which enable simultaneous detection of multiple
analytes, have overcome some of these problems [77][78]. Compared to
traditional techniques, multiplex assays are miniaturized, have higher sen-
sitivity, and need less sample and reagent volume [79]. Schafer et al re-
ported great improvement in short and long-term assay variability using
automated immunoassay techniques compared with ELISA [80].
Claudon et al developed an automated multiplex assay to assess CTX-1,
P1NP, Oc, and intact PTH simultaneously in 20 µL of serum [58]. They
reported that the automated protein – array chip demonstrated similar ana-
lytical precision compared with single assay methods. The new technique,
however, needed less sample volume and showed improved analytical sen-
sitivity.
2.3.4 Label–free biosensors
The majority of techniques mentioned above or currently used to detect
biomarkers need certain radio-, enzymatic- or fluorescent-labeling to re-
port the binding event. There are novel technologies, also known as label-
free biosensors, which do not require labeling and thus allow complexes
to be screened with minimal assay development [81]. Several label-free
bone biosensors were developed during the past years, none of them are
routinely used in clinical practice as they were designed to assess a single
marker and many studies have reported that studying the alteration of the
serum/urine levels of a single marker is not sufficient for assessing bone
health as their changes are not disease-specific [82].
A microchip-based sensor was developed by Caglar et al for determining
calcium ion levels [60]. The technique measured reflectance index of arse-
nazo III immobilized on the surface of polymer beads. They reported that
the microfluidic sensor showed good agreement with other tools used for
calcium ion measurement over a physiological range, adding that its results
were less influenced by competing ions in the samples.
In another biosensor, the concentration or activity of tartrate-resistant acid
phosphatase (TRAP) in blood was assessed using a quartz crystal microbal-
ance (QCM) sensor [61]. In this biosensor, osteoclast function was studied
through measuring the position deflection of a cantilever beam modified
with antibodies against total TRAP, TRAP 5a or TRAP 5b using an optic de-
tection plate.
Yun et al developed an electrochemical biosensor for quantitative POCmea-
surement of CTX [62]. The label-free immunosensor, based on Electrochem-
ical Impedance Spectroscopy (EIS), had a detection limit of 50 ng/mL and
a dynamic range of up to 3 µg/mL. (Figure 2.7)
The sensors mentioned in this category have shown promising results in
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Figure 2.7: Schematic representation of a label-free immunosensor for bone
maker detection. a) A self-assembled monolayer of dithiodipropionic acid
deposited on a gold surface with streptavidin immobilized next as a
self-assembled monolayer. Then the biotinylated antibody was bound to the
streptavidin. b) Antigen-antibody binding reaction and how it hinders the
interfacial electron transfer reaction of K3[Fe(CN)6].adapted from Yun et al[62]
measuring serum levels of a certain biomarker. As mentioned earlier, mea-
suring a single bone turnover marker is not sufficient in identifying individ-
uals at-risk of fracture or for monitoring the osteoporosis treatment process,
suggesting that development of a multiplex biosensor could be valuable
[83].
2.3.5 Conclusion and Future Directions
This section seeks to provide an insight into the current state-of-the-art in
the bone biosensor field, stressing that new strategies must be considered
to bring this important technology into clinical practice.
Bone densitometry and other noninvasive imagingmethods, currently used
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to assess bone quantitatively and qualitatively, tell us little about changes
in bone material composition and biomechanical design during the healing
process [49]. According to the above mentioned explanation and Table 2.2,
sensors categorized in group one (biomechanical sensors) provide valuable
information about shear stress and biomechanical quality of bone regenera-
tion at the graft or implant site. The poor bone quality at the fracture site is
associated with increased mechanical stress on the implant as well as frac-
ture movement under loading, resulting in fixation failure and increased
fracture displacement [84].
Then again, monitoring of bone fracture healing is often performed based
on complex imaging techniques and thus it is not possible to observe the
patient during physiotherapy and outpatient visits [85]. As a result mon-
itoring the biomechanics of the fractured bone and its remodeling process
could be of great importance for clinicians to establish appropriate clinical
treatment principles to minimize complications and enhance the patient’s
quality of life [86].
In other words, this group can help physicians to monitor the healing pro-
cess of the live bone after the surgery but there are still concerns about their
biodegradability over time. We are expecting the next generation of these
biodegradable biomechanical sensors to be less invasive and provide physi-
cians with more evidence about the quality of live bone.
PZT patches are believed to have several advantages over similar technolo-
gies used for this purpose, the most important of which is their low-cost
and negligible weight [87]. However, their bio-compatibility (as the most
popular is lead zirconate titanate) and the acquisition of the signatures has
limited their use. It could be possible that in the near future nano-sized
biodegradable PZT patches will be implanted on bones to monitor their
mechanical properties, utilizing advanced wireless telemetry to further fa-
cilitate remote signature acquisition.
Sensors classified under the second and third group, on the other hand, are
used to gather information on themetabolic status of the bone throughmea-
suring serum or urine levels of different BTMs. As mentioned in the previ-
ous section, BTMs are useful in understanding bone physiology during the
modeling and remolding phases, predicting fracture risk, and monitoring
bone response to treatment. The sensors in these groups are non-invasive.
The sensors in the second group (Multiplex Automated Assays), can as-
sess several markers at the same time but require expensive equipment and
skilled technicians and thus are not always available.
In order to overcome these concerns, the sensors in the third group were
developed. At the time being, the developed label–free biosensors, which
work without the need for skilled technicians, can only assess a single
marker at a time. But considering the fact that a single molecular marker
cannot provide sufficient information to assist the clinicians in monitoring
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the bone remodeling process, further studies are needed to develop label-
free miniaturized sensors that can detect several markers simultaneously
[26].
2.4 Protein immobilization strategies for biosens-
ing purposes
Protein immobilization strategies can be classified based on their selectiv-
ity, ranging from nonspecific binding with low control on protein orienta-
tion (random adsorption), to more complex methods with high controlla-
bility, reproducibility, and stability (site-specific functionalization) [88]. An
overview is provided in Table 2.3.
2.4.1 Physisorption
The most simple and inexpensive approach to immobilizing proteins on
a surface is physisorption (physical adsorption), where proteins can be
adsorbed to various surfaces via non-covalent interactions/intermolecular
forces (such as van der Waals, hydrogen bonding interactions, or combina-
tion of those) [89]. Although physical adsorption offers some advantages
(simplicity, no need for toxic reagents or sophisticated chemical protocols
and possible reusability of the substrate), it generally leads to a surface
coated with proteins in a random orientation or via multiple binding sites
which can give rise to many disadvantages (reducing the accessibility to its
functional sites or conformational changes influencing the proteins activity)
[90][91].
An additional drawback is that physisorption is generally weak, and thus
the adsorbed layer is not stable and highly dependent on environmental
conditions such as pH, ionic strength and temperature. Immobilization
density depends on protein size, as well as physicochemical surface prop-
erties; thus spacers such as polyethylene glycol (PEG) are widely used to
reduce steric hindrance particularly when the immobilization density is too
high [92].
2.4.2 Electrostatic interaction
Electrostatic or ionic interactions provide a stronger binding of immobilized
molecules and thus are more frequently exploited in biochemical assays
[93]. Ionic interactions generally occur between the negatively charged gold
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surface and the positively charged terminals on the protein. Typical posi-
tively charged functional groups such as protonated amine (R-NH+3 ) and
quaternary ammonium cations (NR+4 ) as well as negatively charged car-
boxylate (R-COO−) and sulfonate (R-SO−3 ) ones are mainly involved in the
electrostatic interactions.
While this method does not change protein conformation in a substan-
tial extent, the usage of highly charged supports, which can interact with
charged substrates or products can limit its use [94]. Moreover, despite its
simplicity and reversibility, it is difficult to find suitable conditions under
which the enzyme/antibody remains both strongly bound and fully active.
2.4.3 Covalent binding
Immobilization of proteins based on the formation of covalent bonds is
among the most widely used techniques, mainly because of the stable
nature of the formed bonds [95]. However, covalent linkage may suffer
from reduced activity of proteins (by forming linkage on active sites), toxic
reagents, long incubation times, and complicated chemistry [96].
The activation processes are generally designed to generate electrophilic
groups on the support, which in the coupling step, react with the strong
nucleophiles from the proteins. In other words, for covalent binding, the
immobilization surface is activated via reactive reagents and then reacts
with amino acid residues on the protein, not involved in the reaction mech-
anism, and forms an irreversible linkage. The most frequently used reac-
tions involve lysine (e-amino group), cysteine (thiol group), and aspartic
and glutamic acids (carboxylic acid group) as the side chains of the amino
acids. Bifunctional spacer molecules are commonly used in this approach.
Amine Chemistry
The amino groups of proteins (-NH2) are the most commonly used moieties
for covalent immobilization.
N-Hydroxysuccinimide (NHS) NHS s are the most commonly used
agents that react with protein amine groups, with the formation of stable
peptide bonds [97][98]. NHS is also often used as an activating reagent
for carboxylic acids. Activated acids (basically esters with a good leaving
group) can react with amines to form amides [99]. (Figure 2.8)
1-ethyl-3-(3-dimethylamonipropyl) carbodiimide (EDC) - amide EDC,
the most frequently used carbodiimide, reacts with carboxylic acid to form
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(a)
(b)
Figure 2.8: a) Chemical structure of EDC & sulfo-NHS, b) EDC & sulfo-NHS
crosslinking reaction scheme. Molecules (1) and (2) can be peptides, proteins or
any chemicals that have respective carboxylate and primary amine groups.
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an o-acrylisourea intermediate, which subsequently reacts with primary
amines to form amide bonds [100][101]. Reaction of o-acrylisourea with
amines is slow and can be hydrolyzed in aqueous solution. Thus, EDC is
usually used with NHS. (Figure 2.8)
Carboxylate-EDC+NHS-amine NHS esters can be formed using carbodi-
imide (EDC), NHS, and carboxylates to immobilize proteins [102]. The car-
boxylic group would later be activated with the NHS ester, and then cova-
lently linked to the amine groups of antibodies. (Figure 2.8)
Other chemistries used to immobilize proteins via the exposed amine
groups include sulfhydryl (epoxide), iso(thio)cyanate, azlactone, p-
nitrophenyl ester, glutaraldehyde, sulfonyl chlorides, and cyanogen bro-
mide [103].
Carboxyl Chemistry
The immobilization of proteins using the carboxylic side chains is of great
interest, as the amino acids glutamic and aspartic acid constitute a ma-
jor fraction of the surface exposed amino acids [104]. The carboxylic acid
function of these amino acids, along with the C-terminus, can react with
amines using the routine coupling chemistry also used for solid phase pep-
tide synthesis. This coupling reaction is activated by a carbodiimide like
N,N’-dicyclohexyl carbodiimide (DCC) or EDC and results in a rapid and
quantitative formation of a peptide bond.
Thiol Chemistry
Free cysteines have a relatively low natural abundance in proteins and thus
are an interesting tag for immobilization reactions as random orientations
or multiple contact points are less a problem [105]. They contain a reactive
thiol (SH) group, which is more nucleophilic than a primary amino group.
In proteins with no free cysteines, the aminoacids can be inserted at a site of
interest by site-directedmutagenesis. Maleimides and vinyl-sulfone groups
are themost commonly used chemical groups to selectivelymodify surfaces
toward covalent protein coupling via the free thiols [106] .
A covalent bond can also be established to substrates functionalized with
disulfide probes via a thiol-disulfide exchange under oxidative conditions.
This reaction is selective for cysteines, but similar to natural disulfide
bonds, these couplings are not resistant to reducing agents like mercap-
toethanol or Dithiothreitol (DTT) [107].
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Tyrosine and Tryptophan
Tyrosine and tryptophan are relatively the rarest amino acids on protein
surfaces and can be genetically introduced without changing the overall
charge state or redox sensitivity [108]. They, however, are often overrepre-
sented near active sites of proteins and thus targeting them for modifica-
tion or immobilization needs careful consideration and specific conditions
(acidic environment), which may have undesirable affects on the protein’s
structure and function [109].
2.4.4 Bioaffinity immobilization
The bioaffinity interaction or biospecific adsorption is based on the prin-
ciple of complementary biomolecules interactions, which represents its
biggest advantages, high selectivity, high specificity, and oriented pro-
tein immobilization [110]. Additionally, bioaffinity immobilization can be
reversed using chemical treatment, pH change, or heat treatment [111].
Avidin-biotin, protein A/G-antibody, genetically engineered protein affin-
ity ligands, DNA hybridization, and aptamers are common approaches in
this strategy.
Avidin-biotin
One of the well-established affinity-based immobilization technique
is based on the strong interaction between (strept)avidin (66-69 kDa
tetrameric glycoprotein) and biotin (water-soluble vitamin B), and biotiny-
lated proteins [112]. Avidin binds to biotin via an exceptionally strong non-
covalent interaction, which is rapid and nearly insensitive to pH, tempera-
ture, proteolysis, and denaturing agents. It is also stable, showing no sig-
nificant loss of activity over time. One downside of using the avidin-biotin
system is the high cost of the proteinaceous-binding reagent.
Protein A/G-antibody
Protein A and G are both popular antibody (Immunoglobulin G (IgG)) im-
mobilizing reagents, extracted from bacteria. They specifically bind to the
constant fragment crystallizable region (Fc region) of IgG. Thus, the vari-
able Fragment antigen-binding (Fab) region of IgG is accessible to Ag bind-
ing [113]. An additional benefit of using protein A/G is that antibody can
be detached by acid treatment and the surface made reusable.
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Site-Specific, Covalent Immobilization
Site-Specific covalent immobilization, an oriented covalent coupling of a
protein to a substrate is performed in a controllable way via a unique chem-
ical group or sequence introduced in the protein at a site-specific loca-
tion [114]. Several bioorthogonal chemistries, also known as ’click’ reac-
tions such as, copper or ring-strain catalyzed azide-alkyne cyclo-additions,
Staudinger-ligations, Diels-Alder cyclo-additions, thiol-ene additions, and
oxime formation are commonly used in this regard.
Affinity tags
One of the most important advantages of fusion proteins (chimeric pro-
teins), also known as affinity tags, is the possibility to attach a generating
recombinant fusion part, the preparation of which can sometime be very ex-
pensive or complicated, for immobilization of various proteins [115]. Poly-
histidine tags, in which the C- or N-terminus of proteins are genetically
engineered to have an oligohistidine (His) segment that specifically reacts
with metal ions immobilized on the matrix, are of the most common appli-
cations of this technique [116].
Although the affinity of these tags is much weaker than that of the
streptavidin-biotin linkage, the immobilization could be reversed by
adding competing chelating agents such as ethylenediaminetetraacetic acid
(EDTA), and the controlled orientation of immobilized proteins is another
benefit. The interference of large number of metal-binding proteins or ad-
ditional interactions between the immobilized protein and affinity support,
on the other hand, is a serious limitation.
2.4.5 Conclusion
As described above, each immobilizationmechanism has its drawbacks and
advantages with relative importance depending on fabrication constraints
and application requirements. Thus, attempts have been made to address
the limitations of individual mechanisms, aiming for better protein activity,
more control for protein orientation, less steric hindrance, more protein pat-
terning density, and less nonspecific protein adsorption using a combined
method.
2.4
Protein
im
m
obilization
strategies
forbiosensing
purposes
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Table 2.3: Most common immobilization techniques, their pros and cons
Technique Pros Cons
Physisorption Inexpensive; simple; no need
for toxic reagents or sophisti-
cated chemical protocols; possi-
ble reusability of the substrate
Random orientation of the
antibody or multiple binding
sites, reduced accessibility to
the functional sites or confor-
mational changes influencing
protein activity, weak attach-
ment
Electrostatic Inter-
action
Simplicity, reversibility, stronger
binding and less conformational
change compared with ph-
ysisorption
Limited use because of need
for highly charged support
and suitable condition for anti-
body/enzyme to remain both
strongly bound and fully active
Covalent binding
NHS
Stable nature
Reduced activity of proteins (be-
cause of linkage on active sites),
need for toxic reagents, long
incubation times, complicated
chemistry
EDC-amine
Carboxylate-
EDC+NHS-amine
Carboxyl Chemistry
Thiol Chemistry
Tyrosine & Tryptophan
Bioaffinity immo-
bilization
Avidin- Biotin High selectivity, high speci-
ficity, oriented protein immobi-
lization, reversibility
High cost, complicated proto-
cols
Protein A/G-Ab
Site-specific, cova-
lent immobiliza-
tion
Affinity tags
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3
Scientific Background
3.1 Introduction
This chapter aims to introduce the scientific and technical principles ap-
plied in the experimental chapters of this work. Three major subjects will
be discussed.
￿ The first subject is an overview on biosensors and its types. A special
focus is dedicated to electrochemical sensors.
￿ The second part deals with different electrochemical techniques. The
definition of these techniques will be described.
￿ The last section embraces main principles of microfluidic devices.
3.2 Overview on Immunosensors
3.2.1 Introduction
The concept of using immunological components as sensing agents was
first described within an immunoassay for plasma insulin in human sub-
jects [1]. The ELISA test, developed based on the high dissociation con-
stants (Kd) with which antibodies bind to their target antigen, has since
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then been seen the gold standard for comparison against all newly devel-
oped immunoassays and immunosensors [2]. Briefly, ELISAs involve the
immobilization of a reactant (an antibody or antigen) onto a solid surface,
with enzymes being used as markers for the presence and abundance of a
specific antibody-antigen (Ab/Ag) interaction [3].
The widespread use of antibodies regardless of their high cost, variable
affinity, and short shelf life arises from their exceptional specificity and sen-
sitivity toward their binding partners, i.e. the antigens (Ag). Immunoas-
says, therefore, make use of the sensitivity and specificity of the antibody-
antigen interaction [4]. Several methods exist to transduce a signal created
by the binding of antibody and analyte, each with associated advantages
and disadvantages, leading to a wealth of research into fabrication of im-
munosensors and immunoassays [5].
Most clinical analyses are carried out by specialized staff in laboratories us-
ing desktop instruments, thus assuring the highest possible confidence in
the obtained results. However, there are many cases in which a critical clin-
ical analysis cannot be performed in those optimal conditions because of
the lack of trained analysts or the required facilities, as is often the case in
underdeveloped or isolated areas. In those cases, biosensors can be the only
option to make a trustworthy medical diagnosis.(Figure 3.1)
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Figure 3.1: Process of clinical testing in outpatient situations using central laboratory versus POC methods. The
processes are shown in a simplified format and may sometimes contain additional steps [6].
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3.2.2 What is a Biosensor
The first biosensor was described in 1962 by Clark and Lyons [7]. They im-
mobilized glucose oxidase (GOD) on a semipermeable dialysis membrane
on an amperometric oxygen electrode surface to quantify glucose concen-
tration directly.
According to the International Union of Pure and Applied Chemistry (IU-
PAC), ’A biosensor is a self-contained integrated device which is capable
of providing specific quantitative or semi-quantitative analytical informa-
tion using a biological recognition element (biochemical receptor) which
is in direct spatial contact with a transducer element. A biosensor should
be clearly distinguished from a bioanalytical system, which requires addi-
tional processing steps, such as reagent addition. Furthermore, a biosensor
should be distinguished from a bioprobe which is either disposable after
one measurement, i.e. single use, or unable to continuously monitor the an-
alyte concentration [8].
In other words, biosensors permit the analysis of analytes with great speci-
ficity and sensitivity in a short time [9]. These techniques have the capabil-
ity to be used in POC systems and portable devices [10].
PoC testing is an ’on site’ test, detailed within a large proportion of re-
search. However, none of the existing immunosensors offer a complete set
of the necessary characteristics for a good POC sensor including full au-
tomation, portability, precision, accuracy and sensitivity, low cost and ease
of use [11]. Non-invasiveness is another important characteristic when con-
sidering POC sensor design, preferably using samples such as urine, sweat
or saliva are used. Minimizing the pain associated with blood sampling is
also possible by reducing needed sample volume [11].
The detection process in a biosensor is mainly based on the specific inter-
action between the analyte of interest and the recognition element (such
as an electrode). As a result of this specific interaction, changes in one or
several physicochemical properties (pH, electron transference, heat trans-
fer, change of potential or mass, variation of optical properties, etc.) occur,
which later on are detected and measured by a specific transducer.
It therefore could be concluded that a biosensor is composed of two main
parts: (Figure 3.2)
￿ A bioreceptor or an immobilized sensitive biological element (enzyme,
DNA probe, antibody) recognizing the analyte (enzyme substrate,
complementary DNA, antigen).
￿ A transducer used to convert (bio)chemical signal resulting from the
interaction of the analyte with the bioreceptor into an electronic one.
The intensity of the generated signal is directly or inversely propor-
tional to the concentration of the analyte [12].
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Figure 3.2: Different types of biosensors based on their structure.
3.2.3 Main Types of Immunoassays
Immunosensors could be divided into ’direct’ or ’indirect’ assays, meaning
that the detection mechanism operates either directly via the Ab/Ag inter-
action, or a further label, such as an enzyme or fluorescent molecule, is used
in order to detect whether a binding event has occurred. (Figure 3.3) The
principal challenge for many label-free assays of protein biomarkers is the
occurrence of a relatively less significant change in properties upon target
binding and that the acquired responses are highly specific [13].
In another classification, immunoassays are divided into ’competitive’ and
’noncompetitive’. In competitive assays, the analyte competes in propor-
tion to its concentration with labeled analyte for a limiting number of an-
tibody binding sites. As the analyte concentration increases, more labeled
analyte is displaced, giving a decrease in signal if antibody-bound labeled
analyte is detected, or an increase in signal if the free labeled analyte is de-
tected. In a noncompetitive assay, such as a sandwich immunoassay, which
will be discussed in more detail in the following paragraphs, the signal in-
creases in proportion to the analyte concentration [14].
On the other hand, there are two main types of immunoassays:
Heterogeneous immunoassays In heterogeneous immunoassays, the an-
tibody (or in some cases antigen) is immobilized on a solid support [15][16].
The most commonly used heterogeneous immunoassay is the sandwich as-
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Figure 3.3: Different types of biosensors based on the detection technique.
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say. The procedure usually consists of a capture step with a primary anti-
body followed by a second binding reaction between the captured antigen
and a labeled second antibody. An advantage of this technique is the en-
hanced specificity obtained from two separate recognition steps provided
by the two antibodies that are generally selected to recognize two different
epitopes on the antigen. This is usually the preferred assay format when the
application demands the highest degree of sensitivity and selectivity. A lim-
itation of the sandwich assay is the requirement that the analyte should be
able to bind with two antibodies simultaneously, which generally restricts
its use to molecules with a molecular weight of greater than about 1000 Da.
Homogenous immunoassays Homogeneous immunoassays take place
entirely in the solution phase. They rely on the formation of the antigen-
antibody complex causing a change in the intensity of the label’s signal.
Distinguishing between the bound and unbound states enables the im-
munoassay to be done without a separation step. This simplifies the assay,
removing the antibody immobilization and rinsing steps. An advantage
is that there is no solid phase that can be affected by non-specific binding
[17]. Homogeneous assays are more difficult to develop and generally have
poorer limits of detection and selectivity than heterogeneous assays. They
are commonly used for detecting therapeutic drugs that have a relatively
high concentration in blood.
3.2.4 Immunosensor components
The most commonly used components in immunosensor technology are as
following:
Carbon nanotubes
The importance of single-walled (SWNT’s) and multi-walled (MWNT’s)
CNTs in the development of the immunochemical devices was first re-
ported in 1991 [18]. This was mainly due to their role in enhancing detec-
tion sensitivity compared to sensors incorporating other carbon platforms
(possibly due to increased surface area, their electrocatalytic effects, lower
levels of fouling, being mechanically strong and flexible and excellent elec-
trical and thermal conductivity) [19].
Nanoparticles
Over the past decade, more and more research has been performed on the
use of nano-sized metal particles, particularly noble metal nanoparticles
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with controlled size, morphology, and crystal orientation, as their physical
and chemical properties differ from that of the bulk material [20].[21]. The
inherent benefit of nanoparticles is their ability to significantly enhance sen-
sitivity and lower detection limits of sensors, possibly due to the increased
surface area onto which antibodies can be immobilized, or affecting the re-
fraction of light in SPR-based sensors [22]. These noble metal nanoparticles
are becoming more popular in electrochemical sensing devices, as many
studies have suggested that the use of modified electrodes can improve the
performance of an electrochemical sensor [23].
Among the noble metal nanoparticles, gold nanoparticles (AuNPs) are of
particular interest not only because of their stability, but also because of
their specific physicochemical properties, including the enhanced diffusion
of electroactive species based on their high effective surface area, improved
selectivity, catalytic activity, and higher signal-to-noise ratio and conduc-
tivity [24] [25]. Important here, AuNPs provide a stable surface for protein
immobilization and overcome the need for external electron-transfer me-
diators in electrochemical sensing [26] [27] [28]. The use of AuNPs in this
work is going to be discussed later on in Chapters 4 and 5.
3.2.5 Detection Techniques
As mentioned earlier, biosensors could also be categorized based on their
detection techniques [29]:
￿ Optical [30]
￿ Direct detection by monitoring the light properties: fluorescence,
absorbance, and luminescence/chemiluminescence.
￿ Light property modulation detections: surface plasmon resonance
(SPR), evanescent waves, interferometry, Raman spectrometry,
fiber optics, and optical waveguides [31].
￿ Non-optical
￿ Electrochemical: The electrochemical detection can be used to
measure the concentration of the analyte by converting the ana-
lyte’s chemical signal into the electrical signal via the electrodes
[32].
￿ Amperometry: Amperometric sensors measure the current
signal generated by the redox reaction on the electrode while
a constant potential is applied [33]. Amperometric detection is
based on the fact that the applied voltammetric potential be-
tween the reference and working electrode would cause the
oxidation or reduction of the electroactive species in the vicin-
ity, and induce an electrical current. The change of the current
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is related to the concentration of the analyte. (Figure 3.4)
Such sensors consume a small percentage of analytes during
measurement, and thus either the analyte must be redox active
or use of a redox active label will be necessary. Consumption
of the analyte creates concentration gradients, thereby render-
ing responses are stir - dependent.
The sensitivity of amperometric immunosensors can be im-
proved using a layer-by-layer (LBL) construction approach
utilizing AuNPs or methylene blue to form a uniform and
stable base [34]. This is mainly because increasing the sur-
face area onto which capture agents are immobilized increases
binding events and sensitivity. Cross-linking also prevents
conformational change and unfolding of the antibodies allow-
ing markedly enhanced sensitivity when compared with sim-
ilar constructs, longer storage times and higher resistance to
extremes of pH and temperature. The first technique is to be
discussed later on in Chapter 5 and the latter is already dis-
cussed in Chapter 2.
￿ Potentiometry: In potentiometric detection, analyte is as-
sessed by monitoring the potential of an ion-selective elec-
trode (usually a membrane/surface sensitive to an analyte)
against a reference electrode. The reaction between the sur-
face and the analyte generates a potential proportional to the
logarithm of the electrochemically active material concentra-
tion. (Figure 3.5)
A sensor design which transduces the potential across a
membrane into a digitized signal or field-effect transistors
(FETs) whose semi-conductive surface potential changes upon
a change in analyte concentration are examples of potentio-
metric sensors [36].
￿ Conductometry: Conductometric biosensors can measure the
changes of the electrical conductivity of a medium between
electrodes. Most reactions involve a change in the composi-
tion of the solution. The detection involves measuring the con-
ductivity at a series of frequencies, both in conventional con-
tacted and capacitively coupled contactless conductivity de-
tection (C4D) methods such as potential gradient detection.
￿ Impedimetry: Impedimetric detection method is similar to the
amperometric detectionmethod. The difference between them
is that the AC is used in the impedimetric detection, and thus
the electrolysis of the electrodes can be eliminated. However,
like the conductometric detection method, the sensitivity de-
pends on the difference of the impedance between the back-
76 Scientific Background
Figure 3.4: Schematic diagram of detection mechanism in a sample enzymatic
amperosensor [35].
.
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Figure 3.5: Schematic diagram showing a typical potentiometric cell with an
ion-selective electrode. The ion-selective electrode’s membrane separates the
sample, which contains the analyte from an internal solution containing the
analyte.1
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Figure 3.6: (a) The microchamber is filled with analyte in solution and the
antibodies are redispersed into the solution, some bind with the analyte. (b)
Magnetic particles are attracted to the lower surface. (c) The free and weakly
bound immunosensors which are not bound to analyte are removed from the
lower surface when the upper magnet is switched on.
ground and the analyte.
￿ Magnetic immunosensors: There has been a recent surge of inter-
est in the use ofmagnetic particles within biosensors [38][39]. Elec-
tromagnets can pull immuno-substituted beads towards a binding
site and then weakly bound species can be removed by an oppo-
sitely located electromagnet. This allows a higher level of control
[40]. There are no extra wash stages, giving a simple one-stepmea-
surement once the sample fluid has been added, allowing simplic-
ity and rapid procurement of results necessary for POC. (Figure
3.6)
￿ Piezoelectric: Piezoelectric devices convert a physical or mechan-
ical change into electrical energy and vice versa. The common-
est piezoelectric sensor is the quartz crystal microbalance (QCM),
which exploits the change in the resonance of quartz crystals upon
changes in their mass, allowing binding of antigen to antibody
(when one of these is immobilized on the crystal surface) to be
measured electrically [41] [42].
￿ Mass-Spectrometry
￿ Others such as nuclear magnetic resonance (NMR) spectroscopy,
magneto-resistive, and acoustical
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3.3 Electrochemistry: Principles
One key issue to take into consideration in biosensing platform integration
is the increasing demand for higher sensitivity and selectivity at minimal
costs, and the possibility to monitor biosensing in real-time, especially for
point-of-care platforms, for which simplicity should also be considered [43].
Considering this, calorimetric and electrochemical approaches are the most
promising due to their simplicity, high sensitivity and specificity, in addi-
tion to the fact that in most cases they simply do not require expensive and
complex instrumentations to achieve a sample-in/answer-out biosensing
platform. Moreover, such approaches allow for multiplexing biosensing
enabling their application in a range from low- to high-throughput diag-
nostics.
Electrochemistry combines an oxidation-reduction chemical reaction that
occurs in a liquid phase with an electrical circuit that is completed by solid
conductive materials. Depending on the type of the analysis, either poten-
tial or current may be measured. In this way the kinetics of the reaction
occurring on the electrode is described by the signal produced from elec-
tron transfer through the system [44].
As mentioned earlier, electrochemistry provides powerful analytical tech-
niques encompassing the advantages of instrumental simplicity, moderate
cost and portability. Another advantage to electrochemical assays is that
they are highly sensitive to very low concentrations. The biological com-
ponent in the sensor recognizes its analyte bioselectivity, resulting in a cat-
alytic or binding event that ultimately produces an electrical signal moni-
tored by a transducer that is proportional to analyte concentration [45] [46].
Considering these advantages, an electrochemical biosensor was designed
to fulfill the final objective of this work.
In the following, some basic electrochemistry principles are discussed.
A standard electrochemical experiment, referred to as a three-electrode
setup, uses a reference electrode (REF), working electrode (WE), and
counter/auxiliary electrode (AUX). (Figure 3.7)
￿ Working electrode: A polarizable electrode is used for the working
electrode on which an electrochemical reaction takes place.
￿ Reference electrode: The reference electrode is a potential standard to
supply a constant potential for introducing the electrochemical reac-
tion on the working electrode. The ideal reference electrode provides
a stable, known potential so that any change in Ecell is attributed to
the analyte’s effect on the potential of the metal indicator electrode.2
2Metal indicator electrodes are paired with a reference electrode and can be used to determine the
concentrations of targeted analytes in a solution. In other words, the cell potential will be directly
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Figure 3.7: Schematic representation of a three-electrode system.
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(Equation (3.1))
Ecell = Eind − Ere f + Ej (3.1)
Where Eind refers to the metal indicator potential and Ej to the junction
potential.
Since no current passes through the reference electrode, its poten-
tial remains constant at the value specified by the analyst. This is a
theoretical model and in reality there is a drop in potential between
the working and reference electrodes, since they cannot be placed in-
finitely close to each other [44]. In addition, the ideal reference elec-
trode should be easy to make and to use. Common reference elec-
trodes are ’Standard Hydrogen Electrode’, ’Calomel Electrode’, and
’Silver/Silver Chloride Electrode’.
￿ Auxiliary electrode: The AUX is distinct from the REF, which estab-
lishes the electrical potential against which other potentials may be
measured, and the WE, at which the cell reaction takes place. When
a certain potential is applied to the WE with respect to the REF, the
redox reaction occurs. The reaction generates the current that can be
measured between the WE and the AUX electrodes. The current is
proportional to the concentration of the analyte.
The appeal of potentiostatic techniques is that the thermodynamics of the
system can be controlled by adjusting the potential. For a general electro-
chemical reaction, this relationship is described by the Nernst equation [47].
In other words, the Nernst equation describes the relationship between the
potential applied to an electrode and the concentration of the redox species
on the electrode surface [32]. If an electrode is at equilibrium with the solu-
tion in which it is immersed, the electrode will have a potential, invariant
with time, which is thermodynamically related to the composition of the
solution. In solution, the ’Oxidant’ is capable of being reduced to the ’Re-
ductant’ on the electrode by the following reversible electrochemical reac-
tion.(Equation (3.2))
Oxidant + ne− ￿ Reductant (3.2)
The Nernst equation relates the potential E, which is applied to the elec-
trode and the concentration of the Oxidant and Reductant on the electrode
surface: (Equation (3.3), (3.4))
E = E0 − (RTnF )lnQ (3.3)
influenced by the target analyte concentration.
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also written as,
E = E0 − 0.0592Vn log[Q] (3.4)
where E is the potential difference between the electrodes (V); E0 is the
standard reduction potential (V); R is the universal gas constant (R = 8.314
J/mol.K); T is the temperature (K); n is the number of electrons transferred
in the half reaction; F is the Faraday’s constant (F = 96,484.6 C/mol); Q is
the reaction quotient, which is the ratio of activities of the species (Q = [R][O] ,
where [R] is the surface concentration of the reductant species and [O] is the
surface concentration of the oxidant species).
Cyclic voltammetry (CV) and linear sweep voltammetry (LSV) have re-
ceived great interest as they can be used for the elucidation of electrode
processes and redox mechanisms. Differential pulse voltammetry (DPV)
and square wave voltammetry (SWV) are particularly useful in the deter-
mination of trace amounts of electroactive compounds in pharmaceuticals
and biological fluids. Stripping voltammetry has also been widely utilized
due to its ability to pre-concentrate analytes for ultra-sensitive detection
[48].
3.3.1 Cyclic Voltammetry
CV is a direct current (DC) potentiostatic techniquewhere potential is swept
between two limits at a constant rate and the current at the working elec-
trode ismonitored during the potential scan. The limits are chosen such that
they flank the potential at which the species is expected to oxidize/reduce.
The relationship between potential and time is described by a triangular
waveform. (Figure 3.8).
The voltammogram is a display of current versus potential. (Figure 3.8)
After the initial non-faradaic region, the neutral species starts to get oxi-
dized as the potential becomes more positive. As oxidization occurs on the
electrode, the mass transfer rate of neutral species towards the electrode
increases, and so does the current. This current reaches a maximum peak,
after which the surface concentration of the neutral species starts to decline
due to depletion from the solution, resulting in a reduced oxidation cur-
rent. (Equation (3.5))The process is then repeated in the same manner for
the reverse scan to obtain the reduction behavior. (Equation (3.6))
[FeII(CN)6]3− + e− → [FeII I(CN)6]4− (3.5)
[FeII I(CN)6]4− → [FeII(CN)6]3− + e− (3.6)
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(a) (b)
Figure 3.8: a) Typical excitation waveform for analog CV, b) Theoretical CV for a
reversible reaction of 1mM K3Fe(CN)6 in 1M NaCl.
Activation potentials are the range of potentials at which the reactants
oxidize/reduce without influences associated with diffusion/transport.
Within this range, there is a steep increase in current due to the conver-
sion of the reactants at the electrode surface. This current, also known as
the ’faradaic current’, is the result of direct electron transfer to or from the
analyte. Eventually the reaction is limited by the diffusion of reactants to-
ward the surface or products away from the surface, so the current reaches
a maximum and then tails off.
The peak current (ip) is measured relative to the baseline extrapolated from
the baseline signal so as not to include charging current in the analysis. The
current is measured in ampere (A). Potential is measured in volts (V).
The formal reduction potential E0 for an electrochemically reversible cou-
ple (Equation (3.7)) can be found at the value that corresponds to 85% of the
peak potential and the thickness of the diffusion layer 3 can be estimated
from (Dt)1/2, where D is the diffusion coefficient and t is time in seconds
[49].
E0 = Epa + Epc (3.7)
3The diffuse-layer model depicts the distribution of net charge near the electrode surface which
diminishes as the interfacial region stretches toward the bulk. The random motion of ions results in a
diffuse layer of charge in which the concentration of counter ions is greatest next to the electrode sur-
face and decreases progressively until a homogenous distribution appears in bulk electrolyte. Specific
adsorption of desolved ions at the electrode is weak and therefore the adsorbed inner layer of nega-
tive charge only partially shields the positive charge at the electrode. As a result, a layer of solvated
anions is present adjacent in the diffuse layer.
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Where Epa is the anodic peak potential and Epc is the cathodic one. For a
reversible redox couple, the number of electrons transferred in the electrode
reaction can be determined by the separation between the peak potentials:
(Equation(3.8))
DE = Epa − Epc ≅ 0.059n (3.8)
CV has the capability for rapidly observing redox behavior over a wide
potential range. The potential cycle may be repeated to obtain additional
information about system stability. The step, or scan rate, at which the po-
tential is varied can also be used to extract further information pertaining
to mass transfer profile near the electrode as the thickness of the diffusion
layer can be adjusted by the scan rate.
It should be noted that the choice of the electrolyte affects the intrinsic be-
havior of the redox couple. The activity of the reactants also changes de-
pending on the electrolyte concentration.
In a system where the electron transfer occurs much faster than the diffu-
sion of an electroactive species to the electrode, the peak current, ip (A) for
the forward sweep of the first cycle, can be calculated from the Randles-
Sevcik relationship. (Equation (3.9)) Therefore, CV is useful for quantita-
tive experiments because the current signal is directly proportional to the
concentration of the analyte being measured.
ip = k.n3￿2.A.D1￿2.C.v1￿2 (3.9)
where k is a constant; n is the number of moles of electrons transferred; A
(cm2) is the area of the electrode; D (cm2/s) is the diffusion coefficient; C
(mol/cm3) is the solution concentration and v (V/s) is the scan rate.
This relationship can be used to determine if a reaction is diffusion limited
by simply plotting the peak current versus the square root of the scan rate.
If a linear plot is obtained then the reaction is mass transfer limited. The
slope of the resulting line is also proportional to the diffusion coefficient, as
shown in the Randles-Sevcik equation. (Equation (3.9)) Moreover, the peak
potentials at varying scan rates can be compared to find out if a reaction is
reversible. In a reversible reaction where the electron transfer rate is fast, all
peaks should appear at the same potential at different scan rates. (Figure
3.9).
3.3.2 Differential Pulse Voltammetry
In order to increase speed and sensitivity, many forms of potential mod-
ulation (other than just a simple staircase ramp) have been tried over the
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Figure 3.9: Plot of peak height for K3[Fe(CN)6] reduction at different scan rates.
86 Scientific Background
Figure 3.10: The potential ramps applied to the auxiliary electrode during
selected forms of voltammetry and the corresponding voltammograms. E is the
potential; I, the current; DI, the current difference; IAC, the AC current; t, the
electrode drop time; and m, the points at which measurements are made.
years. DPV is an electrochemical technique where the current is measured
as a function of time and as a function of the potential between the auxil-
iary and reference electrodes. It can be considered as a derivative of linear
sweep voltammetry or staircase voltammetry, with a series of regular volt-
age pulses superimposed on the potential linear sweep or stair-steps. The
current is measured immediately before each potential change, and the cur-
rent difference is plotted as a function of potential. By sampling the current
just before the potential is changed, the effect of the charging current can be
decreased.(Figure 3.10)
3.3.3 Chronoamperometry
Chronoamperometry (CA) is a useful tool for determining diffusion coeffi-
cients and for investigating kinetics and mechanisms. Unlike the CV tech-
nique, CA can yield this information in a single experiment. (Figure 3.11)
When a potential step large enough to cause an electrochemical reaction is
applied to an electrode, the current changes with time (t). The study of this
current response as a function of time is called CA and is studied using the
Cottrell equation: (Equation(3.10))
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Figure 3.11: a) Potential wave form for chronoamperometry and
chronocoulometry, b) Theoretical Anson plots for a blank (A), a redox system
(B), and a system showing adsorption (C).
i = n.F.A.D1￿2.Cb(p.t)1￿2 (3.10)
where n represents number of electrons; F, the Faraday’s constant; D, the
diffusion coefficient; Cb, the concentration of the bulk; and A, the surface
area of the electrode.
Simply stating, the Cottrell equation shows that the current is proportional
to 1
t1/2
. It also helps calculating the diffusion coefficient by simply rearrang-
ing the equation, providing the number of electrons obtained from the CV
experiment and providing values for the other variables. Another useful
parameter to calculate is the ’true’ area of the electrode, where the geomet-
ric area of an electrode is not the same as the electrochemically active area
due to surface roughness.
3.3.4 Chronocoulometry
Chronocoulometry (CC) is an outgrowth of the chronoamperometric tech-
nique with two main advantages:
￿ It helps determine the kinetic rate constant more accurately
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￿ It helps detect adsorption of a species on an electrode surface more
easily
In a CC experiment, the charge used in an oxidation or reduction process is
measured and then plotted with respect to time. The excitation waveform
is the same as that used for CA, but the resulting curve shows an increase
of charge with time, rather than the decrease seen in CA.
Like the CA response curve, the CC curve shows that in most reactions
the diffusion of the reacting species to the electrode takes some time. This
implies that at the start of the experiment (time zero) the only charge mea-
sured is due to the charging of the double layer of the electrode. In cases
where a species is adsorbed on the surface of the electrode, the reaction of
this material can take place at time zero. This reaction gives rise to current
and to a larger value of charge at the initial point than would be expected
for a non-adsorbed species. The technique is therefore also used to calculate
adsorption layer thickness.
Since CC is based on the same assumptions as CA, the charge at any time
can be calculated by simply integrating the Cottrell equation and adding
corrections for the charge due to the double layer and any interfacial in-
teractions (for example, adsorption). The resulting equation is: (Equa-
tion(3.11))
Q = 2n.F.A.Cb.D1￿2.t1￿2
p1￿2 +Qd1 +Q1 (3.11)
where Q is charge; n represents number of electrons in the reaction; F, the
Faraday’s constant; A, the electrode surface area; Cb, the bulk concentra-
tion; D, diffusion coefficient; Qd1, charge due to double layer; and Q1,
charge due to interfacial interaction.
If Q is plotted versus t1/2 the result is the Anson plot. The slope of the plot
would be 2n.F.A.Cb.D
1￿2
p1￿2 if no adsorption is assumed to occur and the inter-
cept is the double layer charge. If adsorption does occur, the line in this plot
would be offset by the charge due to this interfacial phenomenon. It is easy
to differentiate between the charge due to the double layer and that due to
adsorption. (Figure 3.11)
3.3.5 Electrochemical Impedance Spectroscopy (EIS)
Originally developed by Sluyters et al., EIS techniques allow for the char-
acterization of complex processes and interfaces by observation of a sys-
tem’s impedance response to a small periodic alternating perturbation at
steady state or a voltage perturbation [50]. In other words, EIS is highly
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Figure 3.12: Impedance spectra, Nyquist curve, a plot of the real impedance
versus imaginary impedance. The graph is semicircular with higher frequencies
associated near the origin and lower ones away from the origin.
sensitive for measuring electrode surface changes, and allows complex bio-
recognition events to be probed with a simple, label-free, and mediator-free
strategy.
During an impedance measurement, a small amplitude AC signal is im-
posed to excite the surface and the current with respect to the polarizing
potential is monitored with the capacitive (imaginary (Z”)) and faradaic
(real (Z’)) components of impedance being identified, quantified and dis-
played as Nyquist plots to determine the resistive, capacitive and inductive
behavior of the surface at that particular frequency [51]. (Figure 3.12)
From these Nyquist curves, several key parameters and system operations
are deduced. Namely, solution resistance, double layer capacitance (or con-
stant phase elements formation) and electron transfer resistance were cal-
culated to measure solution stability, surface properties or diffusion issues.
Since this plot also contains the frequency information associated with a
particular impedance measurement, it is widely used in impedance analy-
sis.
Impedance changes between electrode surfaces and a surrounding solu-
tion upon a binding event can be transduced into an electrical signal, us-
ing a frequency response analyzer. There are several theories as to how
this binding event affects changes in real and imaginary components of the
system, although it is difficult to identify the origin of these changes. One
theory hypothesizes that binding of larger antigens forms a resistive bar-
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rier, causing the impedance to increase whilst binding of smaller antigens
can facilitate a charge transfer and lower impedance [52]. Another theory is
that when the Ab/Ag complex is formed, the binding events between the
hyper-variable loop regions mean that conformational changes occur and
potential changes are introduced into the system.
During EIS, a signal in the form below is applied: (Equation(3.12))
V(t) = Vm.sin(w.t) (3.12)
where V(t) is the overall signal with an amplitude (Vm) and an angular fre-
quency (w). The resulting current response is measured through Equation
(3.13).
i(t) = Im.sin(w.t + q) (3.13)
The impedance at a particular frequency is then calculated simply by the
following relationship: (Equation(3.14))
Zw = V(t)i(t) (3.14)
3.4 Basic Concepts in Microfluidic devices
3.4.1 Introduction
In the past 10 years, microfluidic technology has evolved from an intrigu-
ing concept to a vigorous growth industry that produces numerous publica-
tions and patents per year and yet can still be considered in its infancy. De-
spite impressive laboratory results, microfluidic immunoassay devices have
yet to make a major impact on the commercial market. A reason for this is
that all of the necessary technologies such as fabricating structures, modify-
ing surfaces, integrating detection, and the chemistry of the immunoassay
need to be combined and optimized in order to compete with existingmeth-
ods that have been perfected over decades [53].
A microfluidic device can be identified by the fact that it has one or more
channels with at least one dimension less than 1 mm. Common fluids used
in microfluidic devices include blood samples, bacterial cell suspensions,
protein or antibody solutions and various buffers. Microfluidic technol-
ogy in general seeks to improve analytical performance by reducing the
consumption of reagents, decreasing the analysis time, increasing reliabil-
ity and sensitivity through automation, and integrating multiple processes
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in a single portable device. These features are particularly suitable for im-
munoassay applications.
Microfluidic systems for biosensing normally consist of a set of fluidic op-
eration units that allow different biomolecules to be detected and assayed
in an easy and flexible manner. Overall, the chip-based platform which has
good integration with micro/nano-fluidic components is capable of sam-
pling, filtration, preconcentration, separation, restacking, and detection for
biomolecules.
Based on their flow type, microfluidic systems can be categorized into two
main types, continuous and discrete.
￿ Continuous microfluidic systems: Continuous-flowmicrofluidic oper-
ation is a promising approach for many well-defined and simple bio-
chemical applications or even chemical separation, because it is easy to
implement and less sensitive to protein fouling problems. They, how-
ever, are less suitable for tasks requiring a high degree of flexibility
or complicated fluid manipulations. These closed-channel systems are
inherently difficult to integrate and scale because the parameters that
govern the flow field vary along the flow path making the fluid flow
at any one location dependent on the properties of the entire system.
￿ Discrete microfluidic systems: Droplet-based microfluidic systems
are currently an emerging area of microfluidic research. One of the
most popular means is to inject multiple laminar streams of aqueous
reagents into an immiscible carrier fluid and therefore to induce flow
instability instantly for forming the droplets [54].
There are several distinctive advantages based on droplet-based mi-
crofluidic systems. First, the systems promise a new high-throughput
technology that enables the generation of microdroplets in excess of
several thousand per seconds. In addition, parallel and serial in-vitro
compartmentalization is possible with this technology. The reagents
are confined inside the droplets in water-in-oil (w/o) emulsions and
reagent transport occurs with no dispersion. This unique feature en-
ables chemical reaction indexing, thereby facilitates many chemical re-
actions in a highly organized manner. Furthermore, fast mixing can
occur within minute volumes of microdroplets (nanoliter to femtoliter
range) due to the short diffusion distance and chaotic mixing within
droplets with the use of twisting channel geometries by stretching,
folding, and reorienting fluid. Another feature is that the variation
of the channel dimensions can regulate the droplet volumes. With a
control of flow rate, the reagent concentrations can be modified ac-
cordingly.
While heterogeneous immunoassays benefit from the high surface
area/volume ratio in the microchannel, homogeneous assays typically take
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advantage of the multiplexing and very fast electrophoretic separations
made possible by the microchip format.
Microfluidic devices can be used to obtain a variety of interesting measure-
ments including molecular diffusion coefficients, fluid viscosity, pH, chem-
ical binding coefficients and enzyme reaction kinetics. Other applications
for microfluidic devices include capillary electrophoresis, isoelectric focus-
ing, immunoassays, flow cytometry, sample injection of proteins for analy-
sis via mass spectrometry, polymerase chain reaction (PCR) amplification,
DNA analysis, cell manipulation, cell separation, cell patterning and chem-
ical gradient formation. Many of these applications have utility for clinical
diagnostics. In pursuit of these goals, special interest should be focused on
the following areas [55]. It should be noted that considering the final goal
of this work, this section is focused on microfluidic immunoassays.
￿ Materials. In addition to practical considerations for fabrication, the
nature of the exposed surface in the channel can be especially impor-
tant because of the large surface area to volume ratios associated with
these dimensions. Given the cost advantage of plastics, which is espe-
cially important in disposable devices, the search for improved plastic
materials for the microfluidic chip will continue.
￿ Surface modification. A problem that will continue to be faced when
working in the microscale is non-specific adsorption. Modification of
the surface of the channels is often necessary to prevent adsorption
of the sample and key reagents, which degrades assay performance.
Non-specific adsorption of biological components of an assay, espe-
cially on plastic, can also create a background signal that determines
the detection limit for an assay. Surface modification will also be used
to improve electroosmotic flow, which requires a charged surface, in
channels made of plastic for Capillary electrophoresis(CE)-based im-
munoassays.4
￿ Introducing sample/reagent andmoving fluidwithin themicrofluidic.
A strategy must be devised to interface the macroscale of the tradi-
tional laboratory to the microscale of the device.
The capability for simultaneous multianalyte analysis will grow, prob-
4Microchip CE-based immunoassays: Miniaturized devices using electrophoresis to perform im-
munoassays have been reported where the assay relies on a difference in the electrophoretic mobilities
of the immunocomplex of antigen and labeled antibody from either of the two components [56]. Thus,
microchip CE assays use a separation step, electrokinetically separating the immunocomplex from the
free antibody. Chip-based microfluidic immunoassays have several advantages over conventional CE
assays. The channel is very small relative to the bulk of the chip, so heat is dissipated much faster
than capillary-based systems. This allows higher field strengths to be used, resulting in faster sepa-
rations and higher resolution. The faster separations, combined with greater capability for integrated
sample preparation and the potential for multiplexing, make chip-based CE a valuable tool for high
throughput applications such as combinatorial chemistry that only supply small sample volumes.
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ably through more complicated multipath microfluidic systems, by in-
tegration with microarrays, or by coded microbeads that carry a num-
ber of different capture antibodies.
￿ Microfluidic design. Design is critical to the device performance char-
acteristics, particularly in accommodating or exploiting the properties
of fluid water on the microscale.
￿ Detection. Detection on small volumes will improve. This is while
different assay techniques use various signal transduction pathways
to recognize an antibody/antigen binding event, and these must be
adapted to the very small volumes.
￿ Integration and miniaturization. The lack of full integration of on-
chip components such as detection has limited the implementation of
microfluidics technology for application outside the laboratory or re-
search facility. Common detection strategies involve microscopes, po-
tentiostats, photomultiplier tubes, lasers, and other hardware that is
bulky, expensive, and requires a trained technician to maintain. Only
one completely on-board system has been reported [57].
On-chip components include miniature pumps and valves, electro-
chemical detectors, and electromagnets to capture beads for a sand-
wich heterogeneous assay.
￿ Reagent stability. As portable devices for use in the field appear, issues
of reagent stability and storage will be dealt with. This is especially
important since the key bio-reagents are fragile.
Some of these specific areas are discussed in detail below:
3.4.2 Materials for the microfluidic devices
The materials used to construct microfluidic immunoassay devices
vary depending on the application, but the vast majority of such de-
vices are constructed of glass, silicon, or polymers [58]. Each of these
materials has its own advantages and limitations.
The glass materials were preferred partly for the biocompatibility to-
ward the biomedical related applications and the ideal surface charac-
teristics where high temperature or strong solvents should appear [59].
However, lack of optical transparency at wavelengths of interest (for
silicon), micromachining difficulties, and comparably high expenses
for both silicon and glass materials have hampered their wider ap-
plications in microfluidics. Tremendous effort has been made to find
alternative materials that are more cost-effective and easier for micro-
machining.
With the development of related fabrication techniques in recent years,
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the polymer/plastic-based microfluidic systems have garnered more
interest than its conventional competitors [60]. In spite of compara-
tively weak bonding and structure deformation during device packag-
ing processes, polymer materials still seem attractive due to the facts
that: they are more economic compared to silicon and glasses, easier
to be fabricated in/on, avoidance of high-temperature annealing and
stringent cleaning, more system integration friendly (e.g., interconnec-
tions), and there exists a wider range of materials to be chosen for
characteristics that are required for each specific application, such as
good optical transparency, biocompatibility, and chemical or mechan-
ical properties. Another important reason for the interest from both
academia and industry on polymer microfluidic devices is the possi-
bility of disposable microfluidic chips toward biomedical and clinical
applications.
One particular polymer that is extensively used in this regard is PDMS.
PDMS is a transparent, elastomeric polymer that can be fabricated
rapidly with features having dimensions as small as 10 nm [61]. The
elastomeric nature of PDMS makes it seal well, and often the adhe-
sion due to conformal surface contact with a smooth, flat surface is
enough to seal microchannels for low pressure applications. Alterna-
tively, PDMS can be bonded irreversibly to itself, glass, or silicon by
treating both bonding surfaces with plasma treatment. Another signif-
icant advantage of PDMS over glass, silicon, andmany other polymers
is that the PDMS fabrication process can be done under normal labora-
tory conditions, as opposed to the confines of a clean room that can be
expensive to maintain or difficult to access [62]. The principal limita-
tions of PDMS for immunoassay applications are due to its hydropho-
bic surface properties. Thus, proteins and other molecules tend to ad-
sorb to an untreated PDMS surface, and the surface is poorly wetted
and prone to forming bubbles in aqueous systems. These limitations
can be reduced or eliminated through chemical or plasma treatment of
the surface [63].
Although PDMS now has an established role in prototyping new de-
signs for microfluidic devices, its usefulness for commercial applica-
tions is limited because the fabrication process does not lend itself to
the mass production accessible to injection molded or embossed hard
plastics [64]. Also, PDMS is not as durable as the more rigid plas-
tics and polymers such as polystyrene, polycarbonate, and polymethyl
methacrylate (PMMA) that are often used in commercial devices.
Thermoplastic polymers, including PMMA and cyclic olefin copoly-
mer (COC), possess low surface free energy and thus tend to be hy-
drophobic or weakly hydrophilic, limiting the strength of bonds which
may be formed between mating substrates [65].
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Thermoplastic polymers have several advantages including the low
material cost, availability of range of material properties tailored for
specific need, and amenability for high- throughput fabrication. They
are receiving attention for their structural strength, optical clarity, and
biocompatibility.
COC is a comparatively new thermoplastic material, and has been
gaining esteem in LOC (Lab-on-chip) fabrication due to its better
chemical properties [66]. COC is a copolymer consisting of ethylene
and norbornene that is synthesized using a metallocene catalyst [60].
Through its characteristic molecular structure and tailored catalyst
technology, COC offers a wide range of grade variations, in terms of
flow properties and heat resistance, such as:
￿ Topas-8007 (Tg = 78○C)
￿ Topas-5013 (Tg = 130○C)
￿ Topas-6015 (Tg = 160○C)
￿ Topas-6017 (Tg = 178○C).
As a result, depending on the specific application, an appropriate sub-
strate material can be selected for the microdevice. Moreover, due to
the olefinic character, COC has good resistance towards hydrolysis,
acids and alkalis, and most organic polar solvents such as acetone,
methanol, and isopropyl alcohol [67]. It can be soluble in organic sol-
vents such as toluene and naphtha. It is characterized as having high
purity, good biocompatibility and excellent optical properties. It has
higher transparency in visible and near ultraviolet regions compared
to PMMA. The refractive index of COC is higher than that of PMMA,
making COC ideally suited for applications that use optical detection
methods. COC is easier to emboss, which is especially important when
using soft PDMS tools because the density of COC is lower than that
of PMMA. The water absorption of COC is 0.01% which is ten times
less than that of PMMA. Thus, the relative humidity changes in the
environment will not significantly affect devices replicated in COC.
Current methods for fabrication of microfluidic devices include proto-
typing techniques (includes hot embossing, injectionmolding, and soft
lithography) and direct fabrication techniques such as laser photoab-
lation or laser micromachining, photolithography/optical lithography
and x-ray lithography [68] [69]. In fact, during the past decade pho-
tolithography techniques have progressed to achieve smaller feature
patterning ability and have been coupled to various plastic/polymer-
based techniques to better suit lab-on-a-chip applications. To date,
most of the current soft lithography processes still rely onmodern pho-
tolithography techniques for master template/mask fabrication. Con-
sequently, the low resolution ability of soft lithography can be gradu-
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ally improved with the high quality masks by modern photolithogra-
phy. Sub-100-nm fabrication resolution can also be achieved by com-
posite layers of stamps [70].
Bonding can also be enhanced through the generation of electrostatic
interactions, and surfaces possessing high specific energy in the form
of polar functional groups, which can produce hydrogen or covalent
bonds across the interface, are capable of providing bond strengths ex-
ceeding that of the bulk polymer [71].
3.4.3 Surface modification
In the microscale environment, the high surface area/volume ratio
magnifies the effects of non-specific binding. This is especially im-
portant in immunoassays where key reagents such as antibodies and
enzyme labels can adsorb to hydrophobic surfaces, seriously degrad-
ing the assay performance. To address this, different strategies have
been applied to block or modify the surface of the microchannel, the
most common of which has been the use of a blocking agent such as
bovine serum albumin (BSA) to pre-coat the surface. While sufficient
for many applications, the surface modification is not permanent, and
the resulting surface is somewhat heterogeneous [72].
As mentioned earlier, heterogeneous assays are distinguished by at-
taching the primary antibody to a solid support, and a separation step
that isolates the desired analyte from any other potential source of sig-
nal. The majority of heterogeneous immunoassay applications use an-
tibodies immobilized on the surface of the device or particles such as
beads as the solid phase. Devices that use the microchannel surface for
antibody immobilization have the advantage of a higher surface area
to volume ratio than a standard well format.
This is while the antibodies that are directly adsorbed on a hydropho-
bic surface by the hydrophobic effect may be partially or completely
denatured due to the conformation changes associated with the ad-
sorption process. A further limitation of immobilization on a hy-
drophobic surface is that blocking steps are usually necessary to limit
the non-specific binding of proteins and small molecules that could re-
duce the effectiveness of the assay. Different strategies to immobilize
antibodies on the surface are discussed earlier in Chapter 2.
3.4.4 Introducing sample/reagent and moving fluid
within the microfluidic.
A strategy must be devised to interface the macroscale of the tradi-
tional laboratory to the microscale of the device. Reagents are typically
3.4 Basic Concepts in Microfluidic devices 97
introduced by way of pressure-, electrokinetic-, or capillary-driven
flow.
Pressure Driven Flow In pressure driven flow, the fluid is pumped
through the device via positive displacement pumps, such as syringe
pumps. One of the basic laws of fluid mechanics for pressure driven
laminar flow, the so-called no-slip boundary condition, states that the
fluid velocity at the walls must be zero. This produces a parabolic
velocity profile within the channel. The parabolic velocity profile has
significant implications for the distribution of molecules transported
within a channel. Pressure driven flow can be a relative inexpensive
and quite reproducible approach to pumping fluids through microde-
vices. With the increasing efforts at developing functional microp-
umps, pressure driven flow is also amenable to miniaturization.
Electrokinetic Flow Another common technique for pumping fluids
is that of electro-osmotic pumping. In devices that use electrokinetic
flow, reagents are typically pipetted or otherwise transferred into a
reservoir on the device, at which point flow is controlled by applying
electric potentials. Similarly, samples introduced by capillary flow are
typically loaded into a reservoir connected to the microchannel.
If the walls of a microchannel have an electric charge, as most sur-
faces do, an electric double layer of counter ions will form at the walls.
When an electric field is applied across the channel, the ions in the dou-
ble layer move towards the electrode of opposite polarity. This creates
motion of the fluid near the walls and transfers via viscous forces into
convective motion of the bulk fluid. If the channel is open at the elec-
trodes, as is most often the case, the velocity profile is uniform across
the entire width of the channel. However, if the electric field is applied
across a closed channel (or a backpressure exists that just counters that
produced by the pump), a recirculation pattern forms in which fluid
along the center of the channel moves in a direction opposite to that at
the walls. In closed channels, the velocity along the centerline of the
channel is 50% of the velocity at the walls.
One of the advantages of electrokinetic flow is that the blunt velocity
profile avoids many of the diffusion nonuniformities that occur with
pressure driven flow. However, sample dispersion in the form of band
broadening is still a concern for electro-osmotic pumping. Another
advantage to electrokinetic flow is that it is straight forward to cou-
ple other electronic applications on-chip. However, electrokinetic flow
often requires very high voltages, making it a difficult technology to
miniaturize without off-chip power supplies. Another significant dis-
advantage of electrokinetic flow is the variability in surface properties.
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Capillary flow Capillary forces result from the interaction of liquid,
gas and solid surfaces, at the interface between them. In the liquid
phase, molecules are held together by cohesive forces. In the bulk
of the liquid, the cohesive forces between one molecule and the sur-
rounding molecules are balanced. However, for the same molecule at
the edge of the liquid, the cohesive forces with other liquid molecules
are larger than the interaction with air molecules. As a result, the liq-
uid molecules at the interface are pulled together towards the liquid.
The overall effect of these forces is to minimize the free surface of the
liquid that is exposed to air. The proportionality between the decrease
in energy of the surface that results from decreasing the surface is de-
scribed by the surface tension.
The flow of a fluid through a microfluidic channel can be character-
ized by the Reynolds number, defined as Equation (3.15), where v is
the maximum velocity of the object relative to the fluid (m/s); L is a
characteristic linear dimension (traveled length of the fluid) (m); µ is
the dynamic viscosity of the fluid (Pa.s or N.s/m2 or kg/(m.s)); n is
the kinematic viscosity (n = µr ) (m2/s); r, is the density of the fluid
(kg/m3) [73].
For many microchannels, L is equal to 4A/P where A is the cross sec-
tional area of the channel and P is the wetted perimeter of the channel.
Due to the small dimensions of microchannels, the Re is usually much
less than 100, often less than 1.0. In this Reynolds number regime, flow
is completely laminar and no turbulence occurs. Laminar flow pro-
vides a means by which molecules can be transported in a relatively
predictable manner through microchannels. The transition to turbu-
lent flow generally occurs in the range of Reynolds number 2000.
Re = inertial f orces
viscous f orces
= r.v.L
µ
= v.L
n
(3.15)
3.4.5 Detection
Different assay techniques use different signal transduction pathways
to recognize an antibody/antigen binding event. Most applications
use a label to increase the sensitivity of detection. Current labels in-
clude metals, redox labels, optical labels and enzymes. The majority of
detection techniques mentioned in the biosensor section can similarly
be adopted in microfluidic devices.
In recent years, microfluidic systems fabricated using micro-
manufacturing techniques integrated with electrochemical sensing
electrodes and microfluidic control devices have attracted consider-
able interest and shown their great potential for chemical analysis and
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biomedical applications.
Electrochemical detection strategies commonly have an innate high
sensitivity and simplicity that can be effectively married to miniatur-
ized hardware. As such, they constitute, arguably, the most practical,
quantifiable, and saleable of all low cost diagnostic assessments of a
protein’s presence.
From among different types of electrochemical techniques mentioned
in the previous section, amperometry is a simple technique and thus
miniaturization and integration can be easily achieved by creating a
three-electrode system in the microfluidic chip [74]. Amperometric
detection method has some advantages including simple, low back-
ground noise. It is the most popular electrochemical detection method
in the microfluidic immunoassay system. However, it is not the uni-
versal method. It requires the analyte to have the electrochemical ac-
tivity; otherwise some additional substances with the electrochemical
activity must be introduced to the immunoassay system for the indi-
rect detection.
Potentiometric detection method has the specificity because it uses the
ion-selective membrane to achieve charge separation. However, the
selective membrane is hard to integrate into the microfluidic system,
which greatly limits the application of this method in the microflu-
idic immunoassay. Conductometric detection method is a universal
detection method but lacks the specificity. According to the princi-
ple, the conductivity between the background solution and the analyte
must be sufficiently different. If there are two kinds of the analytes
which have the similar conductivity, then this method cannot distin-
guish them.
A significant advantage of voltammetry for detection in a microflu-
idic system is the improvement in performance that accompanies the
reduction of electrode size into the low micrometer range. As the elec-
trode diameter is decreased into the low micrometer range, a shift to
nonplanar diffusion (e.g., hemispherical) occurs, causing an increase in
the collection efficiency of the electroactive species at the surface [75].
The practical result is an increase in the signal to noise ratio, which
generally translates into a lower detection limit [76].
3.4.6 Design
The materials, shape, and complexity of different microfluidic systems
vary depending on the intended application. Some devices consist of
a single channel, while others are complex patterns with multiple inte-
grated components. While the on-chip integration of such components
as mixers, valves and detectors has the advantage of increased porta-
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bility, the complexity of the fabrication process increases dramatically,
and the reliability of the device diminishes.
This is while, adding multiple channels or other more complex two-
dimensional designs does not significantly affect the time or difficulty
of fabrication, and so many high-throughput multiplexing applica-
tions can be efficiently addressed using microfluidics [56].
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4
Conjugated AuNP-antibody
nanoprobe Fabrication and
Validation
4.1 Introduction
An electrochemical biosensor usually consists of three parts:
￿ A receptor biomolecule, which incorporates a biological or
biomimetic recognition element (nucleic acid, enzyme, antibody,
tissue, organelles or whole cells) and plays a key role in determin-
ing the sensitivity of the electrochemical biosensors.
￿ A transducer, a conductive phase, which converts biochemical sig-
nal into a measurable one based on the interaction between the an-
alyte and the biological molecule associated with the transducer
surface.
￿ An amplifier, a computerized apparatus/software used to
boost/readout of signal.
An efficient biosensor, therefore, relies heavily on selective/specific
binding of the recognition element with the target analytes as well as
the transducer for signaling the binding event in terms of response
time, signal-to-noise (S/N) ratio, and limits of detection (LoD) [1].
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Therefore, designing sensors with higher efficacy depends on the de-
velopment of novel materials to improve both the recognition and
transduction steps.
Nanomaterials, more specifically noble metal nanoparticles (NPs)
have played an important role in the development of new biosensors
and/or in the enhancement of existing biosensing techniques to ful-
fill the demand for more specific and highly sensitive biomolecular
diagnostics [2] [3]. They can measure between 1 to 100 nm in diame-
ter, have different shapes and can be composed of one or more inor-
ganic/metallic compounds. The majority of them exhibit size-related
properties that differ significantly from those observed inmicron-sized
particles or bulk materials. Recent studies have shown that the label-
ing of biomolecules such as antibodies with noble metal NPs results in
highly sensitive and specific bioassays, while maintaining the bioac-
tivity of the biomarker [4]. The concentration of analytes can also be
detected based on the signal detection of such NPs.
Gold nanoparticles (AuNPs) are the most often used labels in sensor
studies because of their intriguing size dependent electrical, optical,
magnetic, and chemical properties as well as their ease of synthesis,
characterization and surface functionalization [5] [6]. Being redox ac-
tive, AuNPs provide the possibility for the miniaturization of sens-
ing devices to the nanoscale, offering excellent prospects for chemical
and biological sensing. They also offer a suitable platform for multi-
functionalization with a wide range of organic or biological ligands for
the selective binding and detection of biomarkers [7]. This means that
the functional activity of these molecules remain unaffected even after
their immobilization on AuNPs.
Moreover, because of their high surface area to volume ratios, AuNPs
serve as an excellent scaffold to immobilize large quantities of organic
or biomolecules, thus increasing the chance of their interaction with a
target analyte [8]. On the other hand, AuNPs (e.g., citrate capped) are
mostly negatively charged, and can therefore be tailored to electrostat-
ically interact with certain positively charged biomolecules that in turn
can have a highly selective interaction exclusively with the target an-
alyte of interest. Furthermore, biofunctionalized AuNPs also have the
advantage of multiplexing in the detection of analytes. AuNPs offer
size based signal amplification as one of the benefits and thus substan-
tial increase in the size of these particles increases the sensitivity of the
sensor.
In view of the above mentioned facts, broad potential of AuNPs for
signal amplification of antibody–antigen recognition events on sim-
ple, ultrasensitive, multiplexed immunosensors becomes apparent [9].
Thus much attention should be devoted to the preparation and appli-
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cation of antibody-AuNP conjugates with better operability and con-
trollability in biomarker detection. With the developed and discussed
technique herein, a simple, sensitive, and low cost solution has been
modeled to be used for measuring serum levels of biomarkers later on
in this work and in future in single and/or multiplexed sensor sys-
tems.
4.2 Synthesis of a conjugated AuNP-antibody
nanoprobe
4.2.1 Synthesis of AuNPs
Ever since Faraday’s work in 1857, several methods have been applied
to synthesize AuNPs with a good level of homogeneity and provide
fine control over size, shape and surface properties, in order to better
take advantage of their unique physicochemical properties for biosens-
ing [10]. These AuNPs, also known as colloidal gold, can be easily
synthesized in sizes ranging between 3 and 200 nm in diameter and
in different shapes, being the most common the quasi-spherical shape,
mainly due to their surface energy that favors the formation of spheri-
cal particles.
One of the most common approaches for the preparation of AuNPs in
aqueous solution was introduced by Turkevich, and subsequently im-
proved by Frens [11] [12]. In order to synthesize 10–100 nm AuNPs,
generally, tetrachloroauric acid (HAuCl4) is reduced in the presence
of different concentrations of trisodium citrate as a reducing agent.
Briefly, in this work, 200 ml of 0.01 % HAuCl4 solution was brought
to boil with gentle stirring. Thereafter, 4.5 ml of 1 % trisodium citrate
was rapidly added and boiling was pursued for an additional 15 min.
The solution was stirred continuously after removing the beaker from
the hot plate. Once mixing occurred, the color of the solution changed
gradually from light yellow to wine red. The solution was then cooled
down to room temperature. This solutionwas stored at 4○ C for further
use. (Figure 4.1)
The sodium citrate, in this procedure, not only behaves as a reducing
agent but also provides the negative surface charge adsorbed around
the AuNPs, which can repel the particles and restrain the formation
of any aggregation. The concentrations of gold salt and trisodium cit-
rate as well as temperature and mixing rate are main factors defining
the size-distribution of the synthesized gold nanoparticles [13]. The
strength of the observed color of solution is highly dependent on the
quality as well as the size of the developed colloidal gold particles [14].
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Figure 4.1: Colloid gold preparation process.
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4.2.2 AuNP-antibody Conjugation
As mentioned in Chapter 2, conjugation of noble metal nanoparticles
such as gold and silver with biomolecules has mainly been achieved
by one of four major mechanisms: electrostatic adsorption, direct
chemisorption of thiol derivatives, covalent binding through bifunc-
tional linkers, and specific affinity interactions [15].
In view of these facts, the covalent binding through crosslinkers was
used in this work. As the first step, Oc antibody (10 µg/mL) and sulfo-
NHS (100 mM) were incubated for 2.5 hours at room temperature. The
GSH solution (10mM) was then added to the complex and left to react
for another hour. Thereafter the AuNP solution was added.
4.3 Characterization of conjugated AuNP-
antibody nanoprobe
4.3.1 Characterization of AuNPs
In order to obtain information about structure, morphology and size of
the synthesized AuNPs, UV-Vis spectroscopy, TEM analysis and zeta
potential measurements were applied.
The UV–Vis spectrophotometer has been the first optical technique em-
ployed for the characterization of AuNPs. In this method, the width
of the absorption spectra is related to the size distribution range of the
nanoparticles and with increasing particle size, the absorption peak
shifts to longer wavelengths [16]. Generally, gold nanospheres dis-
play a single absorption peak in the visible range between 510-550
nm, mainly at 520 nm due to surface plasmon resonance properties
(SPR) of colloidal AuNPs prepared by the conventional citrate reduc-
tion method [17]. (Figure 4.2) Similarly, the UV-Vis spectrum of the
as-prepared AuNP showed only one band with a maximum l at 520
nm. Lack of a band at around 680 nm indicates the absence of aggre-
gated gold particles [18].
The size and size-distribution of gold nanoparticles developed using
the Turkevich and Frens method is reported to be dependent on the
concentrations of gold salt, trisodium citrate, temperature and mixing
rate. TEM was used to characterize the morphology and determine
the size of the as-prepared AuNPs. According to the results, numerous
uniformly distributed nanoparticles with size distribution of about 5-
10 nm were observed in the solution with very few particles of higher
and lower size distribution. These images also show that the majority
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Figure 4.2: UV–Vis spectra of colloidal AuNPs.
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(a) (b)
(c)
Figure 4.3: TEM results of a) monodispersed gold nanoparticles, b) gold
nanoparticles capped with GSH, c) antibody-conjugated gold nanoparticles.
(For a, scale = 125 KX; for b, scale = 160 KX; for c, scale = 200 KX)
of the developed gold nanoparticles were spherical in shape.(Figure
4.3)
The hydrodynamic diameter of nanoparticles was measured using a
zeta-sizer nano-ZS. (Figure 4.4) The peak mean, about 7.5 nm, shows
the mean diameter of the majority of the particles according to inten-
sity. The particles had a mean zeta potential of 97 mV.
4.3.2 Characterization of AuNP/Ab nanocomplex
AuNP conjugation with different proteins is well studied in the liter-
ature but the mechanisms behind the process are poorly understood.
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(a) (b)
(c)
Figure 4.4: Zeta-potential results of a)gold nanoparticles, b) GSH-capped gold
nanoparticles, c) antibody-conjugated gold nanoparticles.
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Figure 4.5: Chemical reactions occurring in different steps.
Therefore special care needs to be taken throughout the process to en-
sure the quality of the end product. The protocol used for conjugation
of AuNPs to Oc antibody in this work relies on covalent and electro-
static attractions between constituents.
In this reaction, sulfo-NHS acts as a cross-linker facilitating the bond-
ing of an amine group of the antibody to a carboxylic group of GSH.
(Figure 4.5) GSH on the other end provides the thiol groups needed to
bind the antibody complex to AuNPs. In other words, binding of an-
tibody complex to gold atoms happened through thiol linkages, ionic
interactions between the negatively charged gold surface and the pos-
itively charged terminals on the complex, and interactions originating
from absorption of hydrophobic groups on AuNPs.
Another advantage of the above mentioned method is covalent cou-
pling via a cross-linker being specific and controllable. The tertiary
structure of the protein is maintained in this method and thus the an-
tibody remains functional in the future steps.
The conjugates developed through direct absorption of the antibody
on the surface of the nano-colloid particles using non-covalent bonds,
such as London, van der Waals force and hydrophobic interactions
were not stable. (Figure 4.6)
Characterization of the resulting conjugates was done promptly by
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Figure 4.6: Representative schematic showing nanoconjugate formation steps.
TEM and FTIR measurements of freshly prepared solution. (Figure
4.3) According to these results, dispersed AuNPs became aggregated
upon addition of GSH without significant alteration in particle mor-
phology or size. This was also confirmed by DLS, which showed a
slight increase in nanoparticle size from 3.88 to 7.48 nm after GSH ad-
dition. (Figure 4.7)
The attachment of the Ab to GSH-modified gold nanoparticles, on
the other hand, resulted in a considerable increase in size and the
core-shell structure, in accordance with previously reported Ab-
conjugated-nanoparticles [19] [20]. According to DLS, the size of the
antibody-conjugated nanoparticles was as high as 74.3 nm. (Figure
4.4) Adding GSH and Ab also considerably reduced the electro kinetic
potential of the nanoparticles from 42.6 mV to 9.8 mV and 1.8 mV, re-
spectively.
The conjugation of gold nanoparticles with antibodies, Oc in our case,
was also verified by FTIR. (Figure 4.8) The FTIR spectrum of GSH-
modified AuNP showed an obvious absorption peak corresponding
to the N-H stretch at 3213/cm. The –COOH stretch vibration in GSH-
AuNP remained unaltered at 1095/cm, indicating no hydrogen bind-
ing among GSH molecules. The characteristic GSH band seen at
2530/cm, due to –SH groups, was absent because of surface binding
of GSH to AuNP through thiolate linkage.
After the addition of sulfo-NHS and Ab, as expected, the –COOH
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(a) (b)
(c)
Figure 4.7: DLS results of a) gold nanoparticles, b) GSH-capped gold
nanoparticles, c) antibody-conjugated gold nanoparticles.
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(a)
(b)
Figure 4.8: FTIR results of a) GSH-modified gold nanoparticles b)
antibody-conjugated gold nanoparticles.
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stretching vibration band at 1095/cmwas reduced, indicating the con-
jugation of sulfo-NHS to GSHmolecules through the –COOH linkage.
Moreover, a visible band, assigned to the formation of amide crosslink
between the antibody and the sulfo-NHS/GSH complex, appeared at
1339/cm.
4.4 Optimization of AuNP/Ab nanoconjugate
preparation
The preparation of a well-dispersed nanoprobe with uniform size dis-
tribution and no aggregation is of great importance in immunoassay
studies. Therefore lowest amount of antibody enough to stabilize the
gold was determined by incubating 1mL of colloid gold with antibody
solutions at varying concentrations (1 - 50 µg/mL, 1 mL). After 5 min,
0.5 mL of 10% (w/v) NaCl was added and the color of the solution
was noted. The concentration in which the color of the solution turned
blue was considered the minimum required amount for stabilization.
Further tests while using the nanoprobe in an electrochemical sensor
showed that lower concentrations of Ab in the nanoprobe produces
small electrochemical response, suggesting that such low concentra-
tions does not provide sufficient antibody to react completely with the
antigen on the immunosensor surface. (Figure 4.9) Higher concentra-
tions of the nanoprobe, on the other hand, improved the current while
contributing to higher nonspecific adsorption.
4.4.1 Environmental Factors
As mentioned in the literature, environmental factors such as temper-
ature and pH play an important role in the efficiency of the nanoconju-
gate. Previous studies have shown that the thermal optimum depends
on the chemical nature of the protein, adding that hydrogen bonds are
more stable at low temperature, whereas the strength of the hydropho-
bic bonds increases with temperature [21]. Antigen-Ab reactions are
also expected to stabilize at lower temperatures.
According to our results, however, no significant change was reported
when the incubation was performed at a temperature range of 4○ C
to room temperature. As a result, to simplify the process, all the pro-
cesses were performed at room temperature and the optimized incu-
bation time for this temperature was calculated to be 2.5 hours, indi-
cating saturated binding of the immunoreaction.
The pH of the solution is another factor affecting the quality of the end
product. The optimal reaction rate of NHS chemistry proceeds around
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Figure 4.9: Cyclic voltammetry results of 2 different concentrations of
Ab-conjugated gold nanoparticles.
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pH 4.5 – 7.2. In other words, NHS-esters hydrolyze faster in higher
pH, whereas no reaction will take place at pH values lower than 3.5
[22]. As for GSH, best results are achieved by adjusting the pH at val-
ues in which the carboxylic groups are in their protonated form. This
occurs when GSH is as a zwitterion (pH=3-7) [23].
Moreover, extreme pH values induce marked conformational changes
in the Ab molecule that probably may affect its complementarity with
the antigen. On the other hand, since Oc, the Ab used in this work,
has an isoelectric point (pI) of 4.4, at lower pH values it carries more
positive charge and thus positively influences the electrostatic attrac-
tion between the oppositely charged surface carboxyl anions and the
protonated amino group of the ligand [24]. As a result, no attempts
were made to change the negative pH of the sulfo-NHS solution.
4.5 Conclusions
Through the inherent interaction between AuNPs and antibody
biomolecules, a novel gold nanoprobe was developed to be used in
nonenzymatic electrochemical immunoassay. This one-pot method
not only provides a simple method for loading high-content antibody
on nanoparticles but also greatly improves the repeatability and con-
trollability of the nanoprobe preparation. Combined with a disposable
electrode, it could be used for a single/multiplexed electrochemical
immunosensing method.
Generally, these electrochemical sensors have the virtue of high sensi-
tivity and selectivity, but it requires several fabrication steps. Current
nanoprobe has overcome this problem as it provides direct electron
transfer between biomolecules and electrode without any mediators
after being immobilized on the surface. This method of detection will
not only simplify the fabrication steps with better stability but also
the high-content of AuNPs in the nanoconjugate results in accelerated
electron transfer and greatly amplifies the detection signal.
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5
Electrochemical Chip
Preparation
5.1 Introduction
Since most electrochemical reactions occur in close proximity of the
electrode surface, the electrodes itself play a crucial role in the perfor-
mance of electrochemical biosensors. In other words, a biosensor is
created on a solid electrode surface by chemically or electrostatically
attaching bio(macro)molecules such as proteins and nucleic acids. If
the surface is chemically modified, the biochemical molecules bind in
a layer such that they cover the electrode surface. This layer is also
known as the ’recognition layer,’ as its molecules are specific to a target
in the analyte. When the electrode is placed into a sample solution, the
analyte and recognition layer interact, and an electrical signal, charac-
teristic of the analyte, is obtained [1].
The dynamic range of concentration that a biosensor can detect is de-
termined by the maximum loading capacity of this layer. Moreover,
based on the function of chosen material on the electrode, its surface
modification or its dimensions greatly influence its sensing abilities.
According to the literature, electrochemical transducers are made of
different materials including carbon-basedmatrices such as glassy car-
bon, graphite and nano-carbon, different metals such as platinum,
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gold and silver, or polymers with electrical conductivity property. The
desirable characteristics of the materials to be used for this purpose
include:
￿ High versatility in shape and size
￿ Low cost
￿ Easy fabrication
￿ High signal-to-noise ratio
￿ Surface regeneration
￿ Suitable mechanic and conducting characteristics
￿ Long-term stability and lifetime
￿ Biocompatibility
￿ Large surface area
When an electrode is prepared, CV was used to study its properties.
The electrodes were cycled twice in 0.1 mM K3[Fe(CN)6], containing
0.01 MNACl solution from 0.0 V to +1.2 V, at 0.1 V/s scan rate in order
to get stable CV responses suitable for comparison. The same setting
was used all through this work, when a CV was performed.
It is also imperative that their reproducibility, reusability and stability
is studied to guarantee a proper electrical conductivity without losing
its properties over time.
￿ The reproducibility of the electrodes is generally tested by com-
paring the cyclic voltammograms of three prepared electrodes
from different batches. Electrodes with less than 5% difference in
the peak current are considered reproducible.
￿ The reusability of the prepared electrodes is assessed through
evaluating current change during 10 successive CV cycles.
￿ The stability of the electrodes is studied by comparing the baseline
CV and that recorded after continuously stirring the electrodes in
water for 20 min. This process was repeated four times.
￿ As for the storage stability, the cyclic voltammograms of the elec-
trodes preserved at room temperature for a week are compared
with that of a freshly prepared electrode using the same method.
This chapter therefore explains the attempts made to develop the most
appropriate electrode that fulfilled the above mentioned characteris-
tics for our purposes and reports its reproducibility, reusability and
stability characteristics.
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5.2 Electrode Selection
5.2.1 Carbon Electrodes
Carbon is an ideal electrode material due to its wide anodic potential
range, low residual current, chemical inertness, low cost, fast response
time, and ease of fabrication in different configuration and size as well
as suitability for various sensing and detection applications. Com-
pared with platinum or gold, carbon electrodes allow scans to more
negative potentials and better anodic potential windows [2]. Carbon is
observed in several variants such as glassy carbon, graphite, fullerene,
graphene and carbon nanotubes [3].
Pencil Electrodes
As the first step, pencil lead was used as the electrode because of the
good electro-catalytic properties, abundance, high electrochemical re-
activity, good mechanical rigidity, and low cost of the graphite [4].
Graphite, the dark gray, soft and porous material found particularly
in the pencil, has high adsorption capacity, an electrical conductivity
of 2 * 105 s (S/m) at ambient temperature, electrical resistivity of 50
µ.W.m and density of 1.95-2.3 g/cm3 [5].
The anisotropic nature of graphite is the result of two types of bond-
ings acting in different crystallographic directions. In graphite, three
out of four valence electrons of each carbon atom are used in bond
formation with three other carbon atoms while the fourth electron of
each carbon atom forms delocalized p-bonds which spread uniformly
over all carbon atoms. The carbon atoms are arranged hexagonally in
a planar condensed ring. The layers are stacked parallel to each other,
with the atoms within the rings bonded covalently, whereas the layers
are loosely bonded together by Van der Waals forces. Thus, the layers
can easily slip off one to another.
Preparation Technique Pencil lead was extracted from more than 20
brands of regular and mechanical pencils with different rigidity (H1-
H6- HB- B1- B8). A wire and the electrical contact made of a con-
ductive material such as copper was attached to one end of the lead
to make the first generation electrodes. A non-conductive cylindrical
shaft was press-fitted to cover the lead, protecting it from chemical re-
actions while inserted in the probe. (Figure 5.1) In order to facilitate
the fabrication process, the second generation electrodes were made
by simply placing the pencil lead in a plastic tubing or pipette tips.
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(a) (b)
Figure 5.1: First generation of pencil lead electrodes.
Considering the conductive properties of the graphite, the pencil lead
was directly connected to the system. (Figure 5.2)
A combination of pretreatment methods, listed below, were applied to
eliminate any possible impurities in the lead and thus to improve the
reproducibility of the electrodes: (Figure 5.3)
￿ Pencil lead was baked in oven at 50 ○C for 5 min.
￿ Pencil lead was polished with aqueous slurry of 0.3 - 0.5 µm alu-
mina powder on a polishing cloth to a mirror finish.
￿ Pencil lead was placed in a cellulose thimble and then in a soxhlet
extractor for 24 hrs of continuous reflux in methanol. Then it was
washed with 0.1 M HCl, placed in an ultrasonic bath for 10 min
and finally rinsed with water.
￿ Electrochemical cleaning by applying a conditioning potential of
1.4V for 60s, in a cell containing H2SO4 (50 mM).
￿ Electrochemical cleaning by applying a conditioning potential of
1.8V for 5 min, in a cell containing acetate buffer solution (ABS)
(50 mM, pH= 4.8).
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(a) (b)
Figure 5.2: Second generation of pencil lead electrodes.
￿ Electrochemical cleaning by applying 10 cycles in the potential
range of -0.5V to 2V with scan rate of 0.5V/s, in a cell containing
ABS Solution (50 mM, pH= 4.8).
Reproducibility Tests None of the electrodes, even those made from
a single brand, and regardless of applied pretreatment procedures,
produced similar CVs and thus the first and second generation of
hand-made graphite electrodes were considered not reproducible.
(Figure 5.4)
Patterned electrodes have garnered more attention these days because
they offer advantages such as lower cost, disposability and miniatur-
ization [3]. (Figure 5.5)
Unlike the hand-made electrodes, carbon screen printed electrodes
(SPEs), used as standard, produced reproducible results. (Figure 5.6)
5.2.2 Gold Electrodes
The unique physicochemical properties of noble metals, particularly
gold, such as high mechanical strength, rich electronic and catalytic
properties, have been explored to design a new generation of elec-
tronic biosensor devices [6] [7]. These electrical and electrochemical
approaches generally rely on the changes in the ohmic response of an
electrical circuit or the flow of electrons arising from faradaic processes
(i.e., oxidation or reduction) near the surface of an electrode, respec-
tively. Although the direct electrical and electrochemical detection of
biomolecules is possible, many have benefited from the electroactive
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Figure 5.3: Pencil lead was placed in a cellulose thimble and then in a soxhlet
extractor for 24 hrs of continuous reflux in methanol, as a pre-treatment
procedure.
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(a)
(b)
Figure 5.4: Reproducibility studies of the hand-made graphite electrodes a) first
generation b) second generation.
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Figure 5.5: Sample Carbon and Gold SPEs.
or catalytic properties of noble metals as reporters for biosensing with
unprecedented levels of sensitivity [8].
Glass-based Gold Electrodes
Preparation Technique White float glass substrates were thoroughly
cleaned to remove organic residues. They were firstly soaked in RBS
aqueous detergents which assure wetting and penetrating actions on
the residues. The mechanical effect of an ultrasonic bath then permit-
ted the removal and dispersion of the residues. The cleaned substrates
were finally rinsed by soaking in isopropanol (IPA) and DI water, and
dried. Next, a 50 nm titanium tungsten (TiW (10%/90%)) adhesion en-
hancement layer, followed by 500 nm copper, 50 nm titanium tungsten
(TiW (10%/90%)) and a 50 nm gold film were sputtered within one
vacuum cycle of an Alcatel SCM600 system.
Later, however, the Cu layer was eliminated as it was damaged by
H2SO4 used for cleaning. The thickness of the Au layer was also in-
creased to improve conductivity. In the final design, a 50 nm titanium
tungsten (TiW (10%/90%)) adhesion enhancement layer and a 100 nm
gold film were sputtered on the cleaned glass substrate. The metal
films were subsequently patterned by photolithography and subse-
quent wet etching.
The electrode design was fabricated using common computer aided
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(a)
(b)
Figure 5.6: Reproducibility results of a) Carbon SPEs b) Gold SPEs.
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drawing (CAD) software and printed onto a transparent foil by the JD
photo-tools in the UK. The design followed several considerations:
￿ The primary consideration for the relative location of the three
electrodes in a cell is the minimization of the solution resistance.
This was accomplished by keeping the three electrodes as close
together as feasible, while not interfering with the current paths
between one another.
￿ The second important consideration involves the shape and size
of the auxiliary electrode relative to the working electrode. The
Aux should be at least as large in area as the WE, and positioned
symmetrically with respect to the WE so that the current density
and potential experienced along its entire length is constant.
￿ Close proximity of the Ref and WE electrodes is important.
To this end, positive photoresist S1818 was used as masking layer to
wet etch both metal films. A 1.8 µm thick coating of S1818 was spin
coated at 4000 rpm for 60 s and soft baked on a hot plate for 2 min at 90○C. Next, the photoresist was UV exposed through the foil mask with
the desired pattern for 7.5 s at 13 mW/cm2, developed for 30 s in 50 %
Microposit developer and hard baked for 30 min in a convection oven
at 120 ○C. The gold and titanium tungsten films were then wet etched
using a solution of iodine (I2) and potassium iodide (KI) (1:4 (1g I2, 4g
KI, 73ml H2O)) at room temperature, and a 30 % H2O2 solution at 55○C, respectively. Finally, acetone was used to strip the remaining pho-
toresist from the electrode surface.
Since the connection lines between the electrodes and their connec-
tions points were all made of gold, SU-8 was used as an insulation
layer to cover the whole surface, exposing just the electrodes to the
electrolyte solutions. SU-8 was used because it was biocompatible
and spectrophotometry results showed its negligible protein adsorp-
tion rate1 [9].
In this regard, TI PRIME was first spin-coated on the substrate to im-
prove the adhesion of SU-8 to the glass substrate. In the absence of
TI PRIME, the SU-8 layer was delaminated easily. (Figure 5.7) 10-
µm thick layer of the negative-tone photoresist SU-8 3010 was then
spin-coated on the substrate. After the soft bake (65 ○C for 1 min, fol-
lowed by 95 ○C for 3 min), the substrate was allowed to cool down
to room temperature. Next, the coating was exposed to UV radiation
(300 mJ/cm2) through a glass mask, using a double side mask aligner
(EVG 620; Austria). A long pass filter was used to eliminate UV ra-
diation below 350 nm. After the post-exposure bake (65 ○C for 1 min,
followed by 95 ○C for 2 min), the SU-8 was developed (90 s in SU-8
1The process is explained in detail in Chapter 7
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Figure 5.7: SU-8 delamination in the absence of TI PRIME.
developer), followed by a rinse in IPA. Finally, a hard bake was per-
formed (120 ○C for 90 min) to further cross-link the SU-8, after which
the substrates were diced. (Figure 5.8)
In the final design, the electrochemical chip consisted of 6 gold elec-
trodes arranged in 2 by 3 electrode arrays on a glass. The glass was
25.5*85.5 mm2, leaving a 25.5*10 mm2 uncovered area for the contact
pads to be connected to the reader using a printed circuit board (PCB).
The PCB with electrical connection leads and lines to the electrodes
was used to connect the array to the potentiostat. Each gold working
electrode (1.5*1.5 mm2) was placed between one gold pseudo- refer-
ence (1.4*1.4 mm2) and one gold counter electrode (2.5*2.5 mm2). (Fig-
ure 5.9)
The gold electrodes were dried using N2 and kept at 4 ○C prior to use.
Cleaning Technique Upon exposure to a non-cleanroom laboratory
environment, the gold surface is subject to numerous ambient contam-
inants (AuO, hydrocarbons, ...), affecting binding kinetics of thiols in
addition to electrochemical effects. As a result, gold must be cleaned
immediately before it is chemically modified for electrochemical uses.
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(a)
(b)
Figure 5.8: a) Schematic illustration of the cross-section of an electrochemical
chip b) Optical microscope image of one of the electrodes on the electrochemical
chip with SU-8 layer on its edges and connection line.
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Figure 5.9: Structure of the electrochemical chip manifold.
Table 5.1: Common gold cleaning methods [10].
1 Ultraviolet ozone cleaning
2 Potassium hydroxide and hydrogen peroxide cleaning
3 Potassium hydroxide potential sweep
4 Sulfuric acid and hydrogen peroxide cleaning
5 Sulfuric acid potential cycling
6 Hydrochloric acid potential cycling
7 Reducing agent solutions cleaning
8 Aqua Regia cleaning
(Table 5.1)
Before storing the electrodes, they were etched by means of radicals,
formed in the gas mixture plasma, chemically reacting on the surface
of the substrate, and physically by means of ions bombarding the sur-
face in the Reactive Ion Etching (RIE) machine. The goal was to re-
move possible contaminating material deposited on the surface of the
electrodes.(Figure 5.10)
Upon usage, cleaning was performed using electrochemical pretreat-
ment by cycling the electrode from large positive to negative potentials
(+1.4 V to -0.4 V, scan rate 100 mV/s) in sulfuric acid solution (50 mM)
multiple times and the process was continued until a stable CV was
achieved [11]. The peak-current potential-differences obtained from
cyclic voltammetry were used to compare the cleanliness of the gold
electrodes.
At this potential range, gold oxide is formed, which upon reduction
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(a) (b)
Figure 5.10: Microscope image of the gold electrodes a) before and b) after RIE.
can be stripped away, together with other surface contaminants and
possible remnants of the photoresist on the electrode surface. We
found that after approximately 20 cycles, the recorded CVs were re-
producible and features characteristic of a clean gold surface became
visible. Further CVs showed a remarkable repeatability of the as men-
tioned treated Au working electrode.
Performance Analysis Considering the fact that the electrochemi-
cal chip has all the working, auxiliary and reference electrodes all to-
gether, the accuracy of the system was checked as following.
First, as the voltage that is applied to the working electrode is con-
trolled with respect to the reference electrode, the stability of the refer-
ence electrode was measured based on the consistency between cycles
of the potential at which the peaks occurred, compared with an exter-
nal reference electrode was used. The average, standard deviation and
relative standard deviation (RSD) were calculated for the peak poten-
tials within nine successive CV cycles of one measurement. A less than
5% variation was noted between cycles, suggesting not only the refer-
ence electrode was stable over the time period in which the measure-
ment was collected, but also the difference between using an on-chip
and external reference electrode were ignorable.
However, considering the slightly different potential and offsets be-
tween the working and reference electrodes, commonly reported in
sensors using quasi-reference electrodes such as ours, we averaged all
the electrochemical plots for each of the studied electrodes [12].
Moreover, as the current in the system passes between the working
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and counter electrodes, the stability of these electrodes was deter-
mined by examining the variation in maximum current in each peak
and comparing the results to that reported when using an external
counter electrode. Similarly, a less than 5% reported variation sug-
gested the difference between using an on-chip and external counter
electrode to be ignorable.
Reproducibility Tests The as prepared gold electrodes were re-
ported to be stable during successive CV analyses and reproducible.
(Figure 5.11)
Again the results were compared with gold SPE as a standard. (Figure
5.5)
5.3 Surface modification of gold electrodes with
AuNPs
The purpose of electrode modification with nanostructures is to im-
prove the sensitivity and selectivity of the biosensor. The higher
surface-to-volume ratio of nanostructure enhances the electrical prop-
erties, which makes the electrode susceptible to external influences.
Since the dimension of nanostructure becomes similar to the size of the
target biomolecules, measurement sensitivity will increase, and this
will enhance higher capture efficiency [13].
In other words, these electrodes enhance the analytical performance
of the sensor through providing a suitable microenvironment for
biomolecule immobilization, their effects on increasing the surface
area of the exposed gold and facilitated electron transfer between the
immobilized proteins and electrode surfaces. As mentioned earlier,
AuNPs are the most common nanostructures used in this regard.
According to the existing studies, AuNP deposition results in three-
dimensional Au deposits, which have a higher desire to adsorb spe-
cific functional groups [14] [15]. The size, structure, and distribution
of these structures, however, have a strong effect on the performance
of the system and thus should be well controlled.
Diverse strategies have been reported to coat various working elec-
trodes such as platinum, carbon and gold with a layer of AuNPs [16]
[17]. These coating techniques include layer-by-layer (LBL) deposi-
tion of AuNPs, self assembledmonolayer (SAM) development, sol–gel
technique, impregnation, co-precipitation, metal organic-chemical va-
por deposition, incipient wetness, electrodeposition and dip-coating
[18] [19].
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(a)
(b)
Figure 5.11: CV analyses showed the gold electrodes were a) reproducible b)
stable during successive CVs.
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Some of them, such as the fabrication of metal nanoparticles layers
using electron-beam lithography (EBL) or nanotemplating, require ex-
pensive equipment or special templates and are thus less commonly
used [20]. Many studies have also reported that the use of electrodepo-
sition techniques is preferred, compared to physical vapor deposition
(PVD) methods, because of their relatively low-cost and potentially
higher deposition rate and film thickness [21] [22].
The aim of this section is to compare the most common existing meth-
ods for depositing gold nanoparticles on gold electrodes for electro-
chemical sensing purposes and present an optimized, adopted proto-
col to increase the surface area and analytical performance.
5.3.1 Gold Deposition Techniques
In this work, deposition of the gold nanostructures was performed
through different methods. Some of them are simple modification of
methods adopted from literature, whereas others are replications of
techniques previously used for other purposes.
Method 1: Layer-by-layer deposition of AuNP
Previous studies have suggested that the interactions in the spherical
electron density around the gold atoms are responsible for the gold-
gold bond in a reliable way [23]. Moreover, some studies have shown
the high binding affinity of the terminal functional groups on the pe-
riphery of the ligand shell of the gold nanoparticles and the gold elec-
trode surface [24]. They have shown the occurrence of the ligand re-
placement reactions when this binding affinity exceeds that of the lig-
and to the particle. As a result, this kind of deposition could be per-
formed in different ways:
(a) Multilayer AuNP-electrodes - 2 µl of the prepared aqueous solu-
tion of AuNPwas deposited on the gold electrodes2, and was sub-
sequently dried at room temperature. This process was repeated
three times. The electrodes were rinsed with deionized water and
dried in a stream of nitrogen gas before the next layer deposition.
(b) In order to improve the results, the layer-by-layer (LBL) deposi-
tion technique was applied [25]. The LBL method is based on
the alternate deposition of oppositely charged (bio-) polymers, in
our case poly(diallyldimethylammonium chloride)(PDDA) [26].
PDDA is commonly used as a reducing and stabilizing agent
to avoid AuNP aggregation. When deposited through LBL, the
2Preparation of AuNP is explained in Chapter 4
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water-soluble, quaternary ammonium, cationic polyelectrolyte en-
ables control over the total AuNP/polymer thickness. The neg-
atively charged substrate also improves attachment of positive
compounds.
(c) The same process as mentioned in method 1a was repeated using
PDDA-protected AuNPs. The electrode was rinsed with deion-
ized water and dried in a stream of nitrogen gas before the next
layer deposition.
(d) According to another method in literature, the previous process
was repeated on a GSH-modified gold electrode [27].
(e) The gold electrode was immersed in PDDA solution (20 % aq solu-
tion in 0.5 MNaCl) for 10 to 30 min. After drying, 2 µl of prepared
aqueous solution of GSH-modified AuNP was deposited on the
gold electrode and dried at room temperature [28]. This process
was repeated three times. The electrode was rinsed with deion-
ized water and dried in a stream of nitrogen gas before the next
layer deposition.
(f) In another attempt, the PDDA-coated substrate was immersed
into HAuCl4 solution (10 mg/mL) for 15 min [29]. Thereafter, the
electrode was rinsed with deionized water and dried under N2
before the next layer deposition. Subsequently, the electrode was
placed in 0.1 M KNO3 solution and -0.4 V potential was applied
for 60s. The process was repeated three times.
Preparation of PDDA-Protected AuNPs Hereof 250 µL of PDDA so-
lution, 40 mL water, 200 µL 0.5 M NaOH and 100 µL HAuCl4 (10
mg/mL) were mixed and subsequently heated to 100 ○C with gentle
stirring until the color changed to red. The UV-Vis spectrum showed
that the band with a maximum l at 520 nm in the colloid gold solution
was shifted rightward to lmax = 523 nm. (Figure 5.12)
Preparation of GSH-modified AuNPs GSH is a tripeptide
biomolecule (–Glu-Cys-Gly), containing a –SH group which can
easily be adsorbed onto AuNP surface. There are functional groups
(–NH2, –COOH) which have strong affinity to metal ions in GSH
(coordination bonds). A dense layer of GSH-AuNP enlarges the
electroactive surface area and provides carboxylic groups on the
surface of AuNP to covalently bind a dense layer of antibody/protein
for detection. Best results are reported when GSH is available in
zwitterion (pH = 3 - 7) as pH affects the -OH, -COOH, -NH2 groups
in the protein and the aggregation of GSH benefits from H-bonding,
which is pH dependent (Acidic environment best results). The rate of
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(a) (b)
Figure 5.12: a) PDDA structure, b) Schematic of PDDA-Protected AuNP.
aggregation decreases with an increase in NP concentration. (Figure
5.13, 5.14)
A stock solution of glutathione (10mM) was prepared. Dilute HCl so-
lution (10 mM, 100 µL) was added to gold aqueous solution (3 mL)
to lower the pH (∼4) [30]. An aliquot of GSH solution (10 mM, 30 µL)
was added to the acidic gold aqueous solution, until the color changed
from deep red to blue, indicating formation of aggregates amongst
AuNPs.
Method 2: Self assembled monolayer (SAM) development
SAM could be achieved after deposition of cysteamine, mercaptocar-
boxylic acid, 3,3–dithiodipropionic acid, 2-mercaptoethanesulfonate,
4-aminothiophenol, triazole and ultrafin polypyrolle tetradecyl sulfate
as well as by the composite 11-mercaptoundecanoic acid-polyethylene
glycol and many other options on gold electrodes [31] [32]. It has been
proved that the three-dimensional monolayers of S-containing organic
compounds facilitate the electron transfer in the redox reaction occur-
ring at the electrode-solution interface, ensuring an easier access of
reagents to the electrode surface [33].
A thiol molecule consists of (1) a sulfur head group, which forms a
strong, covalent bond with the gold electrode, (2) a hydrocarbon chain
of variable length, which stabilizes the SAM through van der Waals
interactions, and (3) a terminal group, which has different functionali-
ties. In our case, the -SH-terminated thiols of the dithiol usedmade the
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(a)
(b)
Figure 5.13: a) GSH structure, b) Schematic of GSH-decorated AuNP.
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Figure 5.14: UV–Vis spectra of GSH-decorated AuNP solution.
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binding of metallic ions of the gold electrode and gold nanoparticles
to the SAM possible [34]. Studies have shown that the adsorption time
depends on the nature of the molecule, adding that dithiol deposition
from solution needs less time [35]. This is while long chain alkanethi-
ols need 2 - 12 hrs compared with short chain alkanethiols or thiols
with certain end groups different from -CH3 that need at least 24 h to
form a well-ordered SAM.
When using dithiols, the SAM is developed using the following reac-
tions: (Equation (5.1), (5.2))
HS(CH2)nSH + Au → (HS(CH2)nSH)phyAu (5.1)
(HS(CH2)nSH)phyAu + Au → Au − S(CH2)nSAu +H2 (5.2)
Moreover, dithiols provide a more stable SAM compared to alkanethi-
ols because of the formation of two thiolate bonds per molecule in
dithiols and their reductive peak potentials are more negative [36] [19].
On the other hand, these bonds can hinder the transition from the
lying down to the standing up configuration, particularly in dithiols
with short chain length, resulting in smaller chain-chain interactions,
smaller gain in energy and thus higher stability.
Taking this all into account, we decided to use 1, 8–octanedithiol. In
this regard, SAM was prepared by immersing gold electrodes into 1
mM 1, 8–octanedithiol in ethanol for 24 h in a dark environment at
room temperature [37]. The modified electrodes were then taken out,
soaked in distilled water and subsequently dried in a stream of nitro-
gen gas.
Method 3: Electrodeposition
Electrochemical deposition is an important technique as it not only
involves simple instrumentation and operation but also is versatile
and cost effective. It is generally performed through application of an
electrical field to a solution containing the ions of the target material.
Electrically-enhanced diffusion of the reactive ions towards the elec-
trode followed by an electron transfer from or to the ion, results in ox-
idative or reductive deposition of the desiredmaterial on the electrode,
respectively. Figure 5.15 shows a voltammogram of an electrodeposi-
tion process using CV. The reverse scan of the voltammogram in these
experiments exhibits the reduction of Au(III) to Au(0), inducing the
deposition of AuNPs onto the electrode surface according to the fol-
lowing reaction. (Equation (5.3))
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Figure 5.15: a) Voltammograms of the ECV process in 1.0 mMHAuCl4 and 0.5 M
H2SO4 in the presence of 0.1 mM NaCl.
H+[AuCl4]−aq + 3e− → Au0s + 4Cl−aq +H+ (5.3)
Different protocols have been proposed for gold electrodeposition on
gold electrodes. Using them, various morphologies, including rod-like
and dendritic gold nanoparticles, have been obtained in a one-step
process. In this work, electrodeposition was performed in an aque-
ous solution of 1.0 mM HAuCl4 and 0.5 M H2SO4 in the presence of
0.1 mM NaCl as the supporting electrolyte. For the electrodeposition
step, external AgCl reference and Pt. gauze (Alfa Aesar Gmbh & Co,
Germany) as auxiliary electrode was used.
(a) Cyclic voltammetry: Electrodeposition was performed by CV
scanning the potential from - 0.5 V to + 0.5 V, + 1.0 V and + 1.5
V at a scan rate 0.1 V/s for a given number of scans [38]. The pro-
cess was repeated until the CV became reproducibly stable. The
sweeping potential, the scan rate and the number of cycles needed
were then optimized based on the results. This method is called
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ECV all throughout this work.
There was a broad reduction wave at 0.0 V suggestive of AuNP
deposition. As the number of cycles increased, there was a sharp
oxidation peak at 1.0 V. Throughout the electrodeposition process,
the current read at this peak increased during each cycle, which is
consistent with thermodynamics that predicts an easier growth of
previously formed AuNPs than a nucleation of newAuNPs on the
electrode. In addition, the peak area of the reduction of gold oxide
suggests that a large amount of gold nanoparticles have been de-
posited onto the surface of the electrode. After 60 repeated scans,
there was no more change in peak height or shape.
(b) Pulsed electrodeposition: The potential was stepped from - 0.5 V
to + 0.5 V, + 1.0 V and + 1.5 V with a 5 s deposition time [39].
NP-like gold islands were generated on the electrode; the size and
density of the islands increased with increasing number of pulsed
electrodeposition cycles.
5.3.2 Performance Analysis
The comparison between the different protocols applied in this work is
outlined in Table 5.2. Previous studies have suggested that not only the
stability of the AuNP layer but also the density and size of the NPs are
of great importance in the sensors’ analytical performance, stressing
that high density of rather small, spherical-shaped NPs are associated
with best responses [40].
The results of the CV analysis showed that adding a layer of AuNP
using method 1a did not affect the results significantly. (Figure 5.16)
While adding an AuNP-layer is believed to provide a larger surface
area for the subsequent layers to bind, the unstable attachment be-
tween AuNPs and the electrode might be the reason behind the ab-
sence of any change in the results. Similar, results were noted for
electrodes modified using method 1c. Despite the stronger attach-
ment of PDDA-protected AuNPs to the underlying layers, their non-
conductive nature was unfavorable in biosensing processes. This was
shown based on a slight decrease in peak current in CV results, sug-
gestive of reduced conductivity of the surface. (Figure 5.17)
CV analysis of the electrodeposited electrodes (method 3a) showed
higher current compared with methods 1 and 2, indicating that gold
nanoparticles have been successfully attached onto the surface of the
electrode and thus improving the conductivity and surface area.
Figure 5.17 shows a considerable increase in the electrical response af-
ter SAM development. In comparison to LBL, the SAM technique pro-
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(a)
(b)
Figure 5.16: Comparison of voltammograms of bare electrodes and electrodes
developed by a) method 1a and b) method 1b in 0.1 mM K3[Fe(CN)6].
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(a)
(b)
Figure 5.17: Comparison of voltammograms of bare electrodes and electrodes
developed by each of the above-mentioned techniques in 0.1 mM K3[Fe(CN)6].
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Figure 5.18: Voltammograms of electrodes prepared using method 2 in 0.1 mM
K3[Fe(CN)6] over time.
vided a more stable nanoparticle layer (less than 5% variability in peak
currents after 10 CVs). (Figure 5.18)
CV analysis of the electrodeposited electrodes showed higher current
compared with previous methods, causing improved electrode kinet-
ics and a reduction in the oxidation potential (thermodynamically fea-
sible reaction). This is attributed to the larger surface area of the mod-
ified electrodes and synergistic effects of electrical conductivity and
electroactivity of AuNP.
5.3.3 Reproducibility, Reusability, and Stability Tests
The reusability of biosensors is also of great importance. The elec-
trodes modified through LBL deposition were unstable and not re-
producible. On the other hand, adding PDDA to the process did not
improve the bonding of gold nanoparticles to the electrode surface sig-
nificantly and thus no significant improvement was noted in the sta-
bility results (more than 5% variability in peak currents of 10 succes-
sive CVs). Similar results were noted after surface modification using
methods 1d and 1e. This is while the nanostructures were firmly im-
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mobilized on the gold electrode prepared using SAM and ECV tech-
niques, resulting in an acceptable stability and reproducibility.
Similar to electrodes prepared using SAM techniques, there was no
noticeable change of currents during the successive CV cycles (less
than 5% variability in peak currents), which implies that the nano-
structures, prepared using ECV technique, are firmly immobilized on
the gold electrode. (Figure 5.19)
Our results suggested that while AuNPs deposited using both SAM
and electrodeposition techniques provided a stable layer, the elec-
trodes prepared using electrodeposition showed higher current and
thus electron transfer rate and analytical performance. This is while
many of the previous studies had suggested SAM techniques as an ef-
fective way for stable protein attachment [41]. (Table 5.2) It has been
evidenced that several factors including the packing density as well
as chain length of the SAM play an important role in surface cover-
age and electron transfer rate. In other words, if SAM is too densely
packed, similar to our results, it would exhibit a blocking behavior due
to its high resistance, a process which would decrease electron transfer
rate and subsequently delay the sensing process [42].
The study of the storage stability of the ECV-modified electrodes
showed a slight current change (less than 5% variability), show-
ing their long-time stability. (Figure 5.19). This however was not
true for the electrodes prepared using pulsed electrodeposition tech-
niques.(Figure 5.20)
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(a)
(b)
Figure 5.19: Comparison of voltammograms of electrodes prepared using
method 3a in 0.1 mM K3[Fe(CN)6] a) during successive CV cycles b) over several
weeks.
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Figure 5.20: Comparison of voltammograms of electrodes prepared using
method 3a and 3b in 0.1 mM K3[Fe(CN)6].
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Table 5.2: Pros and Cons of different Au-deposition protocols applied in this work
Pros Cons
LBL deposition Simple and rapid Unstable, not reproducible
SAM development Strong bonding to underneath
layer, stable and reproducible
Time consuming, low sensing
performance enhancement
Electrodeposition Acceptable bonding to under-
neath layer, acceptable sensing
performance enhancement, sta-
ble and reproducible
Time consuming, No. of cycles
depend on the electrode charac-
teristics
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5.4 Characteristics of AuNP-coated Gold Elec-
trodes using ECV
Considering the results, the electrodeposition process of AuNP on
gold electrode using ECV method was optimized and the focus of the
remaining part of this section will be on the characterization of the
electrodes modified using this technique.
5.4.1 Electrochemical Behavior
In this work, AuNPs were electrodeposited by ECV starting from
HAuCl4 (Method 3a). The successful AuNP formation on the treated
electrodes was confirmed by showing a typical CV of gold over the
potential range of -0.5 V to +1.2 V in 0.5 M H2SO4 solution. (Figure
5.15) This voltammogram shows a single sharp reduction peak at +0.2
V and oxidation peaks at +1.2 V.
5.4.2 Surface Roughness
The increased current noted in further voltammograms confirmed that
gold nanoparticles immobilized at the gold interface using thismethod
increased the electrode surface area and facilitate the charge transfer
between the AuNPs and the gold electrode. (Figure 5.17)
From the voltammetric responses obtained in K3[FeCN6] information
regarding the real electrode surface area and its roughness were ex-
trapolated. The diffusion coefficient of the mediator was calculated by
performing CV with three different scan rates (0.1, 0.3, 0.5 V/s). The
resulting currents were then plotted against the square root of the scan
rate and the obtained slope was equal to the diffusion coefficient. In
our case, the diffusion coefficient was calculated to be 5e-08 cm2/s.
Chronocoulometry was then performed to measure the electrical
charge passing through the electrode as a function of time. The anal-
ysis of the chronocoulometric data was then performed based on the
Anson equation. (Equation (5.4))
Q = 2.n.F.A.C.D(1￿2).p(−1￿2).t(1￿2) (5.4)
Herein, Q represents the charge (coulombs), n the number of electrons
transferred, A the real electrochemical surface area of the electrode
(cm2), F the Faraday’s constant (96,485 coulombs/mol), C the concen-
tration of the mediator (mol/cm3), D the diffusion coefficient of the
mediator (cm2/s) and t time (s).
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The slope (a) of the as expected linear plot between Q and square root
of time was used to calculate the real electrochemical surface area of
the electrode. (Equation (5.5))
A = a
2.n.F.C.D(1￿2).p(−1￿2) (5.5)
As expected the real electrochemical surface area of the gold electrodes
were calculated to be 0.0784 cm2, which is 2.3 times greater than the
area before electrodeposition (geometric area= 0.0225 cm2). Based on
these results, the roughness factor (ratio of electrochemical surface to
geometrical surface) was calculated to be 3.49 (compared to 1.53 in
bare sputter deposited Au electrodes before electrodeposition). These
results were further confirmed with SEM and AFM.
Electroless gold plating vs. Electrodeposition (ECV)
In another attempt, a group of electrodes were subjected to electroless
gold plating. The technique improved the roughness of the surface
but failed to improve the sensing properties of the electrodes. This
could be explained due to the fact that the deposition of AuNPs on
the surface improves the biocompatibility of the surface and results in
a 3D structure with higher desire to adsorb certain functional groups.
It also improves direct electron transfer from the redox protein to the
electrode surface.
WYKO non-contact optical profiler confirms a significant increase in
the roughness of the surface following electroless gold plating. (Figure
5.21, 5.22).
5.4.3 Surface Modification
In order to further characterize the morphology of the nanostructured
gold film deposits, SEM (Figure 5.23) and AFM (Figure 5.24) analy-
sis was performed. These images also confirmed the considerable in-
crease in the roughness of the surface after electrodeposition and in-
creasing the number of electrodeposition cycles was associated with
growing density of deposited nanoparticles.
Figure 5.25 shows typical nanopyramidal structures obtained from dif-
ferent electrodeposition conditions. An increased number of deposi-
tion cycles was associated with a significant rise in the density of these
nanostructures.
STEM images revealed the formation of nanoclusters of gold nanopar-
ticles with the mean size of 20 nm after the ECV process. (Figure 5.26)
This is while as mentioned earlier, the electrochemical characteristics
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(a)
(b)
Figure 5.21: Representative a) three-dimensional image and b) surface profile of
bare electrode obtained using Wyko profilometry.
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(a)
(b)
Figure 5.22: Representative a) three-dimensional image and b) surface profile of
electroplated electrode obtained using Wyko profilometry.
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(a) (b)
(c) (d)
Figure 5.23: SEMmicrographs of a) bare gold electrode, and gold electrodes after
ECV with b) 5 cycles, c) 10 cycles and d) 30 cycles. (For a, b,c, d, scale = 1.0 µm)
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(a) (b)
(c) (d)
Figure 5.24: AFM topography of a) bare gold electrode, and gold electrodes after
ECV with b) 5 cycles, c) 10 cycles and d) 30 cycles; 5× 5 µm scan size, set point 11
nm
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(a) (b)
(c) (d)
Figure 5.25: AFM height images of the surface of a) bare gold electrode, and gold
electrodes after CV electrodeposition with b) 5 cycles, c) 10 cycles and d) 30
cycles; 5× 5 µm scan size, set point 11 nm
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of AuNPs are reported to be strongly size-dependent, and due to ge-
ometrical considerations, AuNPs of ∼ 20nm lower the probability of
proteins finding sterically suitable sites on gold [43]. The quantum ef-
fects, originated by d-band electrons of the surface shifted towards the
Fermi-level, enables AuNPs to interact in electrocatalytic reactions.
5.4.4 Reproducibility
In order to measure the reproducibility of the as-prepared electrodes,
repeatability studies were performed. In this regard peak current in
similar CVs performed on a group of electrodes were compared. (Fig-
ure 5.27) According to the results, the calculated RSD was (Coefficient
of variation= 5.3%), suggesting high likelihood of producing similar
electrodes.
5.5 Conclusion
The electrode modified through LBL deposition was unstable and not
reproducible. Using SAM and ECV techniques on the other hand, the
nanostructures were firmly immobilized on the gold electrode pre-
pared, resulting in an acceptable stability and reproducibility. CV-
electrodeposition of AuNP (ECV) causes an observable increase in the
peak current of recorded CV curves compared to bare Au electrodes,
causing improved electrode kinetics and a reduction in the oxidation
potential (thermodynamically feasible reaction). Moreover, electrodes
modified using ECV showed better electron transfer rate compared to
other studied methods, making them a better candidate for electro-
chemical sensing purposes.
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(a) (b)
(c) (d)
(e)
Figure 5.26: STEM results micrographs of a) bare Au TEM grid before ECV
electrodeposition by HAADF contrast, and gold electrodes after ECV
electrodeposition with b) 5 cycles, c) 10 cycles, and d) 30 cycles, e) Mean size of
the produced nanoparticles by HAADF contrast. (For a, b, e, scale = 100 nm; for
c, scale = 200 nm; for d, scale = 500 nm)
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Figure 5.27: Histogram showing frequency distribution of peak currents
measured in a group of electrodes prepared using ECV technique.
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Oc& CTX BioSensors:
Characteristics and Validation
6.1 Introduction
As mentioned in Chapter 3, while immunoassays have an extensive
application in clinical and research areas, the immunosensor concept
is yet to be implemented in routine diagnostics [1][2]. There are cer-
tain issues in this regard, the most important of which is the coupling
chemistry of proteins on surfaces, which is critical for optimal func-
tioning. In other words, the optimal orientation of Ab molecules on
the surface is of great importance to obtain a selective and sensitive
detection in a reproducible way without affecting its activity [3]. The
relative lack of long-term stability of biological molecules is the most
serious limitation in commercializing biosensors.
Immobilization methods vary largely based on the surface and pro-
tein properties. Ideally, as mentioned earlier, during the process the
protein conformation should remain intact so that protein functions
are retained. Moreover, the active sites of Ab should be accessible to
reaction partners in order to have a high-performance, reproducible
assay [4]. This is while once immobilized, biomolecules adsorbed on
AuNPs are not free and adopt certain orientation and conformation on
the surface [5]. This raises the question of how the activity of an anti-
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body is affected by conjugation with a gold particle. Although protein-
conjugated gold nanoparticles have been successfully employed as bi-
ological markers for decades, instances of total or partial loss of spe-
cific activity of a protein upon conjugation have also been reported [6].
Therefore, this chapter deals with the immobilization of two main
BTMs (Oc and CTX) on the glass-based gold electrode fabricated as
mentioned in Chapter 5 and coated with AuNPs. To our knowledge, a
biosensor to assess serum levels of Oc has not been developed before.
A step-wise protocol to develop these sensors is explained here.
6.2 Oc Biosensor
6.2.1 Oc
Oc, also known as bone gamma-carboxyglutamic acid-containing
protein (BGLAP), is the most abundant non-collagenous protein in
bone, comprising 1–2% of the total protein content [7]. It is a small
44-aminoacid long protein (5.8 kDa) synthesized exclusively by os-
teoblasts (and odontoblasts). The specific glutamyl residues at posi-
tions 17, 21 and 24 have a second carboxylate group added to form
g-carboxyglutamyl residues (Gla), which stabilizes the a-helical por-
tion. When Oc meets calcium ions, these active sites (3 Gla residue
and 1 Asp) chelate to the ions and Oc folds to a special structure.
Oc is released into the circulation from the matrix during bone resorp-
tion and, therefore, its high levels are considered as a marker of bone
turnover [8]. Previous studies suggest that serum Oc levels, even in
the absence of alkaline phosphatase, is useful in monitoring follow-up
changes that currently cannot be assessed with BMD assessment in os-
teoporosis treatment [9][10]. As mentioned in Chapter 2, Oc is a spe-
cific, sensitive and promising marker to be used for better prognosis
of osteoporosis and for monitoring response to antiresorptive therapy
[11]. (Figure 6.1)
6.2.2 Sensor fabrication process
As mentioned earlier, the glass-based gold electrodes fabricated based
on the method explained in Chapter 5 were used. In order to have an
AuNP layer on the electrodes that would allow Ab molecules to im-
mobilize on the surface, the ECV technique was used.
The final goal of immobilization strategies is to improve assay sensi-
tivity, specificity, reproducibility, and even application. In this regard,
different techniques were modified to form stable and strong bonds
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Figure 6.1: 3D and 2D Structure of Oc.
between the protein and the immobilization surface, minimize non-
specific adsorption of biomacromolecules, keep the proteins in an ac-
tive state, and finally orient proteins for unhindered access of binding
partners. Consequently, controlled experiments against the standards
were performed for verification of the best method and conditions of
immobilization of Oc antibody on the gold electrodes. The applied
protocols are shown in the flowchart in Figure 6.2. The first two proto-
cols were based on physisorption immobilization, whereas the others
were based on covalent attraction between constituents using different
cross-linkers.
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Figure 6.2: Flow chart depicting experimental design for immobilizing antibody on the electrode.
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In the first protocol, fragment antigen-binding (Fab) antibody frag-
ments were deposited onto gold via native thiol groups. Passive ab-
sorption does not provide permanent attachment of the coating as
molecules may desorb from the surface overtime. Proteins may also
lose their properties after being absorbed to the surface, caused by
changes in tertiary structure or binding of active/Ag to the gold sur-
face rendering it inaccessible. In the second protocol, still the bonding
was not strong enough and thus the antibody was washed away dur-
ing the washing steps.
As for other protocols, covalent coupling using different combinations
of EDC and sulfo-NHS was applied. These reactions are not only spe-
cific and controllable but also the number of covalent bonds between
the surface and Ab can be optimized to help maintain the tertiary
structure of the protein.
Here we explain the most complex process (protocol 3), with the maxi-
mum number of steps. The other protocols were tested similarly using
the same concentrations and incubation times mentioned in this pro-
tocol, skipping the non-mentioned materials.
In protocol 3, appropriate amount of a 10 mM solution of GSH was
deposited on the gold surface and left to dry at room temperature for
an hour [12]. GSH bonds with gold through the formation of an Au-S
bond, while providing carboxylate groups for the next layers to react
with. A mixture of EDC/sulfo-NHS was used to facilitate the conver-
sion of the carboxylic acid groups of the monolayer to amine groups
for subsequent Ab attachment. In this regard, the freshly prepared
EDC and sulfo-NHS were mixed with a volume ratio of 1:1 and in-
cubated for 20 min. Appropriate amount of Ab was then added to
the solution and incubated for another 60 min. After gently rinsing
the prepared surface with distilled water, the electrodes were covered
with the solution of EDC/sulfo-NHS/Ab and incubated for 180 min at
room temperature.
In order to block the uncoated surface and to minimize nonspe-
cific adsorption of off-target biomolecules and remove non-adsorbed
proteins, the surface was gently rinsed. Effective removal of ex-
cess EDC/sulfo-NHS after activation is important to prevent protein
crosslinking.
Then the unreacted active functional groups were blocked or deacti-
vated by BSA. 20 µl of 0.2% BSA solution in PBS buffer was added for
1 hr. The electrode was then rinsed for 3 min with 0.1M PBS (Coupling
Buffer) and then 0.1M PBS-Tween 20 (Washing Buffer). PBS- Tween 20
is commonly used tominimize the background noise from non-specific
binding in bioassays. The electrodes were then shaken to remove ex-
cess water.
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While DI water and PBS, used as the rinsing reagents in our experi-
ment, are inert, care was taken while applying these solutions to main-
tain the integrity of the electrode surface as the detachment of the con-
jugates can be an issue.
The Ab-Ag reaction was then tested by introduction of different con-
centrations of Ag solution using a fine pipette.
6.2.3 Characteristics of the Oc electrochemical chip
Surface Modification
Successful electrodeposition of gold nanoparticles on the surface and
immobilization of antibody on the modified surface was verified by
STEM.(Figure 6.3)
To further analyze the chemical composition of different layers, XPS
characterization was employed at different steps. In the first step, the
XPS signature of the S2p doublet (163,9 - 165,1 eV) was suggestive of
the attachment of GSH to the gold surface through the thiol group.
The N1s and C1s core level spectrums noted in the successive steps
mainly originated from the antibody. The presence of satellite (293 eV)
and aromatic (284.3 eV) lines in the XPS spectrum also confirmed the
immobilization of the antibody on the surface has been successful.
Electrochemical impedance spectroscopy (EIS)
As mentioned in Chapter 3, EIS is another powerful method, com-
monly used in electrochemical research, to analyze the electrical re-
sistance of a system. The technique is sensitive to surface phenomena
and changes of bulk properties. Therefore it was applied within this
work to characterize surface modifications and detect binding events
on the transducer surface. The assembly of the layers on the gold elec-
trode surface and the loading of AuNP were confirmed by EIS mea-
surements.
Figure 6.4 shows a Nyquist plot of impedance for the stepwise modi-
fication process of the gold electrode. The data was obtained by using
0.1 mMK3[Fe(CN)6] and upon application of the biasing potential 0.17
V and 5 mV amplitude in the frequency range of 0.1 Hz to 100 kHz. As
already known, the impedance spectra contain a semicircle portion at
higher frequencies relating to the electron transfer limited process and
a linear part at lower frequencies corresponding to diffusion. The di-
ameter of the semicircles showed the charge transfer resistance rate.
In the EIS measurement, the negatively charged ferri/ferrocyanide
couple [Fe(CN)6]3-/4- was employed as the redox marker for electro-
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(a) (b)
(c)
Figure 6.3: STEMmicrographs of a) bare gold nanoparticles by HAADF contrast,
b) AuNP-modified gold electrode by BF contrast, c) Ab functionalized gold
electrode by BF contrast. (For a, scale = 100 nm; for b, scale = 200 nm; for c, scale
= 1.0 µm)
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Figure 6.4: EIS results for each modification step (Marine = Gold electrode with
gold nanoparticles capped with GSH, Pink = Gold electrode with antibody
conjugated gold nanoparticles, Blue = sensor + Ag).
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chemical characterization, and thus the diffusion of [Fe(CN)6]3-/4- and
mass loading of the antigen onto the surface of the electrodes have a
significant effect on the charge transfer resistance.
As can be seen from the Figure 6.4, the bare electrode produces an al-
most straight line Nyquist plot with no semicircle domain, implying
a diffusion-limited electrochemical process of the redox coupling at
the electrode surface. After adding additional layers, a semicircle was
noted, indicating the increase of the interfacial charge transfer resis-
tance. Considering the nature of the layers, the changes in this diame-
ter could be explained. Ab binding caused a physical barrier, limiting
the access of the redox probe to the electrode. Exposure of Ag gener-
ates a further barrier for the electrochemical process, causing a slight
increase in the transfer resistance.
6.2.4 Analytical Procedure
Ag concentration against current read during DPV analysis in each
protocol was used to calculate and plot linear and logarithmic fit R-
squares (degree of fit). The DPV measurements in this work were per-
formed in 0.1 mM K3[Fe(CN)6], containing 0.01 M NaCl, applying fol-
lowing parameters: 0.025 V modulation amplitude, 0.05 s modulation
time, 0.005 V step potential and voltage range from 0.5 to 1.1 V. The re-
sults showed that the immobilizationwasmost effective for sulfo-NHS
activation (protocol 4) as it not only followed the decreasing trend sug-
gestive of the inverse correlation of current and Ag concentration, but
also had the best R-square.
The stability of the immobilization process was also studied by wash-
ing the electrodes with PBS for four times. Again electrodes prepared
using protocol 4 showed the best results. In other words, the results
showed that the immobilization was most effective for sulfo-NHS ac-
tivation and that the best results were achieved when carboxylates (-
COOH), found on the surface after the deposition of GSH on the gold
electrode, were reacted to sulfo-NHS. (Figure 6.5) NHS ester was then
reacted with primary amines (-NH2) of the antibody to form amide
crosslinks.
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Figure 6.5: Chemical reactions occurring on the surface in different steps.
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Afterwards, through plotting the current in that protocol against the
diverse concentrations, the calibration curve was formed. As men-
tioned earlier, as more antigen was introduced onto the surface upon
reaction with the immobilized antibody, the redox marker diffusion to
the surface of the electrode was hindered due to repulsive interactions.
Thus lower current was observed.
Figure 6.6 illustrates the calibration curve plotted using average re-
sponse of the sensor towards its target, Oc Ag, from experiments per-
formed under the conditions described above.
The calibration curve was generated based on the average value of
measurement conducted in triplet set on the sensing interface, which
was treated with different amounts of antigen from the lowest to the
highest concentrations. Parameters such as lower limits of detection
(LLD), upper limits of detection (ULD), and consequently a dynamic
range was calculated. Other assessed parameters included limit of de-
tection (LoD) and limit of quantification (LoQ), sensitivity (slope of the
gradient), reproducibility (standard deviation divided by the average
in percent), tightness of fit (R-square of trend line applied) and behav-
ior (linear, non-linear, etc.).
The LoD and LoQ were calculated using the following equations:
(Equation (6.1), (6.2))
LoD = 3.3 ∗ d
S
(6.1)
LoQ = 10 ∗ d
S
(6.2)
where d is the standard deviation of the response and S is the slope of
the calibration curve.[13]
Figure 6.7 illustrates the relationship between the blank, LoD and LoQ.
For a signal at the LoD, the alpha error (probability of false positive) is
small (1 %) [14]. However, the beta error (probability of a false nega-
tive) is 50 % for a sample that has a concentration at the LoD, suggest-
ing that the sample could contain an impurity at the LoD, but there is
a 50 % chance that the measurement would give a result less than the
LoD. At the LoQ, there is minimal chance of a false negative.
The magnitude of electrochemical response current was linearly de-
pendent to the logarithm of Oc concentration with an R square of 0.92
and slope of 0.75 (sensitivity) over the concentration range. The de-
tection limit was calculated to be 0.65 ng/mL. The device had an LoQ
of 1.97 ng/mL with a correlation coefficient of 0.99. The sensor was
capable of assessing Ag levels in the range of 2.5-90 ng/mL.
184 Oc & CTX BioSensors: Characteristics and Validation
Figure 6.6: Sensor responses to varying Ag concentrations (2.5-90 ng/mL) using
protocol 4.
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Figure 6.7: Illustration of the concept of LoD and LoQ by showing the theoretical
normal distributions associated with blank, LoD, and LoQ level samples..
A schematic illustration of the preparation process of the immunosen-
sor is shown in Figure 6.8.
6.2.5 Real serum measurement
Concentration gradients of serum Oc levels were tested using ECLIA
and run against the number read by the sensor for verification. ECLIA
is a highly sensitive method for the detection of diverse analytes based
on ELISA technology. In this regard, the serum of eight patients whose
Oc levels were recently measured using ECLIA was used. Using the
trend function in Excel and based on the calibration curve, the concen-
tration of Oc in the tested samples were calculated according to the
obtained current. The results were then compared.
According to the results presented in Table 6.1, the coefficients of vari-
ation for the ECLIA and Oc sensor were calculated to be 4.4% and
4.48%, respectively.
The correlation between our sensor results and that of ECLIA was also
investigated and the results are shown in the correlation and Bland
and Altman plots in Figure 6.9. The equation of the trendline in the
correlation plot has a slope of 0.97 and R2 of 0.98. The mean difference
between the twomethods according to the Bland and Altman plot was
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Figure 6.8: A Schematic illustration of the preparation process of the Oc
immunosensor.
Table 6.1: Precision of Oc assay using ECLIA and Oc-Sensor.
Serum samples ECLIA results (ng/mL) Oc-Sensor results (ng/mL)
1 10.3 10.33
2 15 14.71
3 17.1 17.90
4 26.8 24.35
5 29.8 26.88
6 32.1 29.35
7 33.7 32.11
8 45.5 46.16
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(a)
(b)
Figure 6.9: Statistical analysis comparing ECLIA vs. Oc sensor immunoassay a)
Correlation plot, b) Bland and Altman plot.
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Figure 6.10: PDMS-stamps used for microcontact printing of the antibodies on
the electrode surface.
1.06 ng/mL and the 2s limits of the standard deviation (2SD) was 3.03
ng/mL. This indicates that the Oc sensor provides sensitive and spe-
cific results of Oc levels in serum [15].
6.2.6 PDMS-Stamps
Previous studies have considered microcontact printing as an effective
technique for parallel transfer of material to a surface, making stamp-
ing of thousands of microspots of the same molecule simultaneously
over areas larger than 1 cm or developing complex protein pattern pos-
sible [16] [17]. In order to improve the electrode production approach,
we decided to benefit from a combination of hydrophobic and cova-
lent interactions. (Figure 6.10) As described earlier, the simplicity of
physisorption makes it a preferred method for immobilizing proteins
in early, proof-of-concept experiments. In this regard, we used a PDMS
stamp.
The efficacy of the technique, which benefits from an entropically
driven interaction and hydrophobic adsorption rather than the forma-
tion of chemical bonds, depends on well-known experimental vari-
ables such as pH, salt concentration, and temperature. It also requires
multiple inking and stamping steps to have discrete pattern of mul-
tiple protein species, and according to our experience was not repro-
ducible.
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6.3 CTX Biosensor
6.3.1 CTX
Type I collagen accounts for 90% of the organic matrix of the bone,
and is subjected to a series of enzymatic and non-enzymatic intra- and
extracellular post-translational modifications that may induce bone
strength during the normal aging process or on the pace of a disease
[18]. Collagen crosslinking is therefore of great importance in deter-
mining the biomechanical competence of the bone [19]. Several stud-
ies have related the bone content of C-telopeptide (CTX) crosslinks, in
part independent of the bone mineral value, with bone strength, sug-
gesting serum CTX as a reference bone resorption marker [20] [21].
In other words, despite the marked effects of circadian variation and
other factors such as diet on serum levels of CTX, the marker is re-
ported to be sensitive to short-term changes in bone metabolism.
The first serum CTX assay was a competitive polyclonal antibody
ELISA [22] [23]. To overcome the limitations linked to ELISA, sev-
eral label-free immunosensing biosensor for the detection of CTX lev-
els was developed but never commercialized [24] [25].
6.3.2 Sensor fabrication process
Again, the gold electrodes prepared in Chapter 5 and coated with an
AuNP layer using ECV technique were used. The immunosensor was
fabricated by the immobilization of antibodies on the gold electrode
through EDC/sulfo-NHS covalent-linking.
Firstly, 4 µL of a 10 mMGSH solution was coated on the working elec-
trode and dried at room temperature for 1 hr. After gently rinsing
with distilled water, the gold electrodes functionalized with carboxylic
groups were incubated in a mixture solution of 400 mM EDC and 100
mM sulfo-NHS and 10 µg/mL CTX for 2.5 hrs. In order to make this
solution, EDC and sulfo-NHS (1:1 ratio) were first reacted with each
other for 20 min and then CTX Ab was added to the solution and in-
cubated for another 60 min. Subsequently, the electrodes were rinsed
to remove the excess antibody complex.
In order to avoid non-specific binding, 10 µL of BSA solution (0.2%
m/v in 0.1 M PBS, pH 7.4) was deposited on each electrode for 1 h. Fi-
nally, the electrodes were rinsed with 0.1 M PBS and 0.1 M PBS-Tween
20. The electrodes were then shaken to remove excess water. Fully
modified electrodes were stored dry until further use with actual anti-
gen samples, but not longer than one day. The electrode carrying the
conjugated antibodies were treated carefully as the detachment of the
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conjugates can be troublesome if proper handling/pipetting are not
employed during washing/blocking steps.
6.3.3 Characteristics of CTX electrochemical chip
Surface Morphology
We used STEM to determine three-dimensional surface morphology of
the electrodes after every modification step and to study the interac-
tion between CTX antibody and the electrode surface. STEM images of
the fabricated Au nanoparticles on gold surface demonstrated that, the
electrodeposition results in surfaces with highly uniform distribution
of AuNP of approximately 20 nm in diameter. (Figure 6.11, 6.12, 6.13)
As a result, total surface roughness, and thus surface area of the elec-
trode was enhanced. The observation of Ab-functionalized electrodes
indicated the affinity of AuNPs to CTX antibody, and the aggregation
properties of the antibody complex.
XPS similarly confirmed the successful modification of the electrode
surface in every step.
Electrochemical behavior
The AuNP layer enhanced the electrochemical conductivity of the
AuNP-modified electrode compared to the bare one, which is related
to the increased active surface area of the electrode. (Figure 6.11, 6.12,
6.13) As mentioned in Chapter 5, the real electrochemical surface area
of the gold electrodes was 2.3 times greater than the area before elec-
trodeposition, providing a bigger surface for antibody immobilization.
In addition, the CV of AuNP-modified electrodes showed a remark-
able oxidation peak at 0.142 V and a reduction peak at 0.9 V. This sharp
oxidation peak is due to oxide formation and the occurrence of Au
stripping. Therefore, the AuNP-modified electrode displayed an ad-
vantage for signal amplification.
After the addition of the antibody complex, however, a significant sig-
nal reduction in electrical response was noted. This is because of the
binding of antibody on the electrode surface which forms a hydropho-
bic surface that retards the interfacial electron transfer, which will be
reflected as reduced electrical response.
6.3.4 Analytical procedure
The fundamental structural unit of an antibody is two identical heavy
and light chains interconnected by disulfide bridges. The chains are
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(a)
(b)
Figure 6.11: a) STEM micrographs and b) CV of a bare gold electrode.
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(a)
(b)
Figure 6.12: a) STEM micrographs and b) CV of an AuNP-functionalized gold
electrode.
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(a)
(b)
Figure 6.13: a) STEM micrographs and b) CV of an Ab-functionalized gold
electrode.
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entirely composed of constant and variable regions, combining one
interaction site for the antigen. The conformation of amino acids of
antibody in this site determines its antigen binding activity [26]. Sev-
eral non-covalent bonding, such as van der Waals and non-polar hy-
drophobic interactions as well as London dispersion attractive and
steric repulsion forces contribute to themolecular interactions between
the antibody and antigen.
The antibody-antigen reaction on our electrodes was tested by the in-
troduction of Ag solution using a fine pipette. In this regard, concen-
tration gradients of the target, CTX, were prepared and run against the
sensor for verification. The concentration against current read during
DPV analysis was used to calculate and plot linear and logarithmic fit
R-squares (degree of fit).
Under the optimum conditions, the DPV peak current of the im-
munosensor array for detection of CTX decreased proportionally with
the increasing concentration of analytes. (Figure 6.14) A linear re-
sponse was observed over the logarithm of concentration range (1 -
1000 pg/mL) tested and the activity of the receptor-antigen couple was
verified. A slope of 0.004 and a linear regression constant (R2) of 0.96
was obtained from the response curve. The correlation coefficient was
0.82 and the LOQ was calculated to be 16.5. The limit of detection
(LoD) was found to be 5.44 pg/mL, which was much lower than the
normal CTX range in plasma (50-450 pg/mL), indicating the sensitiv-
ity of the assay.
A schematic illustration of the preparation process of the immunosen-
sor is shown in Figure 6.15.
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Figure 6.14: Calibration curve of different CTX concentrations using the
proposed immunosensor for signal tracing and amplification.
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Figure 6.15: Surface preparation is typically made possible by modifying the
gold surface by AuNP, leaving carboxyl groups on the surface which in turn can
be activated using zero crosslength linkers such as (EDC/NHS), rapidly
accepting an antibody and detection can occur under target binding.
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(a)
(b)
Figure 6.16: Statistical analysis comparing ECLIA vs. CTX sensor immunoassay
a) Correlation plot b)Bland and Altman plot.
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Table 6.2: Assay results of clinical serum samples using the proposed and reference (ECLIA) methods.
Serum samples Proposed method (pg/mL) Reference method (pg/mL) Relative error (%)
1 268.02 290 7.58
2 403.13 430 6.25
3 588.43 570 3.23
4 216.38 230 5.92
5 451.03 420 7.39
6 549.55 520 5.68
7 766.34 810 5.39
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6.3.5 Real serum measurement
To evaluate the reliability and application potential of the proposed
immunoassay method, the assay results of CTX in human serum
samples using the proposed method were compared with the refer-
ence values obtained by commercial electrochemiluminescent single-
analyte tests. In this regard, the serum of seven patients whose CTX
levels were recently measured using ECLIA was used. The results are
listed in Table 6.2. Acceptable results with relative errors less than
7.58% indicated good accuracy of the proposed method for real sam-
ple analysis.
The correlation between our sensor results and that of ECLIA was also
investigated and the results are shown in the correlation and Bland
and Altman plots in Figure 6.16. The equation of the trendline in the
correlation plot has a slope of 0.98 and R2 of 0.97.
6.4 Optimization
Several factors affect the LoD and thus sensitivity of an assay. Reduc-
ing the risk of loss of activity of the antibody upon conjugation and
nonspecific binding on exposed gold surfaces plays an important role
in this regard. In this immunosensor however we tried to improve di-
rect immobilization of the antibody bymodifying the electrode surface
by AuNPs and using cross-linkers. Nonspecific binding of antigen on
uncovered gold was also resolved by uniform distribution of AuNPs
on the whole electrode surface.
Analytical signal also depends on the morphology of the electrode’s
surface. This is influenced by factors such as surface roughness. As
a result, the amount of immobilized antibodies, their proper conju-
gation to the surface and improved response signal depends on the
amount and size of AuNPs deposited on the electrode surface. These
are related to the deposition time and scan rate, and were optimized
in Chapter 5.
Factors such as the concentration of GSH and Ab as well as the sulfo-
NHS:EDC concentration and ratio were studied by a grid experiment
where a series of concentrations were tested against each other to ob-
tain the largest signal to noise ratio from the assay. Optimum GSH
concentration was found to be 10 mM; 400 mM EDC: 100 mM sulfo-
NHS: 10 µg/mL Ab ratio of 1:1:1 were the optimum concentration of
the CTX antibody complex. As for Oc, similar concentration of GSH,
sulfo-NHS and Ab concentration was used.
The incubation time is another important parameter affecting the an-
alytical performance of the immunoassay. At room temperature, the
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DPV response following the antibody complex immobilization in-
creased with the increasing incubation time and then tended to con-
stant values after 2.5 hrs. This showed the saturated binding both be-
tween the AuNPs and the antibody.
Similarly, in order to optimize the reaction time, the coupling proce-
dure was repeated each time with a shorter reaction time until the sig-
nal change was too low to be detected. An identical procedure was
repeated for a range of Ag concentrations in each case. The optimized
reaction time, suggestive of saturated binding between the antibody
and antigen, was 80s.
As discussed in Chapter 4, temperature had no significant effect on
the Ab immobilization and Ag-Ab reaction processes. Thus, to sim-
plify the process, all the steps were performed at room temperature
and the optimized incubation time of 2.5 hrs, as calculated in the same
chapter, was used.
The highest activity of both Oc and CTX sensors was observed at pH
4.5, in which all the used material (sulfo-NHS, EDC and GSH as well
as the antibody) are reported to have the best functionality [27] [28].
6.5 Specificity, Cross-reactivity & Cross-talk
To investigate the specificity and cross-reactivity between analytes
and Ab-functionalized surface, the interaction experiments were re-
peated with constant concentration of the opposite antigen along with
PTH. The Oc sensor showed a minimum change from baseline value
(<3%) with respects to CTX (100 ng/mL) and PTH (100 ng/mL) as
interferents, indicating that the sensor did not interact with CTX or
PTH to an appreciable degree over a wide concentration range, which
can be attributed to efficient blocking of nonspecific binding sites on
gold.(Figure 7.9)
As expected, the CTX immunosensor showed obvious responses only
toward its corresponding antigens. Apparently, the cross-reactivity at
the array was again negligible (a minimum change of <3% from base-
line value). (Figure 7.9)
An excellent immunosensor array must exclude cross talk, which gen-
erally results from the diffusion of electroactive indicator produced on
one electrode to neighboring electrodes. In this work, as the Ab com-
plex was immobilized on AuNPs, the Ab-antigen reaction would only
accumulate on the AuNPs, resulting in a localized stripping reaction at
the individual electrode. Hence, the possible cross talk could be well
avoided.
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(a)
(b)
Figure 6.17: a) Electrochemical response measured for CTX (100 ng/mL), PTH
(100 ng/mL) and Oc (100 ng/mL), b) Response measured for CTX sensor
incubated with Oc (100 pg/mL), PTH (100 pg/mL) and CTX (100 pg/mL).
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Figure 6.18: Vacuum packed electrode.
6.6 Reproducibility and Stability
The as-prepared immunosensor array could be stored in dry condi-
tions at 4 ○C. In this way, over 90% of the initial responses remained for
a week of storage. In order to improve the stability, the immunosen-
sors were vacuumpacked and kept at room temperature or at 4 ○C. The
results revealed that the immunosensors lost more than 80% of their
response after two weeks of storage, suggesting that vacuum packing
alone was not effective in protecting the immunosensor over time. It
seems that apart from oxygen, humidity and light can also speed up
the degradation process of the modified electrodes.
The interassay precision of the immunosensor was examined based on
repeated measurements of two different concentrations of CTX with
five immunosensors. The coefficient of variation was 4.1%, indicating
that the immunosensor has acceptable stability and reproducibility.
6.7 Conclusion
In this chapter, electrochemical detection method was applied in
two different biosensor chips to detect serum levels of CTX and Oc.
AuNPs were electrodeposited on gold electrodes to improve the sur-
face area, provide better electron-transfer kinetics, and higher back-
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ground charging current. On the AuNP-modified gold electrode, CTX
and Oc antibodies were covalently immobilized by crosslinkers and
different concentrations of the corresponding antigens were applied
for direct determination.
Due to the excellent electrical properties of the as-prepared im-
munosensor, Oc sensor could detect serum levels of the marker within
the range of 2.5-75 ng/mL. Again, the reference value of Oc for adults
of both gender is 9-42 ng/mL, suggesting that the sensor can accept-
ably detect Oc.
Similarly, CTX levels were successfully measured from 1 pg/mL to
1000 pg/mL. This is while the reference value of the marker is as fol-
lowing:
￿ Males:
￿ <18 years: not established
￿ 18 - 30 years: 155 - 873 pg/mL
￿ 31 - 50 years: 93 - 630 pg/mL
￿ 51 - 70 years: 35 - 836 pg/mL
￿ >70 years: not established
￿ Females:
￿ <18 years: not established
￿ Premenopausal: 25 - 573 pg/mL
￿ Postmenopausal: 104 - 1,008 pg/mL
This suggests that the sensor can acceptably detect CTX.
Compared to conventional methods, the proposed electrochemical
sensors resulted in selective and sensitive measurement of each of the
BTM markers with reduced interference reactions, reduced measure-
ment time, need for less amount of reagent and better stability in a
simplified detection system.
The total assay time for these sensors is about 5 min (loading of anti-
gen, incubation time, flushing with PBS and testing). The good corre-
lation between ECLIA and these sensors showed the chips can be used
in the clinically relevant range. Moreover, the fact that the initial cali-
bration curve was plotted using pure antigen and the serum tested in
the last step also contained other macromolecules suggests the sensor
is specific for the antigen and macromolecules present in serum do not
affect the results. However, the fact that the Oc Ag used to develop our
calibration curve was a full-length protein, while ECLIAwas designed
to measure N-mid Oc may have affected our results.
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Osteokit Fabrication
7.1 Introduction
Nowadays, considering the limited resources, the use of rapid, cheap,
simple-to-operate, disposable, and accurate PoC diagnostics is of great
importance and can have a critical impact on clinical decision-making.
Although advanced diagnostic technologies, such as polymerase chain
reaction (PCR) and ELISA are widely used, their application in devel-
oping countries is limited because of the limited availability of labora-
tory infrastructure, skilled personnel and financial supports [1].
As a result, microfluidic technologies have been widely employed in
developing PoC diagnostics and to miniaturize immunoassays to ad-
dress global health issues because of their potential advantages of low
sample and reagent consumption, high throughput and sensitivity,
large surface-to-volume ratio, and other benefits related to miniatur-
ization [2]. However, as mentioned in Chapter 3 most microfluidic
devices require both complex fabrication processes and external in-
struments [3]. Several aspects need to be considered while design-
ing a microfluidic device, such as selection of materials, dimensions of
the microfluidics devices and fluidic control devices (such as pumps,
valves, and mixers).
Some of the materials used for fabrication of microfluidic devices for
PoC diagnostics include paper (nitrocellulose or cellulose), glass, sili-
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con, plastics (cyclic olefincopolymers or polystyrene), and polycarbon-
ate. Currently, polymers such as PDMS and thermoplastics are most
frequently applied to facilitate the translation of microscale systems
from simple laboratory tools to commercially marketable products [4].
The latter are more favorable as they allow for the production of di-
mensionally stable andmechanically robust components while the fea-
ture fidelity and integrity are easier to maintain during replication pro-
cesses [5]. Among thermoplastics, cyclic olefin copolymer (COC), poly
(methyl methacrylate) (PMMA), polystyrene, and polycarbonate are
frequently used for fabricating microfluidic systems.
Despite the above mentioned advantages, the fabrication of microflu-
idic channels using these materials requires costly and laboratory in-
tensive cleaning, photolithography, and etching or baking steps in
clean room environments. Thus, design iterations to modify the de-
vice is labor and resource-intensive [6]. Besides, proper channel enclo-
surewithout deforming small features orwithout clogging of the chan-
nel during the bonding process is challenging [7] [8]. Nowadays, the
key step to the final integration includes plasma or UV/ozone treat-
ment, thermal fusion, microwave welding, adhesives, surface modi-
fication or solvent bonding, which apart from being costly and time-
consuming, does not always provide acceptable results [9] [10] [11].
Hot embossing and thermal bonding are currently the methods of
choice for fabricating and sealing microfluidic channels in thermo-
plastic materials [12].These methods allow a relatively fast and easy
fabrication of microfluidic devices but they generally need expensive
equipment and a cleanroom environment [13].The temperature and
pressure applied during these steps also limit the variability of the ma-
terials used.
Hot embossing is a popular method for fabricating microfluidic chan-
nels in thermoplastic materials. The fabrication process typically starts
with a PDMS or epoxy-based master mold, which is made using well-
established photolithographic processes [14]. Shrinkage of this mas-
ter mold and subsequent misalignment are quite common with large,
centimeter-order devices [15]. The quality of microfluidic channels
during the replication process is also of great importance. During ther-
mal fusion, the polymer is heated to or slightly above its glass transi-
tion temperature (Tg), and thus becomes soft and sensitive to hetero-
geneities in load distribution during the bonding process.
In this chapter we report the design and fabrication of a sensitive mul-
tiplexedmicrofluidic proteomic platform integrated with electrochem-
ical sensing that can easily be translated into a protein biomarker di-
agnostic. To our knowledge this is the first such device designed as a
step toward developing a PoC system for the measurement of several
7.2 System Design and Fabrication 209
BTMs.
7.2 System Design and Fabrication
7.2.1 Design and Fabrication of sensor chip
The electrochemical chip was the glass-based gold electrode fabricated
in Chapter 5. In brief, it consisted of 6 gold electrodes arranged in a 2
by 3 electrode arrays on a glass. The glass was 25.5*85.5 mm2, leaving
a 25.5*10 mm2 uncovered area, after assembly of the tape and the COC
substrate, for the contact pads to be connected to the read-out circuit
using a custom-made PCB. Each gold working electrode (1.5*1.5 mm2)
was placed between one gold pseudo- reference (1.4*1.4 mm2) and one
gold counter electrode (2.5*2.5 mm2), as depicted in Figure 7.1.
7.2.2 Design and Fabrication of microfluidic manifold
In order to develop a fully operational electrochemical diagnostic pro-
totype, the microfluidic platform consisted of the microchannels and a
chamber necessary to expose electrodes in the electrochemical sensor
chip to the sample, surface modification solution, and detection probe.
All delivered samples and reagents were routed to the waste outlets.
For the fabrication of the microfluidic channel layer, the design of the
microfluidic channels was first drawn in a computer-aided design and
drafting software (Autodesk, USA). The design was then used to fab-
ricate epoxy molds. Figure 7.2 illustrates the process used to fabricate
epoxy (FR-1080)1 mold from PDMS (Sylgard 184) stamps. The PDMS
stamps were themselves fabricated using soft lithography using SU-
8 on a silicon wafer, which was itself structured using photolithog-
raphy. The use of these molds has several advantages. De-molding
process after embossing is straight forward without any special mold
designs. Moreover, complex structures and topographical features at
nano-scale, which cannot be accomplished with a metal mold, can be
replicated with such molds [16].
The microstructured epoxymold was brought into contact with a COC
slide placed on a standard 4" * 4" glass slide. A lamination stack con-
sisting of thick metal plates (carrier or tooling plates), pressure dis-
tribution material (press pad), thin, polished metal plates (separator
plates) and release foil were used to sandwich the epoxy mold and the
1This is the main type of epoxy that is generally used for hot embossing applications (up to 135-140○C).
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(a)
(b)
Figure 7.1: a) Schematics of the electrochemical sensor chip b) Structure of the
microfluidic manifold.
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Figure 7.2: Fabrication process of epoxy molds.
COC slide. (Figure 7.3) The assembly was placed in Vacuum Laminat-
ing Press (Lauffer RLKV 25),for the hot embossing process applying a
load of 3 kN for 5 min at 110 ○ C. Vacuum conditions during the entire
process prevent trapping of air pockets in the cavities. After solidifica-
tion of the polymer, the stack was cooled down to room temperature
in 6 minutes while maintaining a constant force. Then the assembly
was unloaded and the epoxy mold was carefully peeled off from the
embossed COC slide to avoid tearing or ripping of the epoxy mold.
As the next step, thermal bonding with Vacuum Laminating Press was
used to enclose the open structure of the COC slide replica with a glass
slide which also acted as the electrochemical chip (as mentioned in
Chapter 6). In this regard, the stack was loaded into the press, and
bonded at 3kN and 110 ○ C for 10 min and then were cooled to room
temperature under the same pressure, then unloaded. The process
took 20 minutes. This process was associated with several limitations.
(Figure 7.4)
￿ Some deformation was noted of the fabricated microstructure in
the COC.
￿ The process was time-consuming and the stack assembly was
heavy.
Therefore, the microfluidic channels were realized using a double-
sided medical grade tape (3M) of 86 µm thickness, which was pre-
viously laser machined to generate microchannel structures. The CAD
design was used to define the cutting path through the double-sided
tape, using a laser beam. Therefore, any modification of the design
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(a) (b)
(c)
Figure 7.3: a) Si Wafer used to fabricate the PDMS stamp. b) PDMS with
negative copy of SU-8 master. c) Epoxy mold.
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(a)
(b)
Figure 7.4: a) Lamination stack (partially shown). b) Deformed COC after the
embossing process.
214 Osteokit Fabrication
Figure 7.5: Tape was partially cut using laser ablation to facilitate the handling,
aligning and assembling process.
is straightforward and easy to implement. Here, a focused 9.6-µm
wavelength CO2 laser beamwas used to partially cut through the tape
at predefined locations to ease handling, aligning and assembling in
general. Figure 7.5 shows the cross-section of a partially cut tape. It
should be noted that the laser beam spot has a certain diameter (ap-
proximately 100 µm), which we compensated for in the CAD design.
The patterned tape was then used to integrate the microfluidic mani-
fold, i.e. the COC slide, with the glass sensor chip and aligned using a
manual mask aligner (SET MG1410). Using this technique, patterning
of COC was not required anymore.
An exploded-view drawing of the three-layer microfluidic manifold
with the sensor chip is presented in Figure 7.6. In this regard, the sen-
sor chip (gold electrodes on the glass) acted as the bottom layer. The
middle layer (tape) defined the capture/reaction chamber and chan-
nels. The topmost layer in the chip serves as the covering for the chan-
nels. COC was used as this layer as drilling the I/O holes was much
easier in it compared with glass. This layer is a rectangular piece of
COC (COC, Topas 8007) (25.5 mm by 75.5 mm, 1 mm thickness) drilled
with 1 mm diameter holes that serve as the reservoirs to introduce the
sample and buffer solutions as well as to collect the waste. The fluid
flows in the microfluidic channels and reaction occurs in the reaction
cells where the fluid is exposed to the electrodes on the bottom layer.
Figure 7.7 explicitly shows the cross-sectional view of each layer in the
chip.
The channels had a width of 200 µm; this is a safe value considering
that our studies have shown that 100-µm-channels are wide enough
for serum/blood samples to pass through without clogging or sedi-
mentation. The capture/reaction chamber had a width and length of
2.9 mm and 8.9 mm. The height of the channels and chambers were
equal to the thickness of the tape (86 µm). Transparency of the injected
7.2 System Design and Fabrication 215
(a) (b)
(c)
Figure 7.6: Diagram of the microsystem device a) CAD design of each layer, b)
Microfluidic device positioned in between 2 PMMA plates, acting as
microfluidic chip holder, c) Cross-section of the microfluidic device.
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Figure 7.7: Schematic illustration of the build-up of the multilayer microfluidic
device and the microfluidic chip holder.
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fluids hindered the observation of fluid flow; therefore a blue dye was
used to characterize fluid flow profiles in the capture/reaction cham-
ber and channels.
In this approach, each layer is processed as if it was an independent
substrate. These are then aligned and bonded to the other layers.
7.2.3 Design and Fabrication of Holder
In order to interface the microfluidic chip with external fluidic and
electrical connections, a custom-made holder was designed and fab-
ricated in-house by micro-milling in a 1 mm PMMA sheet and cut out
in the dimensions of 65*126 mm2. The docking station, used to house
the chip, functioned as a base with female ports fully integrated into
the device to reduce cost and improve reproducibility and reliability
of the results [17].
The top PMMA plate includes circular, drilled holes of 1 mm diameter
(centered relative to the I/Os) that fit with the corresponding connec-
tion ports in the COC. The ports for incorporating fluidic connectors,
purchased from LabSmith, were glued to these PMMAholes. These in-
terconnects were chosen because of their small footprint that allowed
a high density of fluidic I/O ports and minimal dead volume.
A circular notch of approximately 0.3 mm depth was designed on the
inner surface of this plate to place the Viton O-rings (2 mm inner diam-
eter, 4 mm outer diameter, 1 mm thickness), again centered relative to
the inlets/outlets. The O-rings were used to provide a leak-free inter-
face between the holder and the inlet and outlets on the COC. Tygon
tubing was used to introduce the fluids from a 1 mL Luer-Lok tip, in-
sulin syringe (BD, Franklin Lakes, US). The lower half of the holder
is completely featureless. The two sides were tightened together with
screws after the assembled device was put in between and aligned by
eye.
7.2.4 Assembling and sealing
In order to minimize surface contamination, parts were blown off with
high-pressure nitrogen before the assembling step. The assembly of
the layers started with removing one of the release liners and bond-
ing the micro-patterned adhesive tape to the COC substrate. A roller
was used to avoid the entrapment of air at the interface. Thereafter,
the other release liner was removed, and the micro-positioning table
and the microscope of a mask aligner system were used to align the
COC / tape stack with the glass substrate before bringing them into
contact and creating a tight bond. It should be noted that considering
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the design, the second part can also be performed manually. This pro-
cess of stacking - layer, tape, layer, tape - can be repeated as needed
to complete the microfluidic device. For the final bonding, the entire
assembly was pressed together manually. The microfluidic device was
then placed in the custom-made microfluidic chip holder. (Figure 7.6)
7.3 Microfluidic Characteristics
The improvement of detection sensitivity and analysis time has been
a key motivation for the development of analytical microsystems
[18][19]. Size reduction lowers the consumed reagent and sample vol-
ume and also results in portability. It however may compromise the
detection limit of the device, especially for low flow rates [20]. This
is while the maximum allowed pressure for reliable operation and in-
tegrity of the microfluidic device limits the flow rate itself [21]. There-
fore, the parameters that contribute to the sensitivity and specificity of
the measurements in such devices are as following:
￿ Successful and functional immobilization of the antibodies on sen-
sor surfaces to perform reagentless detection
￿ Amplifying reaction signals
￿ Flawless flow of the solutions in the microchannels during prepa-
ration steps and electrochemical process
￿ Absence of cross talk due to the diffusion of electroactive products
from one electrode to a neighboring one causing interference.
7.3.1 Channel Characterization
The dimensions of the resulting microfluidic channels along with the
characteristics of the material used to make the microfluidic channels
can affect the fluid flow.
Channel Dimension
The narrowest channel, which could be fabricated using the laser-
cutting technique, has a width of around 100 µm, because of the laser’s
beam spot. Therefore the technology is not applicable everywhere, but
it offers a cost-effective, simple and accurate solution for several appli-
cations.
Figure 7.8 presents the difference in the width of the microfluidic chan-
nels seen from the front side and backside of the tape before bonding.
The trapezoidal shape of the cross section is typical for microfluidic
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(a) (b)
Figure 7.8: Optical microscope images of the width of a 100 µmwide
microchannel before bonding seen from the (a) back and (b) front side of the
tape, showing the trapezoidal shape of the microfluidic channels. The dark lines
represent the ablated tape.
channels fabricated using laser-cutting and is due to the laser-cutting
and can be contributed to the focal plane of the laser beam.(Figure
7.9) Due to the trapezoidal cross-section, the width of the microflu-
idic channels varied from to 110 ± 5 µm at the top to 65 ± 5 µm at the
base of the microfluidic channels.
In order to quantify the uniformity of the cross-sectional geometry of
the microfluidic channels along their length, a microfluidic channel
was diced along its length at 5 mm intervals and assessed with an opti-
cal microscope (Nikon Eclipse LV100) and non-contact optical profiler
(WYKO NT3300) to assess its width and height, respectively.2 (Figure
7.10) The low relative standard deviations confirm the uniformity of
the channel dimensions.
Channel Structure
The typical permeability of COC for oxygen ismuch less than the value
observed for other materials popular for the preparation of microflu-
idic chips [22]. This material property is of great importance as the
presence of oxygen in the channel would disturb the reactions and
measurements in different ways.
As mentioned earlier, the material used to fabricate michrochannels
2As dicing the Glass - Tape - COC at 5 mm intervals was troublesome, COC - Tape - COCwas used
instead.
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(a) (b)
Figure 7.9: Optical microscope images of the cross-section of a microfluidic
channel, showing its height before (COC-Tape) and after bonding
(COC-Tape-COC).
(a) (b)
Figure 7.10: a) Cross-section of the chip, prepared by dicing along the length of
the microfluidic channel at 5 mm intervals, b) Channel height and width at 5
mm intervals along the length of a 250µmwide microfluidic channel, measured
using an optical microscope and non-contact optical profiler.
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should provide proper channel enclosure without deforming small
features or clogging the channel during the bonding process [7][8]. To
overcome these concerns we used double-sided tape both as glue to
bond layers and as channel structure.
One of the main purposes for the fabrication of microfluidic devices
with feature size in the micrometer range is to reduce the quantity of
the needed sample. In this regard, non-specific adsorption of proteins
to channel walls and cross talk to other channels should be prohibited
as it may cause unpredictable reduction in the concentration of the as-
say component and slow its transport rate. As a result, controlled pro-
tein adsorption characteristics of thematerial used in themicrochannel
structure is of great importance.
Controlled protein adsorption In order to assess the protein ad-
sorption rate in microchannels, the auto fluorescence of different
COCs/Cyclic Olefin Polymers (COP), the double-sided tape and poly-
mers to be used as the insulation layer on the immunoelectrode were
measured (Chapter 5).
The above mentioned materials were immersed in a 2 mg/mL solu-
tion of FITC-Albumin in 0.05 M phosphate buffer (pH 7.0) for 2 hrs
and subsequently rinsed with DI water [23]. Thereafter the amount of
their protein adsorption capacity was determined by measuring fluo-
rescence (lexcit=495 nm, lemis=520 nm) in the labeled materials using
a fluorescence spectrometer. As it can be seen in Figure 7.11, biocom-
patible polyimide (PI) was the only material which seemed to adsorb
the labeled albumin and thus biocompatible SU-8 was used as the in-
sulation layer instead. The tape, on the other hand, seemed to adsorb
negligible amounts of labeled albumin. It was concluded that cross
talk is not an issue as the tape and other materials used in the Osteokit
had negligible protein adsorption capacity.
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Tx = Treatment
Figure 7.11: Fluorescence emission ratio of different materials to be used in channel fabrication before and after
treatment with FITC.
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Capture/Reaction Chamber characterization
In general, the detection system in the PoC microfluidic immunoas-
say devices must have high sensitivity and short response time [24].
There are several parameters that contribute to the sensitivity of the
capture/reaction step. These parameters include the area of the elec-
trode surface, flow rate of sample and wash into the capture/reaction
chamber, and surface modification step.
Non-optical detection, especially the electrochemical techniques are
important for the microfluidic immunoassay as they are highly sen-
sitive, rapid and can be easily integrated by micromachining technol-
ogy [25]. However, the major disadvantage of this method is the back-
ground noise. As mentioned earlier, AuNPs were used for electrode
modification because of their excellent acceleration of electron trans-
fer and thus signal amplification and low background noise. It was
therefore concluded that AuNPs on the electrodes acted as a powerful
multifunctional layer that improved in situ immobilization of antibod-
ies on the electrodes, amplified themeasured signals and improved the
sensitivity of this electrochemical sensor.
With these parameters in mind, we fabricated a 2.9 * 8.9 mm2 cap-
ture/reaction chamber that was 86µm deep (volume= 2.2 mm3) to
maximize the number of interactions between the agents needed to
functionalize the surface as well as target analytes and the functional-
ized surface.
The special design of the channels along with the application of the
chronoamperometry technique to reduce the measurement time and
the electrolysis risk also helped overcome the bubble formation con-
cern. It should be noted that in the liquid environment, bubbles are
easily generated by electrolysis, and influence the result.
7.3.2 Flow Characterization
For characterizing the fluid flow in the capture/reaction chamber, a
colored dyewas utilized to visualize the flow of the fluids entering and
exiting the capture/reaction chamber. Injecting a colored dye demon-
strated the capability of the device to move fluids both through the
channels and across different layers over the detection zones. Accord-
ing to our design, the fluid is distributed from an open inlet on the top
COC substrate of the device into a single channel, which is connected
to an open outlet on the same layer. During this path, it passes over
the detection zone, which is located on the bottom glass substrate. If
various ports are open, the injected sample can be distributed through
different channels to the outlets. This ability to redirect the sample into
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multiple detection zones makes it possible to use the microfluidic de-
vice for simultaneous measurement of multiple markers in a sample.
No leakage was noticed in between adjacent channels.
Transporting liquids from the inlet to the reaction chamber and to the
outlet is a key step in the microfluidic immunoassay device. In this
project, the fluidic control of the analyte in and out of this chamber was
achieved through capillary motion and pressure-driven flow, gener-
ated by a syringe pump. The flow behavior mainly depends on the in-
let flow rate and thus we tried to introduce liquid into the system with
a constant volumetric flow rate. Flow rates higher than 3500 µL/min
were observed to be associated with gas bubble introduction into the
channels and so were avoided.
Moreover, a wash step was performed at the beginning to ensure the
transfer of remaining air in the interconnects, channels and chambers
to the outlet. This is because when hydraulic pressure is applied,
gas bubbles remaining in the interconnection holes can be trapped in
the reaction region during the detection process and cause significant
problems by disturbing fluid flow or drying electrodes-on-chip [26].
Liquid movement is also controlled by different fluidic resistance
within the parallel channel network. During the experiment, most of
the pressurized solution flows into the reaction chamber because the
fluidic resistance of other channels, which are filled with air at this
point, is higher than that of the reaction chamber. The adopted de-
sign was also accountable for reduced back flow and improved flow
of the solutions without dead volume formation. This was achieved
by computational fluid dynamic (CFD) simulation and testing differ-
ent designs in the lab.
7.3.3 CFD
All numerical computation presented in this work were performed
using COMSOL Multiphysics (Finite Element Method) and Fluent
(Finite Difference Method). Simulation was performed for a two-
dimensional, incompressible Navier-Stokes flow. A no-slip condition
was assumed along the walls of the microchannel and physical val-
ues of water (dynamic viscosity: 1.002e-3 cP; density: 1000 kg/m3)
were used in the numerical computation. The effect of the position of
the inlet and outlet microchannels and the geometry of the recognition
chamber on the flow profile were investigated.
The tests were performed in two states:
￿ Steady state, where the injection time is estimated to be infinite.
This profile studies the velocity and pressure at different points
of the microchannel. Both outlets are considered open all through
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(a) (b)
Figure 7.12: a) Pressure, and b) Velocity change through single microchannel.
the experiments, whereas only one of the inlets is open in each
set of tests. As a result, the pressure at the outlet is equal to one
atmosphere.
￿ Transient state, which aims to study the flow profile in the system.
In this simulation, the channels are considered to be filled with
air before the first injection. A constant flow rate (400 µL/min) is
applied to the inlet, pushing the air out of the outlet.
In order to validate the software setup, a single-channel system was
used. The pressure drop in the channel is shown in Figure 7.12. As it
could be seen, the pressure at the beginning and end of the microchan-
nel are constant and the pressure drop through the channel follows
a linear drop. This could be explained by the small size of the fully
developed length.
The velocity change through the channel is shown in Figure 7.12. In the
inlet, the velocity was minimum and the pressure was maximum. The
considerable velocity increase at the beginning of the channel is due
to the mass conservation law and the fact that the fluid enters a small
channel with a smaller surface area compared to the inlet. Thereafter
the velocity remains constant until it reaches the outlet, where a con-
siderable decrease is noted.
When studying the velocity in the microchannel’s cross-section, in
view of the no-slip condition, the velocity along the walls was ob-
served to be zero and themaximum velocity was reported in the center
of the microchannel.(Figure 7.13) The maximum shear stress, on the
other hand, was noted on the walls and the minimum in the center of
the channel.
The multi-channel network setup was drawn in Gambit software and
studied using Fluent. The design was modified in a way that the mi-
crochannels and the chamber would be filled completely, the back-
flow to other inlets is reduced and no dead volume is noted.
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Figure 7.13: Velocity contours in the channel’s cross-section.
Figure 7.14: Final design of the microfluidic system.
As mentioned earlier, maximum pressure was noted in the inlet. A
considerable pressure drop was observed when the fluid entered the
chamber, where the pressure became equal to that of the closed in-
lets. As the outlet pressure was one atmosphere and the pressure in
the chamber was higher than the atmosphere pressure, the fluid was
guided through the outlet with a negligible back-flow.
It should be noted that in the course of the simulation, dead volumes
were identified in the square chamber along with the inlets and out-
lets, suggesting that the immobilization and washing of the electrodes
would not be effective. Based on these observations, a design modi-
fication was incorporated, where an additional outlet was added and
the angels of the inlets and outlets were changed so that the dead vol-
ume was eliminated, the backflow in other inlets was negligible and
the fluid flow trajectory, the velocity field and pressure were evenly
distributed across the chamber. (Figure 7.14)
Figure 7.15 represents the fluid flow trajectories in the final optimized
design. The results showed that the chamber was completely filled
after the first second, and thereafter the volume fraction of the fluid
remained constant. The system was completely filled after a longer
injection time.
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(a) 0s (b) 0.1s
(c) 0.2s (d) 0.3s
(e) 0.4s (f) 1s
Figure 7.15: Fluid flow trajectories in the final design at different time frames
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(a) 0s (b) 0.1s
Figure 7.16: Fluid flow trajectories in the chamber.
The maximum Reynolds number was computed to be less than 0.01
confirming laminar flow in the microchannels except for the corners.
(Figure 7.16) The reduced shear stress and the turbulent flow observed
at the corners of the chamber increased the risk of possible sedimenta-
tion, pointing out the need for gentle washing after each steps.
7.3.4 Mechanical Stability
Peel test measurements
To assess the adhesion strength of the tape to either side (i.e. the COC
and the glass substrate), a 90○ - peel test was performed using a Mul-
tipurpose Bondtester (Dage 4000) (Nordson, UK). The test was per-
formed both for a 2.5 cm by 6 cm stripe of tape being bonded to the
glass substrate and to the COC substrate. The peeling speed was set at
500 µm/s and the load range at 40 N. After mounting the sample, the
sample movement is automatically adjusted to ensure perpendicular
peeling force to the surface. The peel strength (N/mm) is calculated
by dividing the mean value of the measured peel force (N) in a steady
region by the width of the stripe of tape (mm).
The peel test results are visualized by plotting the peel strength versus
the elapsed test time. (Figure 7.17) An acceptable adhesion strength of
the tape to both the glass substrate (0.18 ± 0.02 N/mm) and the COC
substrate (0.21 ± 0.02 N/mm) is shown. (Table 7.1)
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Figure 7.17: Mean peel strength versus elapsed time of the tape on the glass and
the COC substrates (Tape width = 25 mm).
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Table 7.1: Mean peel force calculated for each stripe of tape bonded to the glass
substrate or the COC substrate (Tape width = 25 mm).
Tape-Glass Tape-COC
Test # Mean peel force (N) N/mm Mean peel force (N) N/mm
1 4.69 0.19 5.69 0.23
2 5.22 0.21 5.19 0.21
3 4.68 0.19 4.81 0.20
4 5.06 0.20 4.92 0.20
5 3.63 0.15 4.44 0.18
6 3.82 0.15 6.12 0.24
7 3.77 0.15 4.74 0.19
8 4.07 0.16 5.60 0.22
9 5.28 0.21 5.32 0.21
10 4.74 0.19 5.47 0.22
11 4.81 0.19 5.38 0.22
Mean ± SD 4.52 ± 0.57 0.18 ± 0.02 5.24 ± 0.46 0.21 ± 0.02
Burst test measurements
In order to measure the pressure at which the microfluidic chip fails,
a pressure transducer (CTE9000, First Sensor, Germany) with an error
accuracy of 0.2 % over the range of 0 - 16 MPa was connected in-line
using Tygon tubing with a syringe pump and a microfluidic chip con-
taining a single channel with an inlet and outlet. (Figure 7.18)
The voltage output of the pressure transducer was monitored using
an oscilloscope, and was converted to a pressure value using a calibra-
tion curve provided by the manufacturer. Colored dye was pumped
through the microfluidic device at different flow rates, starting at 500
µl/min, and the internal pressure buildup was recorded after the volt-
age demonstrated by the oscilloscope became stable for at least 1 min.
As the outlet was open, the pressure at the outlet was considered 1 at-
mosphere. Taking this in mind, the pressure drop in the channel was
calculated.
The burst pressure is defined as the maximum internal pressure
recorded prior to device failure due to delamination at the bonding
interface or fluidic connections. The burst pressure for each flow rate
is the average of 3 measurements.
The burst test showed the ability of the microfluidic device to sustain
typical pressure levels when pumping liquids through themicrofluidic
channels.(Table 7.2)
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(a)
(b)
Figure 7.18: a) Experimental burst test setup, b) Schematic image of the burst test
setup.
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Table 7.2: Pressure drop calculated for different flow rates. (Calculated using
Equation (7.2))
Flow-rate (µL/min) Pressure at center (bar) Pressure drop (bar)
0 - -
200 1.12 0.12
500 1.30 0.29
1000 1.58 0.58
1200 1.70 0.70
1500 1.87 0.87
1700 1.99 0.99
2000 2.17 1.17
2200 2.28 1.28
2500 2.46 1.46
3000 2.75 1.75
4000 3.33 2.33
5000 - -
The measured pressure at the inlet was in concordance with the pres-
sure calculated theoretically. (Figure 7.19) In a rectangular channel, the
equation estimating the pressure drop across the channel is expressed
as follows [6]: (Equation (7.2))
DP = Q.R = 12 ∗ µ ∗Q ∗ l
h3 ∗w(1− 0.63 ∗ hw) (7.1)
in which Q is the volumetric flow rate of the liquid, R is the fluidic
resistance, l is the length of the microfluidic channel (39.3 mm), µ is
the viscosity of the fluid (10-3 Pa.s), w is the width of the microfluidic
channel (0.264 mm), and h is the height of the microfluidic channel
(0.0864 mm).
The experimental burst test results showed that inlet flow rates higher
than 5000 µl/min may fail either at the point of attachment of the in-
terconnect, or at the interface between the two bonded parts.
Pressure drop in the systemwas calculated as the following: (Equation
(7.1))
DP = 8 ∗ µ ∗Q ∗ l
p ∗ r4 (7.2)
in which Q is the volumetric flow rate of the liquid (m3/s), l is the
length of the tubing (m), µ is the viscosity of the fluid (10-3 Pa.s), r is
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(a)
(b)
Figure 7.19: a) Measured vs expected pressure at the inlet for different flow
rates. b) Measured vs expected pressure at the inlet.
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the radius of the tubing (m).
In order to calculate the highest pressure drop in the system, maximum
flow rate (4000 µl/min = 0.06* 10-6 m3/s) tolerated by the channel was
used. Using the parameters shown in Figure 7.18, pressure drop was
estimated to be 0.93 mbar in tubing 1 and 2 and 6.13 mbar in tubing 3.
It could be concluded that the pressure drop in the tubing can be ne-
glected compared to the pressure drop inside the microfluidic channel.
7.4 Conclusion
Currently, developing the microfluidic channels and bonding differ-
ent layers to each other are the bottlenecks in the rapid prototyp-
ing process of microfluidic devices. They considerably prolong the
turnaround time between the design of the microchannel layout and
the fabrication of the final design. We used a cheap, reliable and rapid
method for the fabrication ofmicrofluidic channels using double-sided
tapes, enabling not only highly uniform cross-sectional dimensions
along the channels but also proper adhesion in hybrid systems, com-
posed of different layers.
Our results showed that the laser-cutting procedure for each sample
was performed in 5min and an additional 5minwas needed for the as-
sembly process. These numbers suggest that the technique is fast and
cost-effective compared with the existing microfluidic channel fabri-
cation and bonding techniques. Moreover, modification is not an out-
landish task in these devices any more.
The adhesive is shown to have bond strengths that prevent leakage,
delamination and channel rupture in the typical pressure range used
for microfluidic applications. A further advantage is that the assembly
of the different layers does not require any plasma, heat or additional
treatments and depending on the required precision of the design, can
be performed manually.
This intermediate adhesive layer is therefore believed to solve possi-
ble obstacles met during the manufacturing of hybrid devices. In other
words, while the microfluidic chip described herein has only two lev-
els, a modified version of the fabrication method can be used in appli-
cations requiring a larger number of interconnected tapes across addi-
tional layers. It should be added that this fabrication method is scal-
able to larger platforms as it provides sufficient mechanical strength,
is reproducible in form and operation, applicable to a broad range of
materials, and capable of being produced with high yields.
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Osteokit Validation
8.1 Introduction
Unstable immobilization of antibody on the electrode surface as well
as nonspecific binding are the main factors that determine the detec-
tion limit for an immunoassay [1]. It is known that adsorption of pro-
teins onto bulk metal surfaces leads to their denaturation and loss of
bioactivity [2]. Therefore, as mentioned earlier, the gold electrodes
were modified with AuNPs to overcome these concerns. The AuNP
layer also improved the signals because of their large surface area and
efficient electron conducting features. This chapter deals with surface
modification of electrodes used in Osteokit and its validation process.
8.2 Immunosensing Process
8.2.1 Pretreatment of Working Electrodes
Asmentioned in Chapter 5, in order to coat the working electrode with
a gold nanoparticle layer that would allow sufficient immobilization of
antibodies (Abs) on the surface in later steps, the ECV technique was
used.
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8.2.2 Surface Modification of Sensing Interfaces
The sensing chip was then bonded with the microfluidic chip, making
the device (Osteokit) ready to use. In subsequent steps, the gold sur-
face was modified for capturing antibodies that, during the assay, bind
specifically to the analyte molecules (antigens). (Figure 8.1)
In this regard, the biomarkers were immobilized on the treated surface
through covalent binding using cross linkers [3][4]. As mentioned in
Chapter 6, the electrodes were first activated by injecting an aqueous
solution of 10mM GSH via the loading channel to the reaction cham-
ber and held for incubation for 1 hour. As the next step, the antibody
complex was introduced into the reaction chamber through the inlet
microchannel until the chamber was filled with the sample. The sam-
ple was then allowed to incubate for 2 hrs on the sensor electrodes
(static condition). The antibody complex was prepared by incubat-
ing the antibodies with cross-linkers (100mM s-NHS for Oc, 400mM
EDC/100 mM s-NHS for CTX) for 2.5 hrs in room temperature. The
cross-linkers provided covalent attractions between the constituents,
facilitating the bonding of the primary amine groups (-NH2) of the an-
tibody to the carboxylic group of GSH to form stable amide bonds.
The active parts of the device were washed between each step with DI
to remove unbound fractions. 0.2% (w/v) BSA solution in PBS buffer
was then pumped into the microchannel to immerse the treated elec-
trode for 1 hour and block unreacted active functional groups. The
assembly was kept at room temperature during all steps and finally
rinsed with PBS and then with PBS-Tween 20 thoroughly to remove
unbound analytes and other non-specific entities from the electrode
surface.
8.2.3 Immunosensing strategy
To investigate the applicability of Osteokit for osteoporosis care, we
performed electrochemical immunoassay using fabricated device to
measure serum levels of certain BTMs. All experiments were per-
formed within a day to obtain a good sensitivity because the immo-
bilized antibody (Ab) might be degenerated a few days after the elec-
trochemical chip is fabricated.
For this purpose, different concentrations of Oc and CTX were applied
on the electrode as the analytes for the sensing test, and the chronoam-
perometric signals were recorded. The antibody-antigen reaction pro-
vides a redox current, which is interpreted by the chronoamperometry.
A high quality signal was obtained at + 0.65 V, thus, this potential was
taken as the best value for BTM determination.
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Figure 8.1: A schematic representation of the immunoelectrode fabrication
procedure.
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In this regard, the microfluidic channels were washed using PBS.
Thereafter, the detection solution, K3[Fe(CN)6], was then introduced
into the reaction chamber to fill the chamber for chronoamperometry
measurements (0.1 mMK3[Fe(CN)6] as a redox probe, potential of 0.65
V for 15 s). The measured current at 10s (when the status in the mi-
crochannel was stabilized) was considered as baseline. Then again,
the channels were washed using PBS.
At this step, the desired antigen concentration was injected via the
sample channel and left to incubate in the reaction chamber for 5 min.
The samples were injected sequentially onto the sensing interface and
the signal was recorded. After each measurement, a relatively large
amount of buffer solution was injected to wash the analyte sample out
and fill the reaction channel.
The electrodes-on-chip were utilized in these steps, and a slightly dif-
ferent offset is reported between the working and reference electrodes
in sensors with individualized quasi-reference electrodes, similar to
these ones, that will consequently affect the potentials. The measured
currents were therefore calibrated based on the baseline current for
each electrode to obtain formal potential of the 3-electrode system. In
other words, the current ratio was calculated by dividing the current
measured after incubating the electrodewith the specific concentration
of the antigen by the current measured from the same electrode after
the Ab-functionalization process.
Thereafter, the average of the ratios calculated from several electrodes
incubated with certain antigen concentration was used to develop the
calibration curves 1.
The specific bonding between the antibody and antigen helps im-
prove both the sensitivity and selectivity of the assay. In this re-
gard, sample solutions with different concentrations of each antigen
were loaded into the corresponding chamber where it reacted with the
Ab-functionalized electrode-on-chip. The rate of analyte capture by
surface-bound antibodies can be very slow because flow in microflu-
idic devices is nearly always laminar and mixing occurs only by dif-
fusion. The optimum detection time was established at 5 min. Then,
the channel was flushed by passing PBS solutions through the chan-
nel twice to ensure complete washing and removal of any unbonded
molecules.
1Detailed explanation on how the calibration curve was plotted and the data were extracted from
the plot is discussed in Chapter 6
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8.3 Osteokit characterization
8.3.1 Surface Morphology
Since creating AuNP layer is the first step of surface modification, it
is critically important to have a well-dispersed nanoparticle layer with
uniform size distribution on the surface. The deposition time and scan
rate were therefore properly controlled to assure sufficient deposition
and uniform distribution of AuNPs. According to our results, 60 elec-
trodeposition cycles were needed to produce enough uniformly dis-
tributed nanoparticles with an average size of about 20 nm to cover
the gold electrodes. We used different surface characterization tech-
niques, including SEM, AFM and STEM to characterize the morphol-
ogy of the as-prepared functionalized electrodes. As it can be seen in
Figure 8.2, numerous uniformly distributed nanoparticles were seen
on the AuNP-modified gold electrode. After the immobilization of the
antibody, these nanoparticles aggregated and became larger in size.
8.3.2 Electrochemical Behavior
The electrochemical behavior of the stepwise fabrication of the elec-
trochemical sensor chip was studied using CV, conducted at a po-
tential range from 0 to 1.2 V at 0.1 V/s. The CV curves on the bare
Au, after electrodeposition, and after surface modification with Ab
in K3[Fe(CN)6] are shown in Figure 8.3. The Au electrode showed
well-defined oxidation and reduction behavior of redox moieties
Fe(II)/Fe(III) in the electrolyte. The magnitude of response current of
the Au electrode was found to increase after the electrodeposition of
AuNPs. This suggests the formation of AuNPs, and consequent in-
creased electron transfer rate from the medium to electrode.
When antibodies are immobilized on the working electrode, the con-
ductive area of the working electrode is reduced, the electrical resis-
tance is increased and thus the magnitude of the electrochemical re-
sponse current is further decreased. This suggests successful immo-
bilization of the antibody on the electrode. Furthermore, compared
with bare electrodes, the as prepared AuNPs-based electrode-on-chip
showed a 7.5-fold larger current response. This obvious signal en-
hancement should be attributed to the high loading of AuNPs on the
gold electrode.
Later on, the presence of antigens over working electrode resulted in
an increase in the double layer capacitance and hence reduced electro-
chemical behavior of test solution proportional to the concentration of
the antigen. This was used as the basis for determination of antigen
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(a) (b)
(c)
Figure 8.2: STEMmicrographs of a) bare gold nanoparticles by HAADF contrast,
b) AuNP-modified gold electrode by BF contrast, c) Ab functionalized gold
electrode by BF contrast. (For a, scale = 1.0 µm; for b, scale = 1.0 µm; for c, scale
= 50 nm)
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Figure 8.3: CV measurements of bare (green), AuNP-modified (red),
Ab-functionalized (blue) electrodes.
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concentration.
Incubation time is an important parameter affecting the immunoassay
efficacy. DPV studies revealed that the magnitude of current response
decreases over time due to the increased binding between antibody
and antigen, causing electron transfer resistance. However, no fur-
ther decrease in current was observed after 5 min, indicating saturated
binding of the immunoreaction. Hence, during the electrochemical
sensing measurement the electrode-on-chip was incubated with each
antigen concentration for 5 min.
8.4 Calibration curve
The electrochemical response of Osteokit was studied as a func-
tion of different concentrations of Oc and CTX using chronoamper-
ometry technique under identical experimental conditions (0.1 mM
K3[Fe(CN)6] as a redox probe, potential of 0.65V for 15s), respectively.
(Figure 8.4) It is noted that the sample consumption of this prototype
chip device is only 100 µL, which is much less than the traditional
methods (10 mL).
The magnitude of response current ratio decreased with increas-
ing antigen concentrations; this is due to the formation of immune-
complexes between antibody and antigen resulting in electron charge
transfer hindrance at the electrode electrolyte interface. (Figure 8.5)
The magnitude of current ratio in the Osteokit with CTX immuno-
electrode was linearly dependent to the CTX concentration with an
R square of 0.98. The immunoelectrode exhibited a near linear range
from 1-1000 pg/mL, at a LoD of 206.7 pg/mL, and LoQ of 626.5
pg/mL, with a correlation coefficient of 0.98.
As for Oc, the Osteokit with Oc immunoelectrode exhibited a near lin-
ear relationship between current ratio and logarithmic Oc concentra-
tion from 1 to 100 ng/mL (R2 = 0.93). (Figure 8.5) The LoD was exper-
imentally found to be 1.94 ng/mL. It had a LoQ of 5.89 ng/mL with a
correlation coefficient of 0.96.
Osteokit demonstrated a large dynamic range, which is in the order of
the physiological concentration of the studied antigens in the serum.
Notably, our titration curve revealed an apparent sublinearity at the
low end of the dynamic range for both analytes, which could be at-
tributed to the translation of the actual number of antigens captured
to the quantity of AuNPs.
In order to improve the results, new immunoelectrodes with larger
work area (2.5*2.5 mm2) were used. The magnitude of response cur-
rent increased with a power of 10 in the Osteokits with new electrodes.
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(a)
(b)
Figure 8.4: Graphs obtained for the chronoamperometry detection of several
concentrations of (a) CTX (b) Oc using the Osteokit.
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(a)
(b)
Figure 8.5: Calibration curve obtained from the electrochemical response studies
of Osteokit as a function of a) CTX concentration (1-1000 pg/mL) b) Oc
concentration (1-100 ng/mL).
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(Figure 8.6) Using the new device, the magnitude of current ratio in
the Osteokit with the CTX immunoelectrode was linearly dependent
to the logarithmic concentration of CTX with an R square of 0.96. The
immunoelectrode exhibited a near linear range from 1-2500 pg/mL, at
a LoD of 2.77 pg/mL, and LoQ of 8.40 pg/mL, with a correlation co-
efficient of 0.91. In other words, increasing the area of the work area
significantly improved the results.
8.5 Selectivity and cross-reactivity
Cross-reactivity and selectivity was checked using the same technique
reported in Chapter 6. Osteokit showed a minimum change from
baseline value (3 -- 5 %) with respect to Oc (100 pg/mL) and PTH
(100 pg/mL) as interferents on the CTX immunoelectrode. Similarly
there was no remarkable response for CTX (100 ng/mL) and PTH (100
ng/mL) on the Oc immunoelectrode. These results show that Osteokit
is selective for both CTX and Oc and no cross-talk occurs between the
channels.
8.6 Stability and Repeatability
The sensing interface was used ten times without sacrificing detection
efficiency. When the sensing surfaces were regenerated for more tests,
the detection of either antigen was not as sensitive as before. This
might be a result of losing the activity of the immobilized antibody
by repeatedly using the sensing surfaces.
To investigate the stability of the chips, the sensing interfaces were
stored at room temperature for a week. Compared with the relative
freshly fabricated sensing interfaces, the signal of the conserved sens-
ing interfaces only decreased by 8.1% for Oc and 8.8% for CTX. The
small decrease may be ascribed to the partial degradation of the im-
mobilized antibody.
In addition, the results showed a remarkable reproducibility of results,
tested by the application of the same concentration of either antigen on
different platforms. The results showed that the signal obtained in the
respective channels is highly reproducible for both CTX and Oc (RSD
lower than 8%), indicating an excellent degree of reproducibility for
both detection platforms.
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(a)
(b)
Figure 8.6: a) Graphs obtained for the chronoamperometry detection of several
concentrations of CTX, b) Calibration curve obtained from the electrochemical
response studies of Osteokit as a function of CTX concentration (1-2500 pg/mL),
using immunoelectrodes with larger work area.
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Table 8.1: Precision of Oc and CTX assay using ECLIA and Osteokit.
Oc samples ECLIA results (ng/mL) Osteokit results (ng/mL)
1 27.1 22.7
2 30.8 31.9
3 33.1 29.4
4 25 25.4
5 18.9 18.5
6 15.7 10.6
7 36.9 31.1
8 11.3 18.0
9 17.4 13.8
10 39.7 51.1
CTX samples ECLIA results (pg/mL) Osteokit results (pg/mL)
1 1250 1021.6
2 1400 1126.8
3 1070 916.9
4 455 416.9
5 325 284.6
6 2480 1145.9
7 816 812.1
8 92 26.9
9 1670 1132.7
10 194 92.2
8.7 Real serumMeasurements
To compare the sensitivity of our platform with current gold standard
methods, real samples (here, human serum) previously tested with
ECLIA were used as analyte 2. Again, serum of ten patients whose
Oc and CTX levels were recently measured using ECLIA was used.
Using the trend function in Excel and based on the values of two ad-
jacent points on calibration curve, the concentration of Oc and CTX in
the tested samples were calculated according to the obtained current.
The results were then compared.
According to the results presented in Table 8.1, the coefficients of vari-
ation for the ECLIA and Osteokit were calculated to be 4.6% and 3.7%
for Oc, and 6.4% and 7.7% for CTX.
2Oc samples were obtained from EMRI laboratory and CTX samples were obtained from UZ Hos-
pital
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(a) (b)
(c)
Figure 8.7: Statistical analysis comparing ECLIA vs. Osteokit in Oc
Measurement a,b) Correlation plot, c) Bland and Altman plot.
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(a) (b)
(c)
Figure 8.8: Statistical analysis comparing ECLIA vs. Osteokit in CTX
Measurement a,b) Correlation plot, c) Bland and Altman plot.
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The correlation between our sensor results and that of ECLIA was also
investigated and the results are shown in the correlation and Bland
and Altman plots in Figure 8.7 and 8.8. The R2 of the trend line in
the correlation plot was 0.85 for Oc and 0.87 for CTX. This indicates
that Osteokit has an acceptable correlation with ECLIA in measuring
both Oc and CTX. However, the results are more acceptable for lower
serum levels of CTX. This could be explained due to the fact that the
calibration curve was developed for CTX concentrations between 1 -
1000 pg/mL and the ratio for higher concentrations were extrapolated,
which is not really accurate. The sublinearity of the curve at the higher
concentrations also aggravates the accuracy issues.
8.8 Conclusion
Herein, we presented the development of a microfluidic platform (Os-
teokit) capable of measuring serum levels of several biomarkers. This
platform embodied a unique architecture which enabled low sample
volume requirements, short assay time, simplicity of fabrication and
use, and low cost instrumentation and at the same time portability,
high sensitivity and specificity for the BTMs. The system shortened
analytical time, enhanced detection throughput, and decreased detec-
tion cost. As a result, in terms of speed and economic expenses, the
feasibility of implementation of such diagnostic tests far from the lab-
oratory could be highly pragmatic. Furthermore, we showed this tech-
nology to reproducibly be comparable in sensitivity to the current gold
standard ECLIA.
The application of an electrode with a larger work area in the Osteokit
improved all the results, suggesting that this could be a good start for
future works in this field.
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9
Conclusion and Final Remark
9.1 Main achievements on PhD objectives
The main objective of this work was to develop the first such device
to be used in osteoporosis care with enhanced sensitivity and reduced
analysis time. In this perspective, we developed an electrochemical
biosensor for BTMmeasurement in a microfluidic chip architecture for
identifying individuals at-risk of fracture or monitoring the treatment
process in osteoporotic patients. Our platform consisted of two com-
ponents: a microfluidic control and an electrochemical-sensing mod-
ule.
This fabrication is advantageous in several aspects.
￿ First, the modification of gold electrode with Au nanoparticles
provided a suitable environment for stable immobilization of
BTMs keeping their bioactivity in microreactor environment, and
thus supporting high quality and low-background electrochemi-
cal sensing.
￿ Second, the use of highly specific monoclonal antibodies as
bioaffinity sensing interface not only improved the selectivity but
also allowed the detection with significantly lower amounts of the
sample, compared with conventional methods.
￿ Third, the use of the microchannels provided controlled function-
alization of the sensing platform, while preventing possible con-
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tamination and cross talk.
￿ Fourth, the combination of the adhesive tape and the milled
holder offered a means to rapidly fabricate prototype devices,
which could further be tested and the design refined according
to the performances required. In other words, the modular de-
sign of the chip allows us to easily modify the microfluidic control
module and the electrochemical-sensing module separately.
￿ Fifth, it could be used as a PoC device without the need for trained
personnel.
￿ Sixth, increased assay speed was another advantage of the current
device. While a classical sandwich ELISA typically takes 3-5 h to
prepare, this platform can measure biomarkers in minutes, which
is especially important in PoC setting.
￿ And last, compared with the traditional single-analyte immunoas-
say, the multiplexed microfluidic immunoassay is more efficient
in clinical application since it can quantitatively detect a panel of
biomarkers with improved diagnostic specificity.
The most attractive feature of this microfluidic device is the ease and
accuracy with which it can deliver information on the clinically rele-
vant parameters that a PoC situation would demand. In other words,
this platform is simple in design, inexpensive and easy to fabricate,
and at the same time offers accurate measurements. Moreover, the use
of microfluidic components along with the employment of the electro-
chemical detection, suggests that the proposed device can be operated
as a hand-held device in future. In addition, it should be mentioned
that while serum Oc measurement using traditional techniques needs
extra attention 1, the current PoC device could overcome these con-
cerns.
9.2 Outlook and Future Work
The means to take strategies that can achieve reliable and robust
signal amplification, background signal suppression, or nonspecific
binding prevention is essential for improving the analytical perfor-
mance of a biosensor. With the rapid emergence of nanotechnology
and nanoscience, hybrid bio/nanostructure-based signal amplification
hold great promise in realizing high sensitivity and selectivity for the
1For accurate measurement of serum Oc, blood samples should be collected at a temperature be-
tween 20 and 25 ○C, then centrifugedwithin 90minutes; serummay be stored at -20 ○C in plastic tubes
for up to 26 weeks. Serum may be thawed and refrozen up to 5 times without significant change in
measured serum Oc concentration. [1] [2]
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in situ or online detection of biomolecules.
Although this platform has been designed to be adaptable to different
types of proteomic assays, initial efforts were focused on the develop-
ment of a chip to assay two major BTMs, including Oc and CTX. The
assay system however could easily be adapted to other biomarkers.
In this regard, the process explained in Chapter 7 was modified for
P1NP and the corresponding calibration curve was developed in the
same manner. Results showed that the magnitude of current ratio in
the Osteokit was linearly dependent to the logarithmic concentration
of P1NP with an R square of 0.93. The device exhibited a near lin-
ear range from 5-100 µg/mL, at a detection limit of 1.82 µg/mL, and
LOQ of 5.51 µg/mL, with a correlation coefficient of 0.90. (Figure 9.1)
This is while the reference values for adult male is 22 - 87 µg/L, for
premenopausal women is 19-83 µg/L and postmenopausal women is
16-96 µg/L, suggesting that Osteokit can be used to measure P1NP
levels.
These results require further validation but may suggest a direction
towards which the field of diagnostic biomarkers is moving. Assess-
ing the reproducibility of the results when using real serum and the
LSC between Osteokit and ECLIA are needed. Modifying the design
in order to measure BTMs in whole blood, using a single inlet for the
measurement of all the biomarkers at the same time as well as improv-
ing packaging and long-term stability of the electrodes and fabricating
a portable read-out are the next steps.
Then, the biosensor must be evaluated in the clinical deployment plat-
form to confirm its performance in predicting or diagnosing the clin-
ical phenotype or outcome of interest as demonstrated in the initial
validation phase. It is realistically infeasible to test a large number
of patients in this manner due to financial constraints and/or lim-
ited availability of patient cohorts. Therefore, the use of prospective-
retrospective design and/or biobank samples could be a potential al-
ternative to overcome these obstacles.
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Figure 9.1: Calibration curve obtained from the electrochemical response studies
of Osteokit as a function of P1NP concentration (5 - 100 µg/mL).
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BTMs and their Characteristics
In the following, a list of most important BTMs and a short description
on them is provided. (Table A.1)[1]
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Table A.1: Existing bone turnover markers
Marker 1 Source Clinical Source Assay 2
R
e
s
o
r
p
t
i
o
n
NTX Degradation ofbone matrix Serum or urine ECLIA, ECA, ELISA
CTX Degradation ofbone matrix Serum or urine ECLIA, ELISA, ICMA
Dpd/Pyd Degradation ofbone matrix Urine HPLC, EIA, CLIA, RIA
TRAP Osteoclast Serum RIA, ELISA, EIA, Bone-TRAP
CatK Osteoclast Serum ELISA
Hyp Degradation ofbone matrix Urine ELISA
BSP Osteocyte Serum ELISA
OPG Osteoclast Serum ELISA
F
o
r
m
a
t
i
o
n Oc Osteoblast Serum ECLIA, RIA, ELISA,IRMA
BALP Osteoblast Serum Immunoenzymatic As-say, IRMA, ELISA
P1NP Newly synthesizedbone matrix Serum
Competitive RAI, ICMA,
IRMA
P1CP Newly synthesizedbone matrix Serum RIA, ELISA
1 NTX: Amino terminal telopeptide, CTX: Carboxyterminal telopeptide, Dpd: Deoxypyridinoline, Pyd: Pyridinoline, TRAP: Tartrate-resistant acid
phosphatase, CatK: Cathepsin K, Hyp: Hydroxyproline, BSP: Bone sialoprotein, OPG: Osteoprotegerin, Oc: Osteocalcin, BALP: Bone-specific alka-
line phosphatase, P1NP: Procollagen type 1 N-terminal propeptide, P1CP: Procollagen type 1 C-terminal propeptide.
2 CLIA: Chemiluminescent Immunoassay, ECA: Enzymatic Colorimetric Assay, ECLIA: Electrochemiluminescence Immunoassay, EIA: Enzyme Im-
munoassay, ELISA: Enzyme-linked Immunosorbent Assay, HPLC: High-Performance Liquid Chromatography, ICMA: Immunochemiluminescence
Assay, IRMA: Immunoradiometric Assay, RAI: Radioimmunoassay.
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A.0.1 Bone Resorption Markers
Increased bone resorption induces microarchitectural deterioration of
bone tissue, affecting bone strength. Increased bone resorption in-
duces microarchitectural deterioration of bone tissue, affecting bone
strength. Most biochemical markers of bone resorption such as uri-
nary total pyridinoline (PYD), urinary free deoxypyridinoline (Dpd),
urinary collagen type I cross-linked N- telopeptide (NTX), urinary or
serum collagen type I cross-linked C-telopeptide (CTX) are the prod-
ucts of degradation of bone collagen. Non-collagenous proteins such
as bone sialoprotein or tartrate- resistant acid phosphatase (TRAP) are
also classified in this group.
Type I collagen fragments
Since type I collagen is the main component of the organic matrix of
the bone (more than 90%), collagenolytic peptidases in osteoclasts play
a critical role in the resorption process [2]. During this process, type
I collagen splits into several fragments (the cysteine proteinase and
the matrix metalloproteinase (MMP)). These fragments are the most
sensitive markers of bone resorption in osteoporosis as they can help
estimate the rate of bone degradation.
Cross-linked Telopeptides of type I collagen (CTX) SerumCTX lev-
els follow a circadian rhythm and are reported to be higher in the early
morning [3]. After bone degradation, the non-helical regions of type I
collagen, the location on which the cross-links bond, are released into
the circulation. These products are not reused in the synthesis of new
collagen or metabolized in the liver as they are eventually excreted in
urine [4]. This marker is shown to significantly predict the risk of hip
fracture, independent of bone mass.
C-terminal crosslinking telopeptides generated by metalloproteinase
(CTX- MMP), Cross- linked carboxyterminal telopeptide of type I col-
lagen (ICTP), a trimeric cross-link-containing collagen peptide origi-
nally isolated by trypsin digestion of human bone collagen, and C-
terminal crosslinking telopeptides of type I collagen (CTX), a linear
eight amino acid epitope (EKAHDGGR) are the main fragments found
on the C-telopeptide end of type I collagen [5]. The CTX epitope,
which comprises of a DG-motif susceptible to post- translational mod-
ifications, converts to an isomerized form (alpha to beta CTX) during
the aging process.
The lysine residue (K)within the CTX epitope also participates in inter-
molecular cross-links in mature bone. They are also useful in mon-
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itoring bone metabolic activity and thus can be used to observe the
treatment process in postmenopausal women. Fragments of alpha-
CTX containing the sequence AHDGGR (1209-1214) can be measured
in urine as well, and is useful to confirm suppressed bone turnover in
individuals receiving bone treatments [6]. Elevated urinary levels of
native and age- related forms of CTX (alphaL/alphaD CTX ratio) are
reported in patients with Paget’s disease or osteoporosis. On the other
hand, postmenopausal women with low alpha/beta ratio of urinary
CTX excretion, suggestive of a low degree of isomerization of type I
collagen are at an increased risk of experiencing fracture [7].
N -terminal Crosslinking Telopeptides of type I Collagen (NTX)
On the N-telopeptide end, NTX is measured. The measurement of uri-
nary and serumNTX levels reveals the bone resorption rate during the
osteoporosis treatment; urinary NTX however is more sensitive and
efficient in this regard [8]. Bregenzer et al showed that N-telopeptide
levels could be used not only as a tool for osteoporosis screening but
also for selecting patients with inflammatory bowel disease at-risk of
developing osteoporosis [9]. Chaki et al reported that baseline uri-
nary NTx levels are the most sensitive predictor of bone loss at the
lumbar spine region. Another study revealed NTX to be significantly
correlated with BMD changes at the femoral neck, but not the spine
[10]. NTX, CTX, and ICTP are catabolized to smaller molecules such as
Dpd, Galactosyl hydroxylysine (GHYL), hydroxyproline (Hyp). These
markers however are no longer widely used [11].
Hydroxyproline (Hyp) Hyp constitutes 12±14% of the total amino
acid content of mature collagen. It had long been used as the only
marker of bone resorption; this is while significant amounts of urinary
Hyp derive from the degradation of the newly synthesized collagen in
tissues other than bone and mainly from the diet [12]. Moreover, only
10% of Hyp released during the bone resorption process is excreted in
the urine.
Galactosyl hydroxylysine (GHYL) GHYL, the integral parts of bone
collagen, are released into the circulation during the degradation
of mature collagen. Initially, pyridinium cross- links, pyridinoline
(Pyd) and deoxypyridinoline (Dpd) were measured in the urine [12]
[13]. Compared with Hyp, Pyd and Dpd have a better accuracy and
discrimination power in distinguishing postmenopausal osteoporotic
women. The measurement of these two components is not influenced
Appendix A. BTMs and their Characteristics 267
by the degradation of newly synthesized collagen nor diet. They fol-
low a circadian rhythm and are higher in early morning.
￿ Pyridinoline (Pyd)
Pyd levels were reported to be relatively higher in females and in-
dividuals with vertebral deformities. [13] It is suggested that Pyd
levels have a negative correlation with BMD at lumbar spine and
could help differentiate between pre and postmenopausal women.
￿ Deoxypyridinoline (Dpd)
Dpd is considered as a useful marker for the diagnosis of osteo-
porosis and other metabolic bone diseases [14]. While considered
as a more specific bone marker than Pyd, Dpd can help predict
the risk of vertebral fractures. Urinary excretion of Dpd is posi-
tively correlated with histomorphometric parameters of bone re-
sorption.
Tartrate-resistant acid phosphatase isoform 5b (s-TRACP-5b)
The iron-containing enzyme is synthesized by osteoclasts and alveolar
macrophages [15]. Its production however is not linked specifically
to the osteoclast-mediated collagen degradation, and can be secreted
by all active osteoclasts. Enzymes originating from erythrocytes and
platelets as well as many other circulating inhibitors affect total TRAP
levels [16]. TRACP5b, on the other hand, is a unique indicator of the
number of active osteoclasts in the body and, thus a useful indicator of
bone resorption. Increased serum levels of TRAP5b is noted in certain
diseases such as primary or secondary hyperparathyroidism, Paget’s
and metastatic bone disease where bone resorption and the number of
active osteoclasts is increased [16].
Sclerostin
Sclerostin is a Wnt antagonist produced almost exclusively by osteo-
cytes. Decreased serum sclerostin levels are reported in patients with
primary hyperparathyroidism, indicating that sclerostin is down reg-
ulated by PTH [17]. Several variables including age and serum levels
of hormones such as parathyroid, estradiol, and follicle- stimulating
hormone (FSH) influence serum levels of sclerostin in premenopausal
women. Sclerostin, on the other hand, plays an important role in post-
menopausal osteoporosis [18].
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Matrix metalloproteinase (MMP)
The role of MMP in bone has not been completely identified, but sev-
eral MMPs (the collagenases (MMP-1, -2, -13, and -14) and gelatinases
(MMP-2 and MMP-9)) are reported to be involved in collagen degra-
dation in bone tissue [19]. Increased levels of MMP-9 and tissue in-
hibitors of metalloproteinases (TIMP)-1 and -2 are reported follow-
ing airways injury in chronic obstructive pulmonary disease (COPD).
Bolton et al however showed that the increased levels of circulating
MMP-9 in COPD patients was due to the underlying osteoporosis
rather than the lung problem [20]. MMP-9, therefore, is considered as
an indicator of activated osteoclasts and thus a biomarker of increased
bone resorption.
Osteoprotegerin (OPG)
The discovery of the NF-kappa B ligand (sRANKL) signaling system
and its decoy receptor osteoprotegerin (OPG) has led to a better under-
standing of the bone microenvironment. Chiba et al reported that un-
like sRANKL, there is a significant positive association between OPG
levels and BMD values at lumbar spine in postmenopausal women,
suggesting that OPG is a good predictor of osteoporosis in elderly
women [21].
Cathepsin K (CatK)
Cathepsin K, the predominant collagenase in osteoclasts, plays an im-
portant role in bone resorption [22]. It is suggested that serum levels
of CatK may be useful in the diagnosis of chronic bone disorders such
as osteoporosis. This comes while Adolf et al failed to show any cor-
relation between CatK and other biomarkers including CTX or BAP,
indicating that serum levels of CatK are not suitable for identifying
osteoporotic women [23].
Interalpha-Trypsin-Inhibitor Heavy Chain H4 Precursor (ITIH4)
Bhattacharyya et al reported reduced levels of proteolytic fragments
of a specific signature fragmentation pattern, ITIH4, in high-turnover
patients [24]. They stressed that the plasma kallikrein- sensitive gly-
coprotein indicates the host’s response to increased activity of osteo-
clasts. The protein can therefore help identify individuals at high risk
of fracture.
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Dickkopf-related protein1 (DKK1)
DKK1 is a potent Wnt antagonist that specifically blocks Wnt/b-
catenin signaling process [25]. The expression of serum Dkk1 is highly
but negatively correlated with bone mass at different sites.
A.0.2 Bone Formation Markers
Bone formation markers such as bone-specific alkaline phosphatase,
Oc, and serum type I procollagen (C-terminal/N-terminal), can ex-
press different phases of osteoblast development and function [26].
Procollagen I extension peptides (s-P1NP)
P1NP follows a circadian rhythm and is higher in early morning [27].
While studying the response to treatment in postmenopausal women
who had received teriparatide, P1NP is reported to be the most useful
marker. On the other hand, women with high baseline P1NP levels are
reported to respond better to bisphosphonate treatment [28].
Procollagen type I C -terminal propeptide (P1CP)
Different studies have shown a significant correlation between serum
P1CP levels and the bone formation rate [29]. Unlike P1NP, the clinical
application of P1CP in the assessment of metabolic bone diseases is
still not clear.
Bone alkaline phosphatase (BALP)
Total alkaline phosphatase (TAP) is a well-known enzyme with an im-
portant role in bone formation and mineralization. In adults with nor-
mal liver function, approximately 50% of the TAP originates from the
liver and 50% from the bones [30]. Other dimeric isoforms of TAP orig-
inate from tissues such as intestine, spleen, kidney and placenta.
BALP, an enzyme located on the outer surface of osteoblasts, is one of
the most frequently used biochemical markers of bone formation be-
cause of its regulatory role in the mineralization of the osteoids. BALP
measurement is helpful in diagnosis of bone loss in primary (post-
menopausal and senile osteoporosis) and secondary osteoporosis (due
to metabolic diseases, renal osteodystrophy, Paget disease and . . . ) as
well as in monitoring antiresorptive therapy [31].
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Serum Osteocalcin (Oc)
Oc is the most abundant noncollagenous protein in bone, comprising
1–2% of total protein [32]. The biosynthesis of Oc is regulated by sev-
eral hormones and growth factors, for instance vitamin K is responsi-
ble for its carboxylation. Cathepsin K and matrix metalloproteinases
break Oc into smaller fragments during bone resorption. These frag-
ments are rapidly cleared by the kidneys. The vitamin K-dependent
hydroxyapatite-binding protein is synthesized only by osteoblasts and
odontoblasts, with a small amount being released during matrix re-
sorption. In other words, Oc is a specific indicator of bone formation.
According to its circadian rhythm, serum levels of Oc is higher in early
morning. Akesson et al showed a 20% lower serum concentration of
Oc in women with a previous history of fracture, adding that no such
a decline was reported for PICP, ALP, BALP, calcium, phosphate, and
albumin [33].
￿ Undercarboxylated Osteocalcin (ucOc): Impaired g- carboxylation
of Oc (ucOc) is reported to be suggestive of both vitamin D and vi-
tamin K deficiency in the elderly [34]. High levels of serum ucOc
are linked with a 2- to 3- fold increase in the hip fracture risk, in-
dependent of BMD values [35].
￿ Serum N-terminal Osteocalcin (N-MID Oc): Among BTMs, only
the changes in serum N-terminal Oc is significantly correlated
with BMD changes after 12 months of Hormone Replacement
Therapy (HRT), indicating that the fragment is a suitable predic-
tor for identifying good responders to the treatment [36]. Weng
et al reported that the combination of BALP and N-MID are more
sensitive than BMD in monitoring osteoporosis treatment [37].
Bone sialoprotein (BSP)
BSP, which accounts for 5-10% of the non-collagenous matrix of the
bone, is an important product of active osteoblasts and odontoblasts.
It is thus assumed to reflect bone resorption rate in the body [38]. BSP
levels are believed to decrease rapidly following intravenous bisphos-
phonate treatment.
NH2-Terminal pro C-type Natriuretic Peptide (NT proCNP)
Serum levels of NT proCNP, the product of the CNP gene [recently
identified in growth plate cartilage (and osteoblasts)], are highly cor-
related with growth velocity. In other words, NT proCNP reflects the
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activity of chondrocytes in growth plate and its levels reduce with cor-
ticosteroids use and following hypocaloric diets. The new marker,
which was first used to identify responders to growth hormone de-
ficiency (GHD) treatment, is reported to be effective in monitoring the
effects of new therapies that improve bone formation in osteoporotic
patients [39].
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Material and Apparatus
B.1 Materials and Reagents
Following items were purchased from Sigma-Aldrich:
￿ Chloroauric acid (HAuCl4·3H2O)
￿ sulfo-a-N-hydroxysuccinimide (sulfo-NHS)
￿ L-Glutathione reduced (GSH)
￿ trisodium citrate dihydrate (>99%)
￿ 1, 8-octanedithiol
￿ poly(diallyldimethylammonium chloride) solution (PDDA , Mw
100,000 200,000)
￿ potassium hexacyanoferrate (III) (K3Fe(CN)6)
￿ Phosphate buffered saline (PBS)
￿ Bovine Serum Albumins (BSA)
￿ b-1-ethyl-3-(3-dimethylamonipropyl) carbodiimide (EDC)
￿ PBS-Tween20
￿ Albumin-fluorescein isothiocyanate conjugate (FITC-Albumin)
In this work, sulfo-NHS was used instead of NHS as it is more water
soluble while showing similar reactivity and specificity.
Carbon (DRP-110) and Gold SPEs (DRP-C223AT) were purchased
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from Dropsens (Spain). TOPAS 8007 (COC), supplied by Microflu-
idic Chipshop (Jena, Germany), was used as the upper layer in the
Osteokit. Double-coated polyester diagnostic tape 9965 (3M Medical
Specialties, USA) was used. It consists of a 0.05 mm opaque white
polyester film coated on both sides with a 0.02 mm neutral pressure
sensitive acrylate adhesive and supplied between two clear, 0.05 mm
silicone-coated polyester release liners. According to the manufac-
turer, the tape is bioassay, die cut compatible and printable.
Oc monoclonal antibody (ab13418, ab133612) and full-length Oc pro-
tein (ab152231) were purchased from Abcam Co. (UK). Anti-collagen
type I antibody (MAB1340) and Human Collagen type I (CC050) were
obtained from Merck Chemicals (Belgium). In both cases, monoclonal
antibodies were purchased despite their higher price, as they are more
specifically detecting one target epitope and binding with an antigen
within a mixture of related molecules extremely efficiently, and less
likely to cross-react with other proteins. Moreover, compared with
polyclonal antibodies, considering their very high homogeneity, in
constant experimental conditions, the results are highly reproducible.
PBS was purchased in powder formwas used to prepare a working so-
lution of 10 mM phosphate buffer (NaCl 0.138M, KCl 0.0027M), pH 7.4
at 25 ○C. PBS and PBS-Tween20 were prepared by dissolving 1 pack-
age in 1000 mL of de-ionized (DI) water. PBS was used to prepare the
antibody (10 µg/mL) and antigen solutions.
EDC and sulfo-NHS were dissolved in water at 0.4 M and 0.1 M, di-
vided into small aliquots. EDC aliquots were stored at -20 ○C, whereas
sulfo-NHS was stored at +4 ○C.
The clinical serum samples were obtained from the laboratory of
the Endocrinology and Metabolism Research Institute, affiliated with
Tehran University of Medical Sciences, and the laboratory of the UZ
hospital, affiliated with the Ghent University.
All other reagents were of analytical reagent grade and used without
further purification. Distilled water was used throughout the experi-
ments. All the experiments were carried out at room temperature.
B.2 Apparatus and Method
All electrochemical experiments were performed using a computer-
controlled Dropsens STAT 400 (Dropsens, Spain) in the nanoprobe
and Oc biosensor fabrication, and Autolab PGSTAT101 (Metrohm, The
Netherlands) for the remaining parts of this work. They were car-
ried out in a solution container, at room temperature (23 ○C), using
the three-electrode configuration fabricated in Chapter 5. Electroac-
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tive substance 0.1 mM K3[Fe(CN)6], containing 0.01 M NaCl, and 0.5
M H2SO4 were used as electrolyte solutions.
Cyclic voltammogram (CV) and differential pulse voltammogram
(DPV), the main electrochemical testing methods used in the experi-
ments, were performed to confirm surface modification changes and
to quantify the target molecule concentration at the sample surface.
The CV cycles were performed in 0.1 mM K3[Fe(CN)6], containing
0.01 M NACl solution from 0.0 V to +1.2 V, at 0.1 V/s scan rate. CV
was also used to determine the formal potential of the electrochemical
sensor for DPV. The DPV measurements were performed in 0.1 mM
K3[Fe(CN)6], containing 0.01 M NaCl, applying following parameters:
0.025 V modulation amplitude, 0.05 s modulation time, 0.005 V step
potential and voltage range from 0.5 V to 1.1 V.
For the electrodeposition step, external AgCl reference and Pt. gauze
(Alfa Aesar Gmbh & Co, Germany) as auxiliary electrode was used.
As for the other steps, gold electrodes-on-chip were utilized.
Electrode surface topography as well as the morphology of the Au
deposits were measured using Sirion field emission gun scanning
electron microscopy (FEG-SEM) (FEI Nova 600 Nanolab Dual-Beam
FIB) and atomic force microscopy (AFM). Most high resolution FEG-
SEM pictures with magnifications >2.5kx were achieved in "immer-
sion mode" and with the TLD-SE detector (through the Lens Detector).
AFM images were acquired on a XE-70 (Park Systems) in non-contact
mode (15*15 µm2) using Nanosensors tm (PPP-NCHR).
Scanning transmission electron microscopy (STEM) (Jeol Zeiss -
EM10C JEM-2200FS FEG (S)TEM)- 80 operated under high tension of
200 kV), was used to collect information on the prepared gold nanopar-
ticles and to test for their ability to bind with the proteins. The sam-
ples were prepared using a gold (Au) TEM grid purchased from TED
PELLA, INC (Sweden). A high angle annular dark field (HAADF) de-
tector was used to distinguish the smallest and dispersed prepared
gold nanoparticles from the porous gold substrate. A bright field de-
tector (BF) was used to visualize lager prepared nanoparticles.
X-ray photoelectron spectroscopy (XPS) was performed with an elec-
tron spectrometer (SSI-SSX100) to estimate the composition of the sur-
face and confirm successful immobilization in each step.The trans-
mission electron microscopy (TEM) images were obtained with an
EM10C 80 KV (Zeiss, Germany) transmission electron microscope.
The zeta potential was measured by dynamic light scattering (DLS)
(MALVERN Instrument MAL1001767 UK), at a temperature of 25○C
and a pH of 7.4. The UV–Vis measurements were carried out on a UV
Visible Spectrophotometer SPECORD 250 (Analytik Jena, Germany).
Bruker vertex 70 Fourier transform infrared spectroscopy (FTIR) (Ger-
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many) was used for further study of the nanoconjugates. A Varian
Cary Eclipse fluorescence spectrophotometer equipped with a Varian
Cary-block temperature controller was used to assess the protein ad-
sorption capacity of the material.
In order to quantify the uniformity of the cross-sectional geometry of
the microfluidic channels along their length, the width and the height
of the microfluidic channels were studied at 5 mm intervals using an
optical microscope (Nikon Eclipse LV100) and a WYKO NT3300 non-
contact optical profiler, respectively.
In order to check the accuracy of the sensor, the electrochemilumines-
cence immunoassay (ECLIA, Elecsys 2010 autoanalyzer, Roche Diag-
nostics GmbH, Germany) was used to measure the serum levels of Oc
(intra and inter assay coefficients of variation of 1.2-4.0% and 1.7-6.5%,
respectively) and CTX (Intermediate precision CV of < 20 %).
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